CITATION REPORT List of articles citing

2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

DOI: 10.1093/eurheartj/ehu278 European Heart Journal, 2014, 35, 2541-619.

Source: https://exaly.com/paper-pdf/59329794/citation-report.pdf

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2227	Ischaemic Heart Disease. 1-15		
2226	Neurological Disease. 106-131		
2225			
2224	Biomimetic actuators: where technology and cell biology merge. 2004 , 61, 2497-509		43
2223	Interaction of volkensin with HeLa cells: binding, uptake, intracellular localization, degradation and exocytosis. 2004 , 61, 1975-84		46
2222	Evidence for a novel racemization process of an asparaginyl residue in mouse lysozyme under physiological conditions. 2005 , 62, 199-205		7
2221	Some highlights of a 47 year career in research. 2005 , 62, 1-3		27
2220	The N-terminus of HIV-1 Tat protein is essential for Tat-TAR RNA interaction. 2005 , 62, 355-61		20
2219	Familial hypobetalipoproteinemia: genetics and metabolism. 2005 , 62, 1372-8		123
2218	Alpha-crystallin: an ATP-independent complete molecular chaperone toward sorbitol dehydrogenase. 2005 , 62, 599-605		13
2217	Thiyl radicals in biosystems: effects on lipid structures and metabolisms. 2005 , 62, 834-47		33
2216	Adjunctive manual thrombus aspiration during ST-segment elevation myocardial infarction: a meta-analysis of randomized controlled trials. 2014 , 9, e113481		10
2215	THE SIGNIFICANCE OF PLATELET FUNCTIONAL ACTIVITY TESTING IN THE PREVENTION OF CARDIOVASCULAR COMPLICATIONS IN PATIENTS RECEIVING ANTIPLATELET THERAPY. 2014 , 10, 679-	-687	2
2214	[Antithrombotic treatment in patients with stable coronary artery disease. Which drugs and for how long?]. 2014 , 39, 798-802		1
2213	[Guidelines 2014 - a revival of old and new recommendations]. 2014 , 39, 899-901		
2212	The EHJ: the first years and the future. European Heart Journal, 2014, 35, 3399-407	9.5	2
2211	Revascularization decisions in patients with stable angina and intermediate lesions: results of the international survey on interventional strategy. 2014 , 7, 751-9		101

2210	Intra-aortic balloon counterpulsation in cardiogenic shock: is it really the end of an indication?. 2014 , 48, 325-7	
2209	ESC/EACTS myocardial revascularization guidelines 2014. <i>European Heart Journal</i> , 2014 , 35, 3235-6 9.5	71
2208	Indications for revascularization in patients with left ventricular dysfunction: evidence and uncertainties. 2014 , 148, 2461-5	
2207	Pretreatment with P2Y12 inhibitors in non-ST-Segment-elevation acute coronary syndrome: an outdated and harmful strategy. 2014 , 130, 1904-14; discussion 1914	33
2206	Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors. 2014 , 349, g6419	36
2205	[Antiplatelet therapy in acute coronary syndrome. Prehospital phase: nothing, aspirin or what?]. 2014 , 39, 803-7	
2204	[Antithrombocytic therapy and PCI. Duration of therapy after DCB/stents/scaffolds]. 2014, 39, 819-21	2
2203	[ESC/EACTS guidelines on myocardial revascularization : Amendments 2014]. 2014 , 39, 913-8	2
2202	Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. 2014 , 371, 2155-66	1256
2201	The optimal management of patients on oral anticoagulation undergoing coronary artery stenting. The 10th Anniversary Overview. 2014 , 112, 1080-7	52
2200	How nursing teams were engaged to help deliver clinical research. 2014 , 9, 607-610	
2199	Reply: Extracorporeal membrane oxygenation for acute respiratory failure in adults: the need for pulmonary INTERMACS. 2014 , 190, 1322-3	
2198	Revaskularisation bei schlechter LV-Funktion. 2015 , 4, 320-325	
2197	Comments on the 2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-segment Elevation. 2015 , 68, 1061-7	5
2196	Paclitaxel-Coated Balloon for Recalcitrant In-Drug-Eluting Stent Restenosis. 2015, 8, 1701-3	1
2195	¿Seguimos las recomendaciones de las guãs de revascularizaciñ coronaria? Otro punto de vista. 2015 , 68, 910	
2194	Duraciñ del tratamiento antiagregante plaquetario combinado doble tras la implantaciñ de stents farmacoactivos: el jurado contina reunido. 2015 , 68, 827-829	2
2193	Off-pump versus on-pump coronary artery bypass grafting: Who benefits?. 2015 , 150, 1666-8	1

Resultados iniciais e tardios de pacientes tratados com stent hBrido eluidor de sirolimus ou stent eluidor de everolimus. **2015**, 23, 114-118

2191	Portuguese Society of Cardiothoracic and Vascular Surgery/Portuguese Society of Cardiology recommendations for waiting times for cardiac surgery. 2015 , 34, 683-9	1
2190	Immediate and Long-Term Results of Drug-Eluting Stents in Mammary Artery Grafts. 2015 , 116, 1695-9	6
2189	Efficacy and Safety of Paclitaxel-Coated Balloon for the Treatment of In-Stent Restenosis in High-Risk Patients. 2015 , 116, 1690-4	14
2188	Factors Associated with In-hospital Mortality in Patients with Acute Coronary Syndrome. 2015 , 1, 68-74	2
2187	Welche intrakoronare Diagnostik: funktionell oder morphologisch?. 2015 , 4, 309-314	
2186	Role of cardiovascular magnetic resonance in the guidelines of the European Society of Cardiology. 2016 , 18, 6	92
2185	Is Nebivolol Really Effective in Preventing Contrast Induced Nephropathy?. 2015, 40, 533-41	6
2184	Use of intracoronary physiology indices in acute coronary syndromes. 2015 , 7, 483-495	4
2183	Triple therapy for percutaneous coronary intervention in atrial fibrillation: standard of care, or a nightmare soon to end?. 2015 , 13 Suppl 1, S332-5	2
2182	Clinical significance of non-vitamin K antagonist oral anticoagulants in the management of atrial fibrillation. 2015 , 79, 914-23	10
2181	Impact of Anemia and Dual Antiplatelet Therapy on Mortality in Patients Undergoing Percutaneous Coronary Intervention with Drug-Eluting Stents. 2015 , 5, 17213	5
2180	ST-segment elevation myocardial infarction âlideal scenario for bioresorbable vascular scaffold implantation?. 2015 , 79, 263-70	14
2179	Comparison of Percutaneous Coronary Intervention With Coronary Artery Bypass Grafting in Unprotected Left Main Coronary Artery Disease - 5-Year Outcome From CREDO-Kyoto PCI/CABG Registry Cohort-2 2015 , 79, 1282-9	30
2178	Coronary functional tests in the catheterization laboratory - pathophysiological and clinical relevance. 2015 , 79, 676-84	6
2177	Recommendations for myocardial revascularisation for patients with coronary artery disease. 2015 , 10, 62-63	
2176	Cirugil versus intervencionismo percutĝieo en la enfermedad de tronco y/o 3 vasos: la evidencia frente a la especulaciil. 2015 , 22, 119-125	
2175	Percutaneous Revascularization in a Case of Vasospastic Angina Associated with Polymorphic Ventricular Tachycardia. 2015 , 61, 387-390	

2174	Impact of frailty on outcomes after percutaneous coronary intervention: a prospective cohort study. 2015 , 2, e000294	53
2173	Caring for patients post PPCI: examining a lack of evidence and standards. 2015 , 10, 541-547	3
2172	Dual antiplatelet therapy for coronary artery disease. 2015 , 79, 255-62	12
2171	Design and Rationale of the Femoral Closure versus Radial Compression Devices Related to Percutaneous Coronary Interventions (FERARI) Study. 2015 , 9, 97-103	5
2170	Physiology-guided myocardial revascularisation in complex multivessel coronary artery disease: beyond the 2014 ESC/EACTS guidelines on myocardial revascularisation. 2015 , 2, e000308	5
2169	Quality markers in cardiology: measures of outcomes and clinical practice âll perspective of the Spanish Society of Cardiology and of Thoracic and Cardiovascular Surgery1. 2015 , 22, 315-324	
2168	Antikoagulation und perioperatives Bridging. 2015 , 37, 413-426	О
2167	Kommentar zu den 2014-Leitlinien der Europischen Gesellschaft fr.Kardiologie (ESC) und der Europischen Gesellschaft fr.Ansthesiologie (ESA) zum Management kardiovaskulier Erkrankungen bei nicht-kardialen chirurgischen Eingriffen. 2015 , 9, 283-288	5
2166	Curriculum kardiale Computertomographie. 2015 , 9, 363-374	О
2165	Indicadores de calidad en cardiologã. Principales indicadores para medir la calidad de los resultados (indicadores de resultados) y parmetros de calidad relacionados con mejores resultados en la prôtica clítica (indicadores de prôtica asistencial). INCARDIO (Indicadores de	
2164	Multimodality imaging in coronary artery disease - "The more the better?". 2015 , 57, e462-e469	2
2163	Intravascular ultrasound, optical coherence tomography and near infrared spectroscopy. 2015 , 57, e439-e445	6
2162	Practice Patterns for Outpatients With Stable Coronary Artery Disease: A Case Vignette-based Survey Among French Cardiologists. 2015 , 2, 1662-8	5
2161	Terapia antiplaquetaria doble de 6 o de 12 meses tras implante de stents farmacoactivos de nueva generaciñ: anljisis emparejado de los registros ESTROFA-DAPT y ESTROFA-2. 2015 , 68, 838-845	7
2160	Vascular response after implantation of biolimus A9-eluting stent with bioabsorbable polymer and everolimus-eluting stents with durable polymer. Results of the optical coherence tomography analysis of the BIOACTIVE randomized trial. 2015 , 23, 28-37	
2159	Early and late outcomes of patients treated with hybrid sirolimus-eluting stent or everolimus-eluting stent. 2015 , 23, 114-118	
2158	[Cardiovascular assessment and management prior to non-cardiac surgery. Comment on the new 2014 ESC/ESA guidelines]. 2015 , 40, 1043-7	1
2157	Gef ü rkrankungen und -komplikationen im Rahmen von Herzoperationen. 2015 , 29, 201-212	

2156	Durchfħrung und Befundung der kardialen Magnetresonanztomographie (Kardio-MRT). 2015 , 9, 337-347	
2155	Resposta vascular apß implante de stents liberadores de biolimus A9 com polfhero bioabsorvữel e stents liberadores de everolimus com polfhero durŷel. Resultados da anÿse de tomografia de coer"ncia p̃tica do estudo randomizado BIOACTIVE. 2015 , 23, 28-37	1
2154	Did referral patterns for coronary angiography change in Europe? What can we learn from Denmark?. 2015 , 1, 166-7	
2153	Antikoagulanzien und Thrombozytenaggregationshemmer bei endoskopischen Interventionen. 2015 , 37, 351-363	1
2152	The dogma of aspirin: a critical review of evidence on the best monotherapy after dual antiplatelet therapy. 2015 , 13, 28	1
2151	Implantation of everolimus-eluting bioresorbable scaffolds in a diabetic all-comers population. 2015 , 86, 975-81	6
2150	Clinical effect of cardiac shock wave therapy on patients with ischaemic heart disease: a systematic review and meta-analysis. 2015 , 45, 1270-85	12
2149	Stent length as a potential indicator to select patients who may benefit from long-term dual antiplatelet therapy. 2015 , 7, 419-426	
2148	A 75-year-old woman with chest pain and transient severe left ventricular systolic dysfunction. 2015 , 34, 621.e1-621.e8	
2147	Fractional flow reserve of non-culprit vessel post-myocardial infarction: is it reliable?. 2015 , 15, 127	1
2146	Determinants of outcome in patients with chronic ischemic left ventricular dysfunction undergone percutaneous coronary interventions. 2015 , 15, 137	3
2145	Qualitative and semi-quantitative evaluation of myocardium perfusion with 3 T stress cardiac MRI. 2015 , 15, 164	7
2144	Impact of arrhythmia on diagnostic performance of adenosine stress CMR in patients with suspected or known coronary artery disease. 2015 , 17, 94	13
2143	Feasibility and safety of adenosine cardiovascular magnetic resonance in patients with MR conditional pacemaker systems at 1.5 Tesla. 2015 , 17, 112	14
2142	Cost-minimization analysis of three decision strategies for cardiac revascularization: results of the "suspected CAD" cohort of the european cardiovascular magnetic resonance registry. 2016 , 18, 3	29
2141	Harmonizing Optimal Strategy for Treatment of coronary artery diseasescomparison of REDUCtion of prasugrEl dose or POLYmer TECHnology in ACS patients (HOST-REDUCE-POLYTECH-ACS RCT): study protocol for a randomized controlled trial. 2015 , 16, 409	6
2140	Intra-aortic balloon pump-assisted major hepatectomy in a case with coronary disease. 2015 , 1, 112	2
2139	Current state and future direction of hybrid coronary revascularization. 2015 , 30, 643-9	7

2138	The STENTYS paclitaxel-eluting stent in the treatment of unprotected distal left main. 2015, 86, E131-9	20
2137	Implantation of an Absorb bioresorbable vascular scaffold in the stenotic aortopulmonary collateral artery of a young child with Alagille syndrome. 2015 , 86, E76-80	4
2136	Antiplatelet drugs in patients with enhanced platelet turnover: biomarkers versus platelet function testing. 2015 , 114, 459-68	42
2135	Outcomes after multivessel or culprit-Vessel intervention for ST-elevation myocardial infarction in patients with multivessel coronary disease: a Bayesian cross-design meta-analysis. 2015 , 86 Suppl 1, S15-22	11
2134	Hybrid coronary revascularization: first choice or alternative?. 2015 , 7, 507-510	4
2133	Clinical outcome of 2nd generation drug-eluting stents versus bare-metal stents in percutaneous intervention on vein grafts. 2015 , 7, 511-517	
2132	Diagnosis and prognosis of ischemic heart disease: the framework of cardiac magnetic resonance. 2015 , 16, 653-62	9
2131	Ischaemic heart disease - a selected review of recent developments. 2015 , 30, 657-62	5
2130	Acute myocardial infarction and cardiogenic shock: pharmacologic and mechanical hemodynamic support pathways. 2015 , 26, 535-44	4
2129	Computed Tomography-Derived Fractional Flow Reserve in the Detection of Lesion-Specific Ischemia: An Integrated Analysis of 3 Pivotal Trials. 2015 , 94, e1963	9
2128	Optimal Duration of Dual Antiplatelet Therapy after Drug-Eluting Stents: Meta-Analysis of Randomized Trials. 2015 , 33, 253-63	8
2127	Dual or triple therapy in patients with atrial fibrillation and drug-eluting stents?. 2015, 26, 367-8	1
2126	Plasma levels of carboxypeptidase U (CPU, CPB2 or TAFIa) are elevated in patients with acute myocardial infarction. 2015 , 13, 2227-32	11
2125	Outcomes following implantation of the Biolimus A9-eluting BioMatrix coronary stent: Primary analysis of the e-BioMatrix registry. 2015 , 86, 1151-60	12
2124	Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH: comment. 2015 , 13, 2130-2	3
2123	Antiplatelet and invasive treatment in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and acute coronary syndrome. The safety of aspirin. 2015 , 40, 349-52	8
2122	Platelet Function Testing Before CABG is Recommended in the Guidelines: But Do We Have Enough Evidence?. 2015 , 28, 233-5	8
2121	Triple therapy for atrial fibrillation and percutaneous coronary intervention. 2015 , 30, 690-6	1

2120	Current developments and future applications of intracoronary hemodynamics. 2015, 26, 448-58	1
2119	Out-of-hospital cardiac arrest: defining the role of coronary angiography and intervention. 2015 , 26, 626-33	O
2118	Regional systems-of-care for primary percutaneous coronary intervention in ST-elevation myocardial infarction. 2015 , 26, 713-22	10
2117	Fractional Flow Reserve-Guided Lesion or Patient Management?. 2015 , 128, 3266	2
2116	Short-term rosuvastatin treatment for the prevention of contrast-induced acute kidney injury in patients receiving moderate or high volumes of contrast media: a sub-analysis of the TRACK-D study. 2015 , 128, 784-9	4
2115	Myocardial revascularization in patients with stable angina: for which benefit?. 2015 , 27, 303-312	
2114	ATLANTIC: another reason to investigate the disconnect between stent thrombosis and mortality?. 2015 , 114, 9-10	
2113	Current Practice of Transradial Coronary Angiography and Intervention: Results from the Korean Transradial Intervention Prospective Registry. 2015 , 45, 457-68	9
2112	Intravascular ultrasound as an adjunct tool for angiographically intermediate lesions and complex coronary interventions: patient selection and perspectives. 2015 , 41	1
2111	Pharmacotherapy in the Cardiac Catheterization Laboratory. 2015 , 04,	1
2110	Cardioprotection by remote ischemic conditioning: Mechanisms and clinical evidences. 2015 , 7, 621-32	27
2109	Incremental Value of the CRUSADE, ACUITY, and HAS-BLED Risk Scores for the Prediction of Hemorrhagic Events After Coronary Stent Implantation in Patients Undergoing Long or Short Duration of Dual Antiplatelet Therapy. 2015 , 4,	49
2108	Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis. 2015 , 11, 1133-8	6
2107	Non-culprit lesion percutaneous coronary intervention during acute myocardial infarction - the road not taken?. 2015 , 11, 71-3	
2106	Stenting of Left Main Coronary Artery Stenosis: Data to Clinical Practice. 2015 , 03,	1
2105	The use of modern interventional cardiology tools to verify lesion significance and optimize procedural outcome in a diabetic patient with multivessel disease. 2015 , 11, 233-8	
2104	Bioresorbable vascular scaffold implantation in acute coronary syndromes: clinical evidence, tips and tricks. 2015 , 11, 161-9	9
2103	Everolimus-eluting stent platforms in percutaneous coronary intervention: comparative effectiveness and outcomes. 2015 , 8, 317-29	3

2102 Clinical utility of platinum chromium bare-metal stents in coronary heart disease. 2015 , 8, 359-67	9
Antithrombotic therapy for long-term secondary prevention of acute coronary syndrome in high-risk patients. 2015 , 11, 263-77	5
The search for optimal anticoagulation therapy in ACS: The gap between clinical trials and current clinical guidelines. 2015 , 114, 872-4	
Comparison of the efficacy of drug-eluting stents versus bare-metal stents for the treatment of left main coronary artery disease. 2015 , 128, 721-6	5
Optimizing the duration of dual antiplatelet therapy after implantation of drug-eluting coronary stents. 2015 , 128, 711-3	1
Coronary Artery Disease and Symptomatic Severe Aortic Valve Stenosis: Clinical Outcomes after Transcatheter Aortic Valve Implantation. 2015 , 2, 18	16
2096 Current Status of Antiplatelet Therapy in Acute Coronary Syndrome. 2015 , 13, 40-9	3
Dual Antiplatelet Therapy in Patients with Glucose-6-Phosphate Dehydrogenase Deficiency undergoing PCI with Drug-Eluting Stents. 2015 , 22, 535-41	10
Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in Non-ST elevation acute coronary syndrome. 2015 , 114, 702-7	17
2093 The effect of acenocoumarol on the antiplatelet effect of clopidogrel. 2015 , 114, 708-16	3
Prognosis of STEMI Patients with Multi-Vessel Disease Undergoing Culprit-Only PCI without Significant Residual Ischemia on Non-Invasive Stress Testing. 2015 , 10, e0138474	4
Management of adjunctive antithrombotic therapy in STEMI patients treated with fibrinolysis undergoing rescue or delayed PCI. 2015 , 114, 945-57	1
2090 New Oral Anticoagulants in Coronary Artery Disease. 2015 , 15, 101-5	5
Coronary artery bypass grafting versus percutaneous intervention in coronary revascularization: a historical perspective and review. 2015 , 57	
Non-vitamin K antagonist oral anticoagulants (NOACs) in the cardiac catherisation laboratory: Friends or Foes?. 2015 , 114, 214-6	1
Impact of Coronary Collateral Circulation on In-Hospital Death in Patients with Inferior ST Elevation Myocardial Infarction. 2015 , 2015, 242686	8
Impact of Dabigatran versus Phenprocoumon on ADP Induced Platelet Aggregation in Patients with Atrial Fibrillation with or without Concomitant Clopidogrel Therapy (the Dabi-ADP-1 and Dabi-ADP-2 Trials). 2015 , 2015, 798486	11
Mammario-arterial anastomosis versus aorto-arterial anastomosis as proximal anastomotic sites in coronary artery bypass surgery for patients with multivessel disease. 2015 ,	1

2084	Shock Management for Cardio-surgical ICU Patients - The Golden Hours. 2015 , 1, 75-82	7
2083	Early occlusion of the non-infarct-related coronary artery following successful primary percutaneous coronary intervention in ST-elevation myocardial infarction. 2015 , 11, 136-40	2
2082	Contemporary Antiplatelet Strategies in the Treatment of STEMI using Primary Percutaneous Coronary Intervention. 2015 , 10, 26-31	1
2081	Clinical impact of dual antiplatelet therapy use in patients following everolimus-eluting stent implantation: insights from the SEEDS study. 2015 , 128, 714-20	2
2080	Fractional flow reserve-guided management in stable coronary disease and acute myocardial infarction: recent developments. <i>European Heart Journal</i> , 2015 , 36, 3155-64	45
2079	Impact of high loading dose of atorvastatin in diabetic patients with renal dysfunction undergoing elective percutaneous coronary intervention: a randomized controlled trial. 2015 , 33, 35-41	18
2078	Clinical impact of gastrointestinal bleeding in patients undergoing percutaneous coronary interventions. 2015 , 8,	58
2077	Kommentar zu den 2013 Leitlinien der Europfschen Gesellschaft ff.Kardiologie (ESC) zum Management der stabilen koronaren Herzkrankheit (KHK). 2015 , 9, 159-164	6
2076	Perspectives on the 2014 ESC/EACTS Guidelines on Myocardial Revascularization: Fifty Years of Revascularization: Where Are We and Where Are We Heading?. 2015 , 8, 211-20	13
2075	Preference for oral anticoagulation therapy for patients with atrial fibrillation in Europe in different clinical situations: results of the European Heart Rhythm Association Survey. 2015 , 17, 819-24	12
2074	Double antiplatelet therapy duration: standardize or personalize?. 2015 , 65, 2222-4	2
2073	Cardiac troponin elevation predicts all-cause mortality in patients with acute exacerbation of chronic obstructive pulmonary disease: Systematic review and meta-analysis. 2015 , 191, 187-93	47
2072	Management of antithrombotic therapy in patients undergoing electrophysiological device surgery. 2015 , 17, 840-54	25
2071	Device therapy: Where next in cardiogenic shock owing to myocardial infarction?. 2015 , 12, 383-4	11
2070	Heart disease in pregnancy. 2015 , 29, 579-97	20
2069	The authors reply. 2015 , 87, 862-3	
2068	Comparison of intracoronary versus intravenous administration of adenosine for measurement of coronary fractional flow reserve. 2015 , 8,	38
2067	Dual antiplatelet therapy following drug-eluting stent implantation: how long is long enough?. 2015 , 13, 585-7	2

2066	Fundamentals in clinical coronary physiology: why coronary flow is more important than coronary pressure. <i>European Heart Journal</i> , 2015 , 36, 3312-9a	99
2065	The Role of Ivabradine in Cardiac Rehabilitation in Patients With Recent Coronary Artery Bypass Graft. 2015 , 20, 547-53	3
2064	Stenting of coronary bifurcation lesions: a literature and technical review. 2015 , 17, 45	10
2063	Kriterien der Deutschen Gesellschaft fî.Kardiologie âlHerz- und Kreislaufforschung fî.âlhest Pain Unitsâll 2015 , 9, 171-181	20
2062	Risks and benefits of triple oral anti-thrombotic therapies after acute coronary syndromes and percutaneous coronary intervention. 2015 , 38, 481-91	6
2061	The endovascular approach for in-stent restenosis in femoropopliteal disease. 2015 , 13, 391-401	3
2060	Platelet function test-guided strategy: lost in translation?. 2015 , 8, e002716	1
2059	Are at least 12 months of dual antiplatelet therapy needed for all patients with drug-eluting stents? All patients with drug-eluting stents need at least 12 months of dual antiplatelet therapy. 2015 , 131, 2001-9; discussion 2009	2
2058	Longer- Versus Shorter-Duration Dual-Antiplatelet Therapy After Drug-Eluting Stent Placement: A Systematic Review and Meta-analysis. 2015 , 163, 118-26	38
2057	Long-Term Results of Drug-Coated Balloons for Drug-Eluting In-Stent Restenosis: Gaining Perspective. 2015 , 8, 885-8	6
2056	Long-term prognosis of complete percutaneous coronary revascularisation in patients with diabetes with multivessel disease. 2015 , 101, 1233-9	12
2055	The NICE recommendation for drug-coated balloons and its global impact. 2015 , 9, 87-94	4
2054	Coming safely to a stop: a review of platelet activity after cessation of antiplatelet drugs. 2015 , 6, 141-50	13
2053	Antiplatelet therapy: Defining the optimal duration of DAPT after PCI with DES. 2015, 12, 445-6	12
2052	Filling a gap in the ESC Journal Family: a warm welcome to the EHJ - Quality of Care and Clinical Outcomes. 2015 , 1, 3-6	
2051	Drug-Coated Balloon Angioplasty for De Novo Stenosis: The Balloon is Backâ R eloaded!. 2015 , 8, 2010-2012	5
2050	[ESC guidelines 2015. Non-ST-elevation acute coronary syndrome]. 2015, 40, 1027-33	9
2049	Triple Antithrombotic Therapy in Atrial Fibrillation Patients With an Indication for Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A Case-Based Review of the Current Evidence. 2015 , 8, e003217	1

2048	A conservative strategy in non-ST-segment elevation myocardial infarction âl£onstraints and prognosis: The situation in Portugal. 2015 , 34, 315-328		7
2047	Platelet reactivity and antiplatelet management in diabetic patients with coronary artery disease. 2015 , 7, 283-293		
2046	Restoring platelet function in patients on P2Y12 receptor inhibitor treatment: still some issues to be solved!. 2015 , 8, e003257		3
2045	Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study. 2015 , 8, e002786		47
2044	Effects of Renin-Angiotensin-Aldosterone System Blockers and Renoprotective Regimens on Contrast-Induced Nephropathy. 2015 , 66, 972		
2043	Short- and Long-Term Patient Outcomes From Combined Coronary Endarterectomy and Coronary Artery Bypass Grafting: A Meta-Analysis of 63,730 Patients (PRISMA). 2015 , 94, e1781		35
2042	Indicadores de calidad en cardiologã. Principales indicadores para medir la calidad de los resultados (indicadores de resultados) y parinetros de calidad relacionados con mejores resultados en la pritica clítica (indicadores de pritica asistencial). INCARDIO (Indicadores de Calidad en Unidades Asistenciales del fiea del Corazfi): Declaracifi de posicionamiento de		33
2041	The role of imaging in coronary artery disease - What do the ESC guidelines say. 2015 , 57, e405-e407		
2040	Bivalirudin versus unfractionated heparin: a meta-analysis of patients receiving percutaneous coronary intervention for acute coronary syndromes. 2015 , 2, e000258		9
2039	PEGASUS-TIMI-54-Studie: Weniger ischmische Ereignisse aber mehr Blutungskomplikationen bei Infarktpatienten unter verlägerter dualer Plätchenhemmung. 2015 , 9, 332-333		
2038	IMPROVE-IT-Studie. 2015 , 9, 329-331		
2037	Myokardiale Perfusionsdiagnostik der koronaren Herzerkrankung. 2015 , 9, 421-433		
2036	Intravascular fibrin molecular imaging improves the detection of unhealed stents assessed by optical coherence tomography in vivo. <i>European Heart Journal</i> , 2017 , 38, 447-455	9.5	37
2035	Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development. 2015 , 11, 547-64		13
2034	Platelet Reactivity: Is There a Role to Switch?. 2015 , 58, 278-84		4
2033	Guʿʿʿʾ ESC 2015 sobre el tratamiento de los stidromes coronarios agudos en pacientes sin elevaciti persistente del segmento ST: Grupo de Trabajo de la Sociedad Europea de Cardiologt (ESC) para el tratamiento de los stidromes coronarios agudos en pacientes sin elevaciti persistente del		20
2032	Comentarios a la gu [®] ESC 2015 sobre el tratamiento de los s [®] dromes coronarios agudos en pacientes sin elevaci [®] persistente del segmento ST. 2015 , 68, 1061-1067		6
2031	Overview of the pharmacological challenges facing physicians in the management of patients with concomitant cardiovascular disease and chronic obstructive pulmonary disease. 2015 , 1, 205-11		21

2030	Cardiac surgery 2014 reviewed. 2015 , 104, 1006-20	6
2029	Bivalirudin in stable angina and acute coronary syndromes. 2015 , 152, 1-10	5
2028	An intact small animal model of myocardial ischemia-reperfusion: Characterization of metabolic changes by hyperpolarized 13C MR spectroscopy. 2015 , 309, H2058-66	28
2027	Antiplatelet Efficacy of Fixed-Dose Aspirin-Clopidogrel Combination in Patients with Stable Coronary Artery Disease Treated with Drug-Eluting Stent Implantation. 2015 , 35, 833-42	2
2026	Current strategies for bridging dual antiplatelet therapy in patients requiring surgery. 2015 , 7, 137-148	2
2025	Fractional flow reserve: conundrums, controversies and challenges. 2015 , 7, 543-552	3
2024	FD-OCT and IVUS for detection of incomplete stent apposition in heavily calcified vessels: novel insights. 2015 , 2, e000292	3
2023	Registro Absorb Italiano (BVS-RAI): an investigators-owned and -directed, open, prospective registry of consecutive patients treated with the Absorbâ®VS: study design. 2015 , 16, 340-3	12
2022	Impact of the learning curve on procedural results and acute outcome after percutaneous coronary interventions with everolimus-eluting bioresorbable scaffolds in an all-comers population. 2015 , 16, 455-60	12
2021	FFRCT: Solid PLATFORM or Thin Ice?. 2015, 66, 2324-2328	5
2020	A 75-year-old woman with chest pain and transient severe left ventricular systolic dysfunction. 2015 , 34, 621.e1-8	1
2019	Portuguese Society of Cardiothoracic and Vascular Surgery/Portuguese Society of Cardiology recommendations for waiting times for cardiac surgery. 2015 , 34, 683-689	
2018	Retrograde approach to chronically occluded coronary arteries âla step forward in CTO PCI. 2015 , 7, 221-223	
2017	Treating coronary artery disease in patients with a history of cerebrovascular disease. 2015 , 108, 606-11	3
2016	An update on drug-eluting stents versus bare-metal stents in PCI treatment: are there any remaining indications for BMS use?. 2015 , 7, 497-505	1
2015	Do Not Use Novel Antiplatelet Agents in Patients on Oral Anticoagulants After Stenting. 2015 , 8, 1890-2	2
2014	Effect of Drug-Coated Balloons in Native Coronary Artery Disease Left With a Dissection. 2015 , 8, 2003-2009	70
2013	The year in cardiology 2014: coronary intervention. <i>European Heart Journal</i> , 2015 , 36, 347-52b 9.5	O

2012 Antiplatelet properties of oral anticoagulants. 2015 , 181, 413-4	5
Stable coronary artery disease: Seeking best practice by looking at diagnostic accuracy and prognostic stratification. 2015 , 181, 399-402	
2010 Choice of optimal anticoagulant to support primary PCI: out with the new, in with the old. 2015 , 65, 39-43	2 5
A randomized trial of a dedicated bifurcation stent versus provisional stenting in the treatment of coronary bifurcation lesions. 2015 , 65, 533-43	89
Triple therapy for atrial fibrillation and ACS with or without PCI: don't drop aspirin just yet. 2015 , 65, 515-6	8
Reply: Triple therapy for atrial fibrillation and ACS with or without PCI: don't drop aspirin just yet. 2007 2015 , 65, 516-8	1
Impact of Rosuvastatin on contrast-induced acute kidney injury in patients at high risk for nephropathy undergoing elective angiography. 2015 , 115, 867-71	22
Prasugrel plus aspirin beyond 12 months is associated with improved outcomes after TAXUS Libert'paclitaxel-eluting coronary stent placement. 2015 , 131, 62-73	48
2004 Acute coronary syndromes and coronary intervention. <i>European Heart Journal</i> , 2015 , 36, 323-4) .5
2003 Qui, quand, comment revasculariser le diabtique ?. 2015 , 2015, 17-22	О
Are we ready for a new paradigm shift in percutaneous revascularization of chronically occluded vessels with well-developed collaterals?: from leaving 'em all to stenting 'em all. 2015 , 8, 280-282	5
Comentarios a la gull de prŷtica cllica de la ESC/EACTS 2014 sobre revascularizacili miocŷdica. 2001 2015 , 68, 92-97	3
2000 Dual antiplatelet treatment after stenting. 2015 , 385, 325-6	1
1999 Percutaneous circulatory assist devices for high-risk coronary intervention. 2015 , 8, 229-244	74
1998 Dual antiplatelet treatment after stenting - Authors' reply. 2015 , 385, 326	
1997 Surgery for coronary artery disease. 2015 , 33, 78-85	
Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials. 2015 , 65, 1298-1310	252
1995 Bioresorbable drug-eluting stents: an immature technology in need of mature application. 2015 , 8, 198-2	00 16

(2015-2015)

1994	Long-term forecasting and comparison of mortality in the Evaluation of the Xience Everolimus Eluting Stent vs. Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) trial: prospective validation of the SYNTAX Score II. <i>European Heart Journal</i> , 2015 , 36, 1231-41	9.5	79
1993	Management of cardiogenic shock complicating acute myocardial infarction. 2015 , 4, 278-97		20
1992	ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. <i>European Heart Journal</i> , 2015 , 36, 1252-63	9.5	296
1991	Comments on the 2014 ESC/EACTS guidelines on myocardial revascularization. 2015 , 68, 92-7		2
1990	Economic implications of intra-aortic balloon support for myocardial infarction with cardiogenic shock: an analysis from the IABP-SHOCK II-trial. 2015 , 104, 566-73		8
1989	Antithrombotic therapy after left atrial appendage closure. 2015 , 13, 105-9		8
1988	Life-threatening complete atrioventricular block associated with ticagrelor therapy. 2015 , 182, 379-80		24
1987	Prasugrel and ticagrelor compared to clopidogrel in non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary interventions: Certainties and uncertainties. 2015 , 181, 443-5		3
1986	Culprit-vessel versus complete revascularization during primary angioplasty in ST-elevation myocardial infarction: an updated meta-analysis. 2015 , 178, 171-4		6
1985	Computerized decision making in myocardial perfusion SPECT: The new era in nuclear cardiology?. 2015 , 22, 885-7		3
1984	Actualizaciñ en cardiopatñ isquínica y cuidados críticos cardiolígicos. 2015 , 68, 234-241		7
1983	Current antiplatelet agents: place in therapy and role of genetic testing. 2015 , 39, 328-36		2
1982	Treatment of in-stent restenosis with bioresorbable vascular scaffolds: optical coherence tomography insights. 2015 , 31, 255-9		20
1981	PCI and CABG surgery in 2014: CABG surgery versus PCI in CADsurgery strikes again!. 2015 , 12, 75-7		5
1980	Percutaneous Mechanical Ventricular Support in Acute Cardiac Care: A UK Quaternary Centre Experience Using 2.5L, 3.8L and 5.0L Impella Catheters. 2015 , 4, 47-58		11
1979	Clopidogrel Response Variability: Etiology and Clinical Relevance. 2015 , 9, 1		O
1978	Is FAME 2 a breakthrough for PCI in stable coronary disease?. 2015 , 104, 283-7		6
1977	Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal	9.5	61

1976	Management of cardiogenic shock. European Heart Journal, 2015, 36, 1223-30	9.5	299
1975	Optimal medical therapy improves clinical outcomes in patients undergoing revascularization with percutaneous coronary intervention or coronary artery bypass grafting: insights from the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial at		122
1974	Stent selection and antiplatelet therapy duration: one size does not fit all. 2015 , 65, 816-819		3
1973	Pretreatment with antiplatelet drugs in invasively managed patients with coronary artery disease in the contemporary era: review of the evidence and practice guidelines. 2015 , 8, e002301		46
1972	Myocardial viability as integral part of the diagnostic and therapeutic approach to ischemic heart failure. 2015 , 22, 229-45		37
1971	Stenting versus surgery for significant left main disease. 2015 , 17, 18		6
1970	Percutaneous Coronary Interventions for Chronic Total Occlusions: More Benefit for the Patient or for the Interventionist's Ego?. 2015 , 31, 974-9		11
1969	Trimetazidine Decreases Risk of Contrast-Induced Nephropathy in Patients With Chronic Kidney Disease: A Meta-Analysis of Randomized Controlled Trials. 2015 , 20, 539-46		16
1968	Dual Antiplatelet Therapy for 6 Months vs 12 Months After New-generation Drug-eluting Stent Implantation: Matched Analysis of ESTROFA-DAPT and ESTROFA-2. 2015 , 68, 838-45		2
1967	First medical contact in patients with STEMI and its impact on time to diagnosis; an explorative cross-sectional study. 2015 , 5, e007059		27
1966	Prolonged dual antiplatelet therapy after drug-eluting stent reduces the risk of stent thrombosis and major cardiovascular events but increases the rate of bleeding. 2015 , 20, 99		
1965	ANZSCTS Response to the Discussion Paper: Proposed Recommendations for Myocardial Revascularisation. 2015 , 24, 646-8		O
1964	Impact of immature platelets on platelet response to ticagrelor and prasugrel in patients with acute coronary syndrome. <i>European Heart Journal</i> , 2015 , 36, 3202-10	9.5	59
1963	Oral dual antiplatelet therapy: what have we learnt from recent trials?. <i>European Heart Journal</i> , 2016 , 37, 344-52	9.5	11
1962	Rationale and design of the RT-AF study: Combination of rivaroxaban and ticagrelor in patients with atrial fibrillation and coronary artery disease undergoing percutaneous coronary intervention. 2015 , 43, 129-32		22
1961	Prognostic impact of high residual platelet reactivity after chronic total occlusion percutaneous coronary intervention in patients with diabetes mellitus. 2015 , 201, 561-7		6
1960	A 24-year-old male with acute coronary syndrome due to the circumflex coronary artery thrombosis. Diagnostic challenge in everyday practice. 2015 , 198, 131-3		
1959	Drug-eluting stent treatment of left main coronary artery disease: the case for a sirolimus-eluting, autoexpandable alternative. An optical coherence tomography analysis. 2015 , 199, 119-20		5

1958	Infant euthanasia is morally unacceptable. 2015 , 149, 1684-5	3
1957	A balanced assessment of the STICH trial. 2015 , 149, 1683-4	O
1956	Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose?. 2015 , 16, 1983-95	9
1955	Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3âPRIMULTI): an open-label, randomised controlled trial. 2015 , 386, 665-71	527
1954	Utilizaciñ de la cirugñ de revascularizaciñ coronaria en nuestro medio. ¿Seguimos las recomendaciones de las guñs?. 2015 , 68, 635-636	7
1953	Optical coherence tomography imaging during percutaneous coronary intervention impacts physician decision-making: ILUMIEN I study. <i>European Heart Journal</i> , 2015 , 36, 3346-55	140
1952	Modifying angiographic syntax score according to PCI strategy: lessons learnt from ERACI IV Study. 2015 , 16, 418-20	10
1951	Early development of coronary artery aneurysms after implantation of biolimus-eluting stent with biodegradable polymer. 2015 , 184, 487-488	2
1950	Left main coronary artery and ostial left anterior descending coronary artery stenting in a single coronary artery during NSTEMI. The OCT response. 2015 , 184, 499-501	3
1949	Double or triple antithrombotic combination therapy in patients who need anticoagulation and antiplatelet therapy in parallel. 2015 , 1, 191-7	8
1948	Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the Setting of Primary Percutaneous Coronary Intervention: Results of a Nonrandomized Observational Study. 2015 , 8, 1064-1074	4
1947	[Management of stable chronic coronary artery disease]. 2015 , 40, 645-54; quiz 655-6	1
1946	Coronary artery fistulas as a cause of angina: How to manage these patients?. 2015 , 16, 306-9	4
1945	The Ideal Anticoagulation Strategy in ST-Elevation Myocardial Infarction. 2015 , 58, 247-59	7
1944	More transparency for a therapeutic window in platelet P2Y12 inhibition?. <i>European Heart Journal</i> , 2015 , 36, 1714-7	2
1943	Clinical outcomes according to diabetic status in patients treated with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents: prespecified subgroup analysis of the BIOSCIENCE trial. 2015 , 8,	27
1942	Percutaneous coronary intervention in the elderly. 2015 , 199, 342-55	20
1941	America vs Europe and the 2014 Non-ST Elevation Acute Coronary Syndrome Guidelines. 2015 , 8, 385-91	1

1940	Clinical picture and risk prediction of short-term mortality in cardiogenic shock. 2015 , 17, 501-9	321
1939	Anemia in Intensive Cardiac Care Unit patients - An underestimated problem. 2015 , 60, 307-14	8
1938	New-onset atrial fibrillation after recent coronary stenting: Warfarin or non-vitamin K-antagonist oral anticoagulants to be added to aspirin and clopidogrel? A viewpoint. 2015 , 196, 133-8	16
1937	Platelet GP IIb-IIIa Receptor Antagonists in Primary Angioplasty: Back to the Future. 2015 , 75, 1229-53	20
1936	Practical experience with ticagrelor: an Australian and New Zealand perspective. 2015, 31, 1469-77	6
1935	Update: Acute Heart Failure (VII): Nonpharmacological Management of Acute Heart Failure. 2015 , 68, 794-802	O
1934	Cangrelor: A Review in Percutaneous Coronary Intervention. 2015 , 75, 1425-34	13
1933	Complex Disease, Partial Revascularization, and Adverse Outcomes in Patients Treated With Long-Term Warfarin Therapy Who Underwent Percutaneous Coronary Intervention. 2015 , 116, 350-4	
1932	Everolimus Eluting Stents Versus Coronary Artery Bypass Graft Surgery for Patients With Diabetes Mellitus and Multivessel Disease. 2015 , 8, e002626	47
1931	Update on percutaneous intervention for left main coronary artery stenosis. 2015 , 13, 933-43	1
1930	Intravascular Ultrasound for the Diagnosis and Treatment of Left Main Coronary Artery Disease. 2015 , 4, 361-381	4
1929	Complete revascularisation in patients with diabetes. 2015 , 101, 1176-7	1
1928	Dual antiplatelet therapy duration and mortality. 2015 , 385, 2149	О
1927	Preoperative Statin Therapy and Renal Outcomes After Cardiac Surgery: A Meta-analysis and Meta-regression of 59,771 Patients. 2015 , 31, 1051-60	30
1926	Thrombus aspiration in patients with ST elevation myocardial infarction: meta-analysis of 16 randomized trials. 2015 , 15, 175-87	3
1925	Dual antiplatelet therapy after carotid stenting: lessons from 'big brother'. 2015 , 49, 621-622	2
1924	Pre-hospital ticagrelor in ST-segment elevation myocardial infarction: Ready for prime time?. 2015 , 194, 41-3	4
1923	Prevention of cardiovascular disease in rheumatoid arthritis. 2015 , 14, 952-69	57

(2015-2015)

1922	A Prospective Randomized Trial of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis of Drug-Eluting Stents: The RIBS IV Randomized Clinical Trial. 2015 , 66, 23-33		186
1921	Pharmacodynamic Effects of Ticagrelor Dosing Regimens in Patients on Maintenance Ticagrelor Therapy: Results From a Prospective, Randomized, Double-Blind Investigation. 2015 , 8, 1075-1083		4
1920	Duration of dual antiplatelet therapy after drug-eluting stent implantation: will we ever reach a consensus?. <i>European Heart Journal</i> , 2015 , 36, 1219-22	9.5	24
1919	Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. <i>European Heart Journal</i> , 2015 , 36, 1762-71	9.5	218
1918	Efficacy of Long-Term Blocker Therapy for Secondary Prevention of Long-Term Outcomes After Coronary Artery Bypass Grafting Surgery. 2015 , 131, 2194-201		47
1917	Post-PCI Antithrombotic Therapy in Patients Requiring Long-Term Anticoagulation. 2015 , 17, 41		
1916	[Author's reply]. 2015 , 39, 197		
1915	The Transradial Approach and Antithrombotic Therapy: Rationale and Outcomes. 2015 , 4, 213-223		
1914	Update on ischemic heart disease and intensive cardiac care. 2015 , 68, 234-41		2
1913	Comparison among patientså ß 5 years having percutaneous coronary angioplasty using drug-eluting stents versus bare metal stents. 2015 , 115, 1179-84		7
1912	"Fishing" in the era of TOTAL: Thrombectomy in primary PCI. 2015 , 189, 91-3		2
1911	Comparison of Strut Coverage at 6 Months by Optical Coherence Tomography With Everolimus-Eluting Stenting of Bare-Metal Stent Restenosis Versus Stenosis of Nonstented Atherosclerotic Narrowing (from the DESERT Study). 2015 , 115, 1351-6		6
1910	Percutaneous coronary interventions in the diabetic patient: where do we stand?. 2015 , 8, e001944		22
1909	Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial. 2015 , 313, 1113-21		66
1908	Impact of tailored anti-P2Y12 therapies in acute coronary syndromes. 2015 , 16, 493-9		3
1907	Prolonged dual antiplatelet therapy after drug-eluting stenting: meta-analysis of randomized trials. 2015 , 104, 887-901		19
1906	Duration of dual antiplatelet therapy after coronary artery stenting: where is the sweet spot between ischaemia and bleeding?. <i>European Heart Journal</i> , 2015 , 36, 1207-11	9.5	34
1905	Impact of time from symptom onset to drug administration on outcome in patients undergoing glycoprotein IIb-IIIa facilitated primary angioplasty (from the EGYPT cooperation). 2015 , 115, 711-5		10

1904 Rponse biologique et clinique aux AAP. **2015**, 2015, 32-34

1903	The arranged marriage of cangrelor and bivalirudin. 2015 , 8, 434-435	1
1902	On-pump versus off-pump coronary artery bypass surgery in patients with preoperative anemia. 2015 , 149, 1018-26.e1	4
1901	A nationwide survey on perception, experience, and expectations of hybrid coronary revascularization among top-ranked US hospitals. 2015 , 169, 557-63.e6	6
1900	Reply: Has Prasugrel Been Compared Correctly With Clopidogrel in Non-ST-Segment Elevation Acute Coronary Syndrome?. 2015 , 65, 1717-1718	
1899	Acute coronary syndrome and scombroid syndrome. 2015 , 187, 317-8	7
1898	[Comments on predictors of the use of the early invasive strategy in women with non-ST-elevation acute coronary syndrome]. 2015 , 39, 196-7	
1897	Left main revascularization: reality versus the real world. 2015 , 8, e002380	3
1896	Culprit or multivessel revascularisation in ST-elevation myocardial infarction with cardiogenic shock. 2015 , 101, 1225-32	44
1895	Survival in patients without acute ST elevation after cardiac arrest and association with early coronary angiography: a post hoc analysis from the TTM trial. 2015 , 41, 856-64	61
1894	Coronary procedures in German hospitals: a detailed analysis for specific patient clusters. 2015 , 104, 555-65	7
1893	Early results of first versus second generation Amplatzer occluders for left atrial appendage closure in patients with atrial fibrillation. 2015 , 104, 656-65	53
1892	DAPT-Studie. 2015 , 9, 7-8	
1891	A Dutch perspective on the ESC/EACTS guidelines on myocardial revascularisation. 2015 , 23, 290-1	2
1890	Duale Pl û tcheninhibition nach Stentimplantation: kîzer oder l û ger. 2015 , 15, 41-44	2
1889	How to balance risks and benefits in the management of CKD patients with coronary artery disease. 2015 , 28, 403-13	13
1888	Activated clotting time during percutaneous coronary intervention: a test for all seasons or a mind tranquilizer?. 2015 , 8,	2
1887	Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation: The ISAR-TRIPLE Trial. 2015 , 65, 1619-1629	331

(2015-2015)

1886	Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. 2015 , 350, h1618	218
1885	Prolonged antiplatelet therapy after drug-eluting stents. 2015 , 385, 2332-3	2
1884	Pharmacokinetics and pharmacodynamics of ticagrelor when treating non-ST elevation acute coronary syndromes. 2015 , 11, 977-93	1
1883	Close encounters with errors of the second kind: evaluating risks and benefits of long-term dual antiplatelet therapy. <i>European Heart Journal</i> , 2015 , 36, 1216-8	2
1882	Dual antiplatelet therapy after acute coronary syndrome: a cardiologist-based optimal decision. 2015 , 101, 832-3	
1881	Comparison of Ticagrelor Versus Prasugrel to Prevent Periprocedural Myonecrosis in Acute Coronary Syndromes. 2015 , 116, 339-43	24
1880	Nuevas gulls de la EACTS de revascularizacili miocŷdica 2014. 1." parte. Principales novedades y perspectiva del cirujano. 2015 , 22, 31-38	
1879	Genetically Determined Platelet Reactivity and Related Clinical Implications. 2015, 22, 257-64	4
1878	Everolimus-eluting stents or bypass surgery for multivessel coronary disease. 2015 , 372, 1213-22	187
1877	Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction. 2015 , 65, 2211-21	193
1876	Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs. 2015 , 386, 303-10	97
1875	Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. 2015 , 385, 2371-82	275
1874	Causes, assessment, and treatment of stent thrombosisintravascular imaging insights. 2015 , 12, 325-36	31
1873	Trial of everolimus-eluting stents or bypass surgery for coronary disease. 2015 , 372, 1204-12	287
1872	Prasugrel hydrochloride for the treatment of acute coronary syndromes. 2015 , 16, 585-96	4
1871	Multicenter evaluation of dynamic three-dimensional magnetic resonance myocardial perfusion imaging for the detection of coronary artery disease defined by fractional flow reserve. 2015 , 8,	43
1870	Risk stratification in 3-vessel coronary artery disease: Applying the SYNTAX Score II in the Heart Team Discussion of the SYNTAX II trial. 2015 , 86, E229-38	16
1869	A multidisciplinary consensus document on follow-up strategies for patients treated with percutaneous coronary intervention. 2015 , 85, E129-39	5

1868	Comparative Effectiveness of Hybrid Coronary Revascularization vs Coronary Artery Bypass Grafting. 2015 , 221, 326-34.e1	33
1867	Can BRIGHT restore the glow of bivalirudin?. 2015 , 313, 1323-4	8
1866	Early and late clinical outcomes of endovascular, surgical, and hybrid revascularization strategies of combined carotid and coronary artery diseases: the FRIENDS study group (Finalized Research In ENDovascular Strategies). 2015 , 17, A23-A28	2
1865	Cangrelor for the treatment of arterial thrombosis: pharmacokinetics/pharmacodynamics and clinical data. 2015 , 11, 625-37	4
1864	Perioperatively acquired disorders of coagulation. 2015 , 28, 113-22	20
1863	Safe contrast volumes for preventing contrast-induced nephropathy in elderly patients with relatively normal renal function during percutaneous coronary intervention. 2015 , 94, e615	15
1862	Timing of staged percutaneous coronary intervention before transcatheter aortic valve implantation. 2015 , 115, 1726-32	22
1861	Intra-aortic Balloon Pump Therapy for Acute Myocardial Infarction: A Meta-analysis. 2015 , 175, 931-939	76
1860	Comparison of coronary artery bypass graft surgery and percutaneous coronary intervention in patients with diabetes. 2015 , 17, 377	2
1859	A Review of the Key Clinical Trials of 2014. 2015 , 4, 5-23	7
1858	Long-term follow-up of the viability guided angioplasty after acute myocardial infarction (VIAMI) trial. 2015 , 186, 111-6	5
1857	Evaluating the bioequivalence of clopidogrel generic formulations. 2015 , 31, 861-4	2
1856	Universal definition of myocardial infarction: clinical insights. 2015 , 131, 13-21	21
1855	Impact of prasugrel pretreatment and timing of coronary artery bypass grafting on clinical outcomes of patients with non-ST-segment elevation myocardial infarction: From the A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST-Elevation Myocardial Infarction	14
1854	Comparison of 5-Year Outcomes After Coronary Artery Bypass Grafting in Heart Failure Patients With Versus Without Preserved Left Ventricular Ejection Fraction (from the CREDO-Kyoto CABG Registry Cohort-2). 2015 , 116, 580-6	15
1853	Outcome of extracorporeal membrane oxygenation support for complex high-risk elective percutaneous coronary interventions: A single-center experience. 2015 , 44, 309-13	34
1852	Intracoronary Adenosine for Maximal Hyperemia: Less Is MoreâMore or Less?. 2015 , 8, 1431-1432	1

1850	A carotid extra-media thickness, PATIMA combined index and coronary artery disease: Comparison with well-established indexes of carotid artery and fat depots. 2015 , 243, 307-13	12
1849	Impact of urgent coronary angiography on mid-term clinical outcome of comatose out-of-hospital cardiac arrest survivors presenting without ST-segment elevation. 2015 , 94, 61-6	20
1848	Intracoronary Adenosine: Dose-Response Relationship With Hyperemia. 2015, 8, 1422-1430	81
1847	Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of 9.5 randomized trials. <i>European Heart Journal</i> , 2016 , 37, 390-9	232
1846	Cardiovascular MR Manual. 2015,	5
1845	Coronary artery aneurysm following drug-coated balloon treatment. 2015 , 16, 505-7	2
1844	High-speed rotational atherectomy of the left main coronary artery: a single-center experience in 50 high-risk patients. 2015 , 16, 284-9	7
1843	Unmatched Results After Double Kissing Crush Stenting Technique in Distal Left Main Coronary Artery Treatment?. 2015 , 8, 1343-1345	
1842	2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of	426
1841	Cardiology (ESC)Endorsed by: Association for European Paediatric and Congenital Cardiology Rationale and design of the Prospective LongitudinAl Trial of FFRCT: Outcome and Resource IMpacts study. 2015 , 170, 438-46.e44	13
1840	Bioabsorbable drug-eluting vascular scaffold for the treatment of coronary in-stent restenosis: A two center registry. 2015 , 16, 401-5	2
1839	Antiplatelet Therapy During PCI for Patients with Stable Angina and Atrial Fibrillation. 2015, 17, 64	1
1838	Noninvasive Fractional Flow Reserve Derived from Coronary Computed Tomography Angiography for the Diagnosis of Lesion-specific Ischemia. 2015 , 4, 481-489	
1837	Quality Markers in Cardiology. Main Markers to Measure Quality of Results (Outcomes) and Quality Measures Related to Better Results in Clinical Practice (Performance Metrics). INCARDIO (Indicadores de Calidad en Unidades Asistenciales del Eea del CorazE): A SEC/SECTCV Consensus	1
1836	Mortality benefits with CTO PCI: moving the goalpost closer. <i>European Heart Journal</i> , 2015 , 36, 3199-201 _{9.5}	2
1835	Summary of the ESC/EACTS 2014 Guidelines on myocardial revascularization. Prepared by the Czech Society of Cardiology. 2015 , 57, e381-e402	
1834	How does coronary stent implantation impact on the status of the microcirculation during primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction?. <i>European Heart Journal</i> , 2015 , 36, 3165-77	60
1833	The saga of the duration of dual antiplatelet therapy after drug-eluting stent placement. 2015 , 108, 469-71	2

1832	Post-cardiac arrest extracorporeal life support. 2015 , 29, 497-508	9
1831	Fractional Flow Reserve in Acute Myocardial Infarction: A Guide for Non-Culprit Lesions?. 2015 , 4, 39-46	2
1830	Impact of multivessel revascularization on health status outcomes in patients with ST-segment elevation myocardial infarction and multivessel coronary artery disease. 2015 , 66, 2104-2113	9
1829	Optimal- vs. standard-antiplatelet therapy on platelet function and long-term clinical outcomes in patients with high on-treatment platelet reactivity: 2-year outcomes of the multicentre, randomized Optimal-antiPlatelet Therapy (OPT) trial. 2015 , 17, B23-B31	2
1828	Continuation of Dual-Antiplatelet Therapy Following Percutaneous Revascularization with a Drug-Eluting Stent: What Duration Is Optimal?. 2015 , 17, 63	2
1827	Optimal duration of dual antiplatelet therapy after coronary stent implantation. 2015 , 116, 1631-6	1
1826	Vorhofflimmern nach Herzoperation: Wie und wie lange behandeln?. 2015 , 4, 98-103	1
1825	Post-Resuscitation ECG for Selection of Patients for Immediate Coronary Angiography in Out-of-Hospital Cardiac Arrest. 2015 , 8,	43
1824	Bioresorbable Scaffolds Versus Metallic Drug-Eluting Stents: Are We Getting Any Closer to a Paradigm Shift?. 2015 , 66, 2310-2314	12
1823	Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet Therapy. 2015 , 8, 1552-62	36
1822	Clinical development of rivaroxaban: emerging new clinical evidences?. 2015 , 11, 565-83	
1821	Rationale and Design of Sodium Tanshinone IIA Sulfonate in Left Ventricular Remodeling Secondary to Acute Myocardial Infarction (STAMP-REMODELING) Trial: A Randomized Controlled Study. 2015 , 29, 535-542	14
1820	Surgical Revascularization versus Percutaneous Coronary Intervention and Optimal Medical Therapy in Diabetic Patients with Multi-Vessel Coronary Artery Disease. 2015 , 58, 306-15	10
1819	Is There Still a Survival Advantage to Bypass Surgery Over Percutaneous Intervention in the Modern Era?. 2015 , 58, 335-41	3
1818	Bypass Grafting Versus Percutaneous Intervention-Which Is Better in Multivessel Coronary Disease: Lessons From SYNTAX and Beyond. 2015 , 58, 316-34	6
1817	Efficacy of various percutaneous interventions for in-stent restenosis: comprehensive network meta-analysis of randomized controlled trials. 2015 , 8, e002778	17
1816	Diabetes y cribado de enfermedad coronaria: ¿dfide centramos el esfuerzo?. 2015 , 68, 830-833	5

1814	Experience and Long-Term Follow-Up of Graft Patency. 2015 , 100, 1367-73	33
1813	Duration of Dual Antiplatelet Therapy After Coronary Stenting: A Review of the Evidence. 2015 , 66, 832-847	90
1812	Alternative stents in ST-segment elevation myocardial infarction: improving the efficacy of primary percutaneous coronary intervention. 2015 , 11, 347-57	1
1811	Prognosis after revascularization for left main coronary artery disease: insights from the crystal ball. <i>European Heart Journal</i> , 2015 , 36, 1212-5	3
1810	Dual antiplatelet therapy: optimal timing, management, and duration. 2015 , 1, 198-204	22
1809	A numerical investigation of the functionality of coronary bifurcation lesions with respect to lesion configuration and stenosis severity. 2015 , 48, 3103-11	11
1808	[Acute coronary syndrome]. 2015 , 140, 97-103	O
1807	Percutaneous Transcatheter Assessment of the Left Main Coronary Artery: Current Status and Future Directions. 2015 , 8, 1529-39	17
1806	Impact of atorvastatin or rosuvastatin co-administration on platelet reactivity in patients treated with dual antiplatelet therapy. 2015 , 243, 389-94	9
1805	Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial. <i>European Heart Journal</i> , 2016 , 37, 365-74	99
1804	Diabetes and Screening for Coronary Heart Disease: Where Should We Focus our Efforts?. 2015 , 68, 830-3	1
1803	Medical and Invasive Management of Coronary Artery Disease in Patients on Anticoagulants. 2015 , 163-174	
1802	Intracoronary imaging: see more, better or worse?. <i>European Heart Journal</i> , 2015 , 36, 3356-8 9.5	2
1801	Noninvasive Fractional Flow Reserve Derived From Coronary CT Angiography: Clinical Data and Scientific Principles. 2015 , 8, 1209-1222	144
1800	Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk. 2015, 373, 2038-47	497
1799	Role of Endovascular Closure of the Left Atrial Appendage in Stroke Prevention for Atrial Fibrillation. 2015 , 17, 65	2
1798	Mean platelet volume and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor. 2015 , 16, 1739-47	13
1797	Interventional Cardiology in the Elderly. 2015 ,	

1796	Value of Hybrid Imaging with PET/CT to Guide Percutaneous Revascularization of Chronic Total Coronary Occlusion. 2015 , 8, 26		12
1795	Bilateral Versus Single Internal Mammary Artery Grafting in the Elderly: Long-Term Survival Benefit. 2015 , 100, 1374-81; discussion 1381-2		20
1794	In-stent restenosis treatment: quest for the best device. 2015 , 386, 627-8		2
1793	Ischaemic stroke and ST-segment elevation myocardial infarction: fast-track single-stop approach. <i>European Heart Journal</i> , 2015 , 36, 2348-55	9.5	3
1792	Absorb bioresorbable stents for the treatment of coronary artery disease. 2015 , 12, 545-57		6
1791	Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention: the ARCTIC-GENE study. 2015 , 71, 1315-24		25
1790	Fractional flow reserve versus angiography for guidance of PCI in patients with multivessel coronary artery disease (FAME): 5-year follow-up of a randomised controlled trial. 2015 , 386, 1853-60		295
1789	2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of	9.5	2187
1788	Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. 2015 , 17, 1467-507		803
1787	Comparison of Successful Myocardial Reperfusion and Adverse Events in Patients With ST-Elevation Myocardial Infarction Who Underwent Rescue Percutaneous Coronary Intervention After Failed Fibrinolytic Therapy With Versus Without Manual Coronary Thrombus Aspiration. 2015 ,		3
1786	Antiplatelet therapy in acute coronary syndromes. 2015 , 16, 2133-47		19
1785	Atherosclerosis, neoatherosclerosis, and vascular disease. European Heart Journal, 2015 , 36, 2121-3	9.5	3
1784	Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis. 2015 , 386, 655-64		186
1783	Stable coronary artery disease: revascularisation and invasive strategies. 2015 , 386, 702-13		108
1782	Duration of clopidogrel-based dual antiplatelet therapy and clinical outcomes after endeavor sprint zotarolimus-eluting stent implantation in patients presenting with acute coronary syndrome. 2015 , 26, 521-7		4
1781	Novel Antiplatelet Agents: The Current State and What Is Coming Down the Pike. 2015 , 58, 267-77		16
1780	Cardiovascular evaluation of potential transplant recipient: from non-US perspective. 2015 , 87, 863		
1779	The authors reply. 2015 , 87, 863-4		

	Detection of viable myocardium and scar tissue. 2015 , 16, 1062-4	10
1777	Differential Prognostic Effect Between First- and Second-Generation Drug-Eluting Stents in Coronary Bifurcation Lesions: Patient-Level Analysis of the Korean Bifurcation Pooled Cohorts. 2015 , 8, 1318-1331	25
1776	Drug coated balloon angioplasty in elderly patients with small vessel coronary disease. 2015 , 9, 389-96	9
1775	Controversies in Cardiology. 2015 ,	
1774	Severity of Remodeling, Myocardial Viability, and Survival in Ischemic LV Dysfunction After Surgical Revascularization. 2015 , 8, 1121-1129	38
1773	Myths to Debunk to Improve Management, Referral, and Outcomes in Patients With Chronic Total Occlusion of an Epicardial Coronary Artery. 2015 , 116, 1774-80	53
1772	Percutaneous coronary intervention in the UK: recommendations for good practice 2015. 2015 , 101 Suppl 3, 1-13	68
1771	Percutaneous coronary intervention: FAME is lasting. 2015 , 386, 1806-7	3
1770	Stent Fracture After Sirolimus-Eluting Stent Implantation: 8-Year Clinical Outcomes. 2015, 8, e002664	14
1769	Actualits en mäecine dâlirgence. 2015 , 5, 280-286	
1768	Adenosine as an Adjunct Therapy in ST Elevation Myocardial Infarction Patients: Myth or Truth?. 2015 , 29, 481-93	7
1768 1767		7
1767	2015, 29, 481-93 Management strategies in patients affected by chronic total occlusions: results from the Italian	
1767	2015, 29, 481-93 Management strategies in patients affected by chronic total occlusions: results from the Italian Registry of Chronic Total Occlusions. <i>European Heart Journal</i> , 2015, 36, 3189-98 9.5	120
1767 1766	2015, 29, 481-93 Management strategies in patients affected by chronic total occlusions: results from the Italian Registry of Chronic Total Occlusions. <i>European Heart Journal</i> , 2015, 36, 3189-98 Aspirin dosing in cardiovascular disease prevention and management: an update. 2015, 40, 499-511 Comparison of combination therapy of high-dose oral N-acetylcysteine and intravenous sodium bicarbonate hydration with individual therapies in the reduction of Contrast-induced Nephropathy	120
1767 1766 1765	Management strategies in patients affected by chronic total occlusions: results from the Italian Registry of Chronic Total Occlusions. <i>European Heart Journal</i> , 2015 , 36, 3189-98 Aspirin dosing in cardiovascular disease prevention and management: an update. 2015 , 40, 499-511 Comparison of combination therapy of high-dose oral N-acetylcysteine and intravenous sodium bicarbonate hydration with individual therapies in the reduction of Contrast-induced Nephropathy during Cardiac Catheterisation and Percutaneous Coronary Intervention (CONTRAST): A Long-term ticagrelor therapy in patients with prior myocardial infarction significantly reduces	120 4 29
1767 1766 1765	Management strategies in patients affected by chronic total occlusions: results from the Italian Registry of Chronic Total Occlusions. <i>European Heart Journal</i> , 2015 , 36, 3189-98 Aspirin dosing in cardiovascular disease prevention and management: an update. 2015 , 40, 499-511 Comparison of combination therapy of high-dose oral N-acetylcysteine and intravenous sodium bicarbonate hydration with individual therapies in the reduction of Contrast-induced Nephropathy during Cardiac Catheterisation and Percutaneous Coronary Intervention (CONTRAST): A Long-term ticagrelor therapy in patients with prior myocardial infarction significantly reduces ischaemic events, albeit with increased bleeding. 2015 , 20, 132	120 4 29

1760	Switch From a Long-term to a Short-term Ventricular Assist Device as a Bridge to Heart Transplantation. 2015 , 68, 636-8		
1759	Duration of Dual Antiplatelet Therapy After Drug-eluting Stents Implantation: The Jury Is Still Out. 2015 , 68, 827-9		
1758	Are We Following the Recommendations of the Clinical Guidelines? Another Point of View. 2015 , 68, 910		
1757	A conservative strategy in non-ST-segment elevation myocardial infarction - constraints and prognosis: The situation in Portugal. 2015 , 34, 315-28		7
1756	Intracoronary abciximab in diabetic patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. 2015 , 73, 32-7		5
1755	Balfi de contrapulsacifi: ¿ha llegado el momento de su jubilacifi?. 2015 , 15, 25-30		
1754	[Evolution of cardiovascular risk factors in patients undergoing percutaneous coronary intervention]. 2015 , 25, 171-6		
1753	Left main reconstruction as an alternative method to CABG after primary PCI complication. 2015 , 67, 259-61		1
1752	Intracoronary vs intravenous abciximab in interventional cardiology: A reopened question?. 2015 , 73, 8-10		2
1751	Treatment strategies for coronary in-stent restenosis: systematic review and hierarchical Bayesian network meta-analysis of 24 randomised trials and 4880 patients. 2015 , 351, h5392		77
1750	Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack: Results from TRA 2°P-TIMI 50. 2015 , 132, 1871-9		30
1749	Comparative Effectiveness and Safety of New-Generation Versus Early-Generation Drug-Eluting Stents According to Complexity of Coronary Artery Disease: A Patient-Level Pooled Analysis of 6,081 Patients. 2015 , 8, 1657-66		22
1748	Effect of Intravascular Ultrasound-Guided vs Angiography-Guided Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial. 2015 , 314, 2155-63		258
1747	[Management of patients treated for acute ST-elevation myocardial infarction in Tunisia: Preliminary results of FAST-MI Tunisia Registry from Tunisian Society of Cardiology and Cardiovascular Surgery]. 2015 , 64, 439-45		4
1746	Molecular mechanism of endothelial and vascular aging: implications for cardiovascular disease. <i>European Heart Journal</i> , 2015 , 36, 3392-403	9.5	145
1745	Paclitaxel-eluting balloon and everolimus-eluting stent for provisional stenting of coronary bifurcations: 12-month results of the multicenter BIOLUX-I study. 2015 , 16, 413-7		28
1744	The benefits of revascularization in chronic heart failure. 2015 , 12, 112-9		8
1743	Long-term secondary prevention after high-risk stenting: a good drug for a bad stent. 2015 , 131, 13-6		3

1742	6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial. 2015 , 65, 777-786	266
1741	Long term experience with a novel interventional cardiology network model: Learned lessons. 2016 , 5, 87	4
1740	Single coronary artery originating from the right sinus Valsalva presenting as typical angina pectoris. 2016 , 2016,	
1739	Prognostic Value of Gai's Plaque Score and Agatston Coronary Artery Calcium Score for Functionally Significant Coronary Artery Stenosis. 2016 , 129, 2792-2796	2
1738	Shorter- versus Longer-duration Dual Antiplatelet Therapy in Patients with Diabetes Mellitus Undergoing Drug-eluting Stents Implantation: A Meta-analysis of Randomized Controlled Trials. 2016 , 129, 2861-2867	3
1737	CLINICAL CASE OF THROMBOLYTIC THERAPY OF RECURRENT ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION IN PATIENT WITH LONG HISTORY OF ISCHEMIC HEART DISEASE. 2016 , 12, 302-305	
1736	Diagnostic performance of non-invasive fractional flow reserve derived from coronary computed tomography angiography: current perspectives. 2016 , 1	
1735	Clinical significance of new oral anticoagulants in the prevention of thromboembolic complications in patients with atrial fibrillation: not all dreams come true. 2016 , 12, 465-470	1
1734	Peri- and postinterventional antithrombotic therapy in TAVI. Do we need antiplatelet therapy?. 2016 , 36, 44-5	
1733	Koronarerkrankungen âlaktuelle Momentaufnahme in Deutschland. 2016 , 24, 95-97	
1732	Cost and efficacy of myocardial revascularization in the drug-eluting stent era: how much for how much?. 2016 , 2, 225-228	
1731	Fractional Flow Reserve Measurement by Coronary Computed Tomography Angiography: A Review with Future Directions. 2016 , 2, 125-135	1
1730	Dual anti-platelet therapy after coronary drug-eluting stent implantation and surgery-associated major adverse events. 2016 , 116, 172-80	10
1729	"One-Time" versus Staged Multivessel Intervention in Intermediate to Very High-Risk Patients with Non-ST-Segment Elevation Acute Coronary Syndromes. 2016 , 46, 774-783	3
1728	Evaluation of safety and efficacy of NexGen - an ultrathin strut and hybrid cell design cobalt-chromium bare metal stent implanted in a real life patient population - the Polish NexGen Registry. 2016 , 12, 217-23	6
1727	Comparison of Percutaneous Coronary Intervention Versus Coronary Artery Bypass Graft in Aged Patients With Unprotected Left Main Artery Lesions. 2016 , 57, 682-688	13
1726	Improving outcomes in coronary artery disease. 2016 , 205, 111-2	
1725	Head to Head Comparison of Two Point-of-care Platelet Function Tests Used for Assessment of On-clopidogrel Platelet Reactivity in Chinese Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention. 2016 , 129, 2269-74	9

1724	Coronary artery disease (CAD) in chronic kidney disease patients. 2016 , 28, 44-52	1
1723	Primary left main coronary artery thrombus aspiration as a standalone treatment: sailing in uncharted waters. 2016 , 12, 258-61	1
1722	Physiologic Assessment of Coronary Artery Disease: Focus on Fractional Flow Reserve. 2016 , 17, 307-20	7
1721	Efficacy and safety outcomes of fractional flow reserve in guiding clinical therapy of non-ST-segment elevation myocardial infarction compared with angiography alone in elderly Chinese patients. 2016 , 11, 1751-1754	6
1720	Noninvasive FFR derived from coronary CT angiography in the management of coronary artery disease: technology and clinical update. 2016 , 12, 269-78	21
1719	Impact of coexisting multivessel coronary artery disease on short-term outcomes and long-term survival of patients treated with carotid stenting. 2016 , 12, 760-5	1
1718	Influence of segmented vessel size due to limited imaging resolution on coronary hyperemic flow prediction from arterial crown volume. 2016 , 310, H839-46	3
1717	Potential Utility of the SYNTAX Score 2 in Patients Undergoing Left Main Angioplasty. 2016 , 106, 270-8	3
1716	Syntax Score and Major Adverse Cardiac Events in Patients with Suspected Coronary Artery Disease: Results from a Cohort Study in a University-Affiliated Hospital in Southern Brazil. 2016 , 107, 207-215	5
1715	Bioresorbable vascular scaffolds in patients with acute myocardial infarction: a new step forward to optimized reperfusion?. 2016 , 8, E417-23	6
1714	Preventive percutaneous coronary intervention and aspiration thrombectomy-updates in the management of ST-elevation myocardial infarction. 2016 , 8, 1908-12	4
1713	Stenting or bypass surgery for unprotected left main coronary artery disease-still a long rally to go. 2016 , 8, 2292-2295	2
1712	Shedding light on the mechanisms of stent thrombosis with optical coherence tomography. 2016 , 8, E1057-E1059	
1711	Drug-eluting stent restenosis treatment: an "old" stent, a "new" balloon or a "newer" scaffold?. 2016 , 8, 3478-3483	O
1710	Understanding and managing in-stent restenosis: a review of clinical data, from pathogenesis to treatment. 2016 , 8, E1150-E1162	160
1709	Percutaneous coronary intervention versus bypass grafting in left main coronary artery disease. 2016 , 8, 2677-2679	
1708	No clinical benefit from manual thrombus aspiration in patients with non-ST-elevation myocardial infarction. 2016 , 12, 32-40	
1707	Risk factors for in-hospital mortality after coronary artery bypass grafting in patients 80 years old or older: a retrospective case-series study. 2016 , 4, e2667	4

Evidence and controversies regarding the screening for subclinical hypothyroidism in patients with 1706 cardiovascular disease. 2016, 8, E446-50 1705 Dual antiplatelet therapy duration after drug-eluting stents: how long?. 2016, 8, E844-6 4 1704 Myocardial revascularization: do age and sex matter?. 2016, 8, E1244-E1248 2 1703 What is the Optimal Duration of Dual Antiplatelet Therapy After Stenting?. 2016, 1, 233-243 Unakzeptabel hohe Letalitesrate bei Myokardinfarktpatienten: Was 'tun? Der Beitrag eines 1702 1 integrierten Qualitesmanagement-Ansatzes. Eine Fallstudie aus der Schweiz.. 2016, 21, 295-299 1701 Fractional Flow Reserve Assessment of Coronary Artery Stenosis. 2016, 11, 77-82 4 1700 Repeat revascularization after coronary bypass graft surgery. 2016, 22, 169-174 1699 Coronary microvascular dysfunction: a great challenge for Cardiology. 2016, 10, 1 Fractional Flow Reserve Assessment of a Significant Coronary Stenosis Masked by a Downstream 1698 Serial Lesion. 2016, 2016, 1987238 Ramipril and Losartan Exert a Similar Long-Term Effect upon Markers of Heart Failure, Endogenous Fibrinolysis, and Platelet Aggregation in Survivors of ST-Elevation Myocardial Infarction: A Single 4 Centre Randomized Trial. 2016, 2016, 9040457 Oral anticoagulants in coronary heart disease (Section IV). Position paper of the ESC Working Group 1696 21 on Thrombosis - Task Force on Anticoagulants in Heart Disease. 2016, 115, 685-711 1695 Coronary stent technology: a narrative review. 2016, 205, 277-81 12 Extracorporeal Membrane Oxygenation as a Bridge for Heart Failure and Cardiogenic Shock. 2016, 1694 5 2016, 7263187 Spotlight on unmet needs in stroke prevention: The PIONEER AF-PCI, NAVIGATE ESUS and GALILEO 7 trials. 2016, 116, S33-S40 Percutaneous assist devices in acute myocardial infarction with cardiogenic shock: Review, 1692 16 meta-analysis. 2016, 8, 98-111 Off-pump Coronary Artery Bypass Grafting as a Standard Surgical Revascularization Strategy. 2016, 1691 22. 231-238 1690 The Role of Cardiovascular Magnetic Resonance Imaging in Heart Failure. 2016, 2, 115-122 21 Mortality in primary angioplasty patients starting antiplatelet therapy with prehospital prasugrel or 1689 5

clopidogrel: a 1-year follow-up from the European MULTIPRAC Registry. 2016, 12, 143-51

1688	Extracorporeal Membrane Oxygenation Support for Complex Percutaneous Coronary Interventions in Patients without Cardiogenic Shock. 2016 ,	2
1687	Patient profile and periprocedural outcomes of bioresorbable vascular scaffold implantation in comparison with drug-eluting and bare-metal stent implantation. Experience from ORPKI Polish National Registry 2014-2015. 2016 , 12, 321-328	9
1686	New Approaches to the Role of Thrombin in Acute Coronary Syndromes: Quo Vadis Bivalirudin, a Direct Thrombin Inhibitor?. 2016 , 21, 284	2
1685	Intensive plaque modification with rotational atherectomy and cutting balloon before drug-eluting stent implantation for patients with severely calcified coronary lesions: a pilot clinical study. 2016 , 16, 112	9
1684	Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. Results from a prospective, randomised, double-blind, placebo-controlled study. 2016 , 115, 622-31	21
1683	Prevention of cardiovascular events with antiplatelet treatment: does time of intake matter for aspirin and ADP receptor blockers?. 2016 , 115, 3-6	7
1682	Association between the Gensini Score and Carotid Artery Stenosis. 2016 , 46, 639-645	21
1681	Comparison of dual antiplatelet therapy prescribed as one-pill versus two-pill regimen. A pooled analysis of individual patient data from the three MR-CAPCIS trials. 2016 , 116, 78-86	3
1680	The benefits of drug-eluting stents in the treatment of coronary artery disease. 2016 , 9	1
1679	Comorbidities on kidney transplantation waiting list relative to the status of the potential recipient. 2018 , 14, 941-944	3
1678	Which platelet function test best reflects the in vivo plasma concentrations of ticagrelor and its active metabolite? The HARMONIC study. 2016 , 116, 1140-1149	9
1677	Multimodality Imaging for Left Ventricular Hypertrophy Severity Grading: A Methodological Review. 2016 , 24, 257-267	17
1676	Antithrombotic management in patients with percutaneous coronary intervention requiring oral anticoagulation. 2016 , 12, 290-302	2
1675	Relationship between high on aspirin platelet reactivity and oxidative stress in coronary artery by-pass grafted patients. 2016 , 27, 151-5	3
1674	Comparison of long-term prognostic value of baseline SYNTAX and clinical SYNTAX scores in ST-segment elevation myocardial infarction patients with multivessel disease. 2016 , 27, 311-8	3
1673	Early and late diastolic strain rate vs global longitudinal strain at rest and during dobutamine stress for the assessment of significant coronary artery stenosis in patients with a moderate and high probability of coronary artery disease. 2016 , 33, 1512-1522	13
1672	Pancreatic cancer control: is vitamin D the answer?. 2016 , 25, 188-95	6
1671	Antiplatelet and Anticoagulation Treatment in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome: Comparison of the Updated North American and European Guidelines. 2016 , 24, 170-6	2

1670	Assessment of Ticagrelor Versus Clopidogrel Treatment in Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. 2016 , 68, 115-20	24
1669	Combined Coronary Revascularization: Single-Center 10-Year Experience. 2016 , 11, 40-5; discussion 45	
1668	Fo ATP synthase C subunit serum levels in patients with ST-segment Elevation Myocardial Infarction: Preliminary findings. 2016 , 221, 993-7	19
1667	Preprocedural High-Sensitivity Cardiac Troponin T and Clinical Outcomes in Patients With Stable Coronary Artery Disease Undergoing Elective Percutaneous Coronary Intervention. 2016 , 9,	13
1666	Clinical recommendations on Cardiac-CT in 2015: a position paper of the Working Group on Cardiac-CT and Nuclear Cardiology of the Italian Society of Cardiology. 2016 , 17, 73-84	15
1665	Diagnostic value of ischemia severity at myocardial perfusion imaging in elderly persons with suspected coronary disease. 2016 , 17, 719-28	3
1664	Comparison of Immature Platelet Count to Established Predictors of Platelet Reactivity During Thienopyridine Therapy. 2016 , 68, 286-293	45
1663	Predictors of Early (1-Week) Outcomes Following Left Atrial Appendage Closure With Amplatzer Devices. 2016 , 9, 1374-83	34
1662	The effectiveness of intra-aortic balloon pump for myocardial infarction in patients with or without cardiogenic shock: a meta-analysis and systematic review. 2016 , 16, 148	11
1661	Results From the International Drug Coated Balloon Registry for the Treatment of Bifurcations. Can a Bifurcation Be Treated Without Stents?. 2016 , 29, 348-56	10
1660	Angiographic and clinical outcomes of patients treated with everolimus-eluting bioresorbable stents in routine clinical practice: Results of the ISAR-ABSORB registry. 2016 , 87, 822-9	22
1659	SYNTAX score-0 patients: risk stratification in nonobstructive coronary artery disease. 2016 , 105, 901-911	9
1658	Method for Studying the Myocardial Blood Flow Reserve by Load Dynamic Single-Photon Emission Computed Tomography. 2016 , 160, 864-6	1
1657	Effect of Fractional Flow Reserve (â@.90 vs >0.90) on Long-Term Outcome (>10 Years) in Patients With Nonsignificant Coronary Arterial Narrowings. 2016 , 118, 465-72	
1656	Minimally Invasive Multivessel Coronary Surgery and Hybrid Coronary Revascularization: Can We Routinely Achieve Less Invasive Coronary Surgery?. 2016 , 12, 14-9	19
1655	The descending branch of the lateral circumflex femoral artery as an alternative conduit for coronary artery bypass grafting: Experience from an anatomical, radiological and histological study. 2016 , 29, 779-88	7
1654	Revascularization heart team recommendations as an adjunct to appropriate use criteria for coronary revascularization in patients with complex coronary artery disease. 2016 , 88, E103-E112	22
1653	Planned versus provisional rotational atherectomy for severe calcified coronary lesions: Insights From the ROTATE multi-center registry. 2016 , 88, 881-889	24

1652	Sustained increase in platelet aggregation after the cessation of clopidogrel. 2016 , 43, 161-5		1
1651	Absolute Myocardial Blood Flow and Flow Reserve Assessed by Gated SPECT with Cadmium-Zinc-Telluride Detectors Using 99mTc-Tetrofosmin: Head-to-Head Comparison with 13N-Ammonia PET. 2016 , 57, 1887-1892		69
1650	Myocardial perfusion 320-row multidetector computed tomography-guided treatment strategy for the clinical management of patients with recent acute-onset chest pain: Design of the CArdiac cT in the treatment of acute CHest pain (CATCH)-2 randomized controlled trial. 2016 , 179, 127-35		4
1649	Revascularization for Left Anterior Descending Artery Stenosis: A Review of the Evidence That Supports Practice. 2016 , 24, 136-40		1
1648	Anesthesia for the Endovascular Management of Aortic Disease. 2016 , 54, 52-75		1
1647	Clinical Value of CYP2C19 Genetic Testing for Guiding the Antiplatelet Therapy in a Chinese Population. 2016 , 67, 232-6		46
1646	Dynamic changes in left ventricular function after a percutaneous coronary intervention: prevalence, predictors, and prognosis. 2016 , 27, 199-206		1
1645	Eminence, common sense, and evidence: a comment to the Andreas Grîtzig lecture 2015. European Heart Journal, 2016 , 37, 2020-2	9.5	1
1644	Thin strut bare metal stents in patients with atrial fibrillation: Is there still a need for BMS?. 2016 , 88, 358-66		9
1643	Rotational atherectomy before paclitaxel-eluting stent implantation in complex calcified coronary lesions: Two-year clinical outcome of the randomized ROTAXUS trial. 2016 , 87, 691-700		50
1642	PREDICT score and CYP2C19 polymorphism independently predict lack of efficacy of clopidogrel in cardiology patients. 2016 , 43, 379-81		3
1641	State of the art: Oral antiplatelet therapy. 2016 , 5, 2048004016652514		5
1640	Preoperative intra-aortic balloon pump improves the clinical outcomes of off-pump coronary artery bypass grafting in left ventricular dysfunction patients. 2016 , 6, 27645		13
1639	Switching between thienopyridines in patients with acute myocardial infarction and quality of care. 2016 , 3, e000384		8
1638	Does cardiac rehabilitation favour the young over the old?. 2016 , 3, e000450		10
1637	Contemporary assessment of coronary hemodynamics in the catheter laboratory. 2016 , 12, 601-604		
1636	Stable Coronary Artery Disease. 2016 , 138-147		
1635	The Management of Cardiogenic Shock and Hemodynamic Support Devices and Techniques. 2016 , 163-	167	

1634	Percutaneous Coronary Intervention in Unprotected Left Main. 2016 , 168-174	
1633	Percutaneous Coronary Intervention of Arterial and Vein Grafts. 2016 , 201-204	1
1632	In-Stent Restenosis in New Generation DES Era. 2016 , 213-223	
1631	Thrombus-Containing Lesions. 2016 , 233-243	
1630	Specialized Balloons in Percutaneous Coronary Intervention. 2016 , 244-247	
1629	Renal Insufficiency and the Impact of Contrast Agents. 2016 , 274-281	
1628	Balance of Ischemia and Bleeding in Selecting Antithrombotic Regimens. 2016 , 389-396	
1627	Parenteral Anticoagulant Agents in PCI. 2016 , 408-414	
1626	Parenteral Antiplatelet Agents in PCI. 2016 , 415-420	
1625	The Optimal Duration of Dual Antiplatelet Therapy After PCI. 2016 , 436-442	
	The Optimal Duration of Dual Antiplatelet Therapy After PCI. 2016, 436-442 Screening of Coronary Artery Disease in Diabetic Patients: Who and How? - Reply. 2016, 80, 544	
		14
1624	Screening of Coronary Artery Disease in Diabetic Patients: Who and How? - Reply. 2016 , 80, 544 The IMPACT Study (Influence of Sensor-Equipped Microcatheters on Coronary Hemodynamics and	14 5
1624	Screening of Coronary Artery Disease in Diabetic Patients: Who and How? - Reply. 2016 , 80, 544 The IMPACT Study (Influence of Sensor-Equipped Microcatheters on Coronary Hemodynamics and the Accuracy of Physiological Indices of Functional Stenosis Severity). 2016 , 9,	
1624 1623 1622	Screening of Coronary Artery Disease in Diabetic Patients: Who and How? - Reply. 2016, 80, 544 The IMPACT Study (Influence of Sensor-Equipped Microcatheters on Coronary Hemodynamics and the Accuracy of Physiological Indices of Functional Stenosis Severity). 2016, 9, Early Invasive Strategy for Unstable Angina: a New Meta-Analysis of Old Clinical Trials. 2016, 6, 27345 Unfractionated Heparin during the Interruption of Antiplatelet Therapy for Non-cardiac Surgery	5
1624 1623 1622	Screening of Coronary Artery Disease in Diabetic Patients: Who and How? - Reply. 2016, 80, 544 The IMPACT Study (Influence of Sensor-Equipped Microcatheters on Coronary Hemodynamics and the Accuracy of Physiological Indices of Functional Stenosis Severity). 2016, 9, Early Invasive Strategy for Unstable Angina: a New Meta-Analysis of Old Clinical Trials. 2016, 6, 27345 Unfractionated Heparin during the Interruption of Antiplatelet Therapy for Non-cardiac Surgery after Drug-eluting Stent Implantation. 2016, 55, 333-7 Adverse clinical outcomes associated with a low dose and a high dose of aspirin following	5
1624 1623 1622 1621	Screening of Coronary Artery Disease in Diabetic Patients: Who and How? - Reply. 2016, 80, 544 The IMPACT Study (Influence of Sensor-Equipped Microcatheters on Coronary Hemodynamics and the Accuracy of Physiological Indices of Functional Stenosis Severity). 2016, 9, Early Invasive Strategy for Unstable Angina: a New Meta-Analysis of Old Clinical Trials. 2016, 6, 27345 Unfractionated Heparin during the Interruption of Antiplatelet Therapy for Non-cardiac Surgery after Drug-eluting Stent Implantation. 2016, 55, 333-7 Adverse clinical outcomes associated with a low dose and a high dose of aspirin following percutaneous coronary intervention: a systematic review and meta-analysis. 2016, 16, 169 Infarct size and left ventricular remodelling after preventive percutaneous coronary intervention.	545

1616	Assessment of platelet function in patients receiving tirofiban early after primary coronary intervention. 2016 , 8, 135-140		1
1615	The prognostic utility of GRACE risk score in predictive cardiovascular event rate in STEMI patients with successful fibrinolysis and delay intervention in non PCI-capable hospital: a retrospective cohort study. 2016 , 16, 212		6
1614	Comparison between National Institute for Health and Care Excellence (NICE) and European Society of Cardiology (ESC) guidelines for the diagnosis and management of stable angina: implications for clinical practice. 2016 , 3, e000406		7
1613	Drug-eluting stents versus bare-metal stents for stable ischaemic heart disease. 2016 ,		1
1612	Mortality pattern and cause of death in a long-term follow-up of patients with STEMI treated with primary PCI. 2016 , 3, e000405		34
1611	Prasugrel Use in Real Life: A Report From the Outpatient Setting in France. 2016 , 39, 378-84		1
1610	Plaque Modification of Calcified Vessels-Orbital Atherectomy. 2016 , 6, 163-168		
1609	Acute coronary syndromes and diabetes mellitus. 2016 , 57, 375-377		12
1608	Outcome of cardiac surgery in patients with low preoperative ejection fraction. 2016 , 16, 97		52
1607	[Ischemic burden vs. coronary artery morphology: What is crucial for the indication of revascularization?]. 2016 , 41, 376-83		
1606	Do acute myocardial infarction and stroke mortality vary by distance to hospitals in Switzerland? Results from the Swiss National Cohort Study. 2016 , 6, e013090		10
1605	Drug-Eluting or Bare-Metal Stents for Coronary Artery Disease. 2016 , 375, 2604-2605		5
1604	Fractional flow reserve to guide and to assess coronary artery bypass grafting. <i>European Heart Journal</i> , 2017 , 38, 1959-1968	5	15
1603	Kommentar zu den â½014 ESC/EACTS Guidelines on Myocardial Revascularizationâlder European Society of Cardiology (ESC) und der European Association for Cardio-Thoracic Surgery (EACTS). 2016 , 10, 359-370		1
1602	Current Approach to Heart Failure. 2016 ,		
1601	[Myocardial ischaemia detection in women]. 2016 , 65, 433-439		
1600	Percutaneous treatment of left main disease: Still learning about the optimal PCI strategy. 2016 , 17, 494-496		1
1599	Myocardial Revascularization in Heart Failure. 2016 , 229-241		

	After Both First-Generation and Second-Generation Drug-Eluting Stent occurs in Patients With Drug-Eluting Stent Restenosis. 2016 , 9,	6
Revascularizatio 1597 on Clinical Practi	on of Unprotected Left Main Coronary Artery Disease: Implications of Evolving Data ice. 2016 , 9,	3
	s Surgery Versus Percutaneous Coronary Intervention in Left Main and Multivessel ental Data-How Do We Apply It?. 2016 , 9, 2490-2492	
	Bypass Surgery Versus Drug-Eluting Stent Implantation for Left Main or Data. 2016 , 9, 2481-2489	31
1594 Nationale Verso	orgungsleitlinie (NVL) Chronische KHK. 2016 , 13, 50-68	
	plete Percutaneous Revascularization in Patients With Multivessel Coronary Artery matic Review and Meta-Analysis. 2016 , 5,	23
1592 Drug-eluting ste	ents versus bare-metal stents for acute coronary syndrome. 2016 ,	2
	nised Controlled Trial and Feasibility Study of Future Care Planning in Patients with Disease. 2016 , 6, 24619	21
	elor yields an antiplatelet efficacy similar to that of standard-dose ticagrelor in an open-label randomized controlled trial. 2016 , 6, 31838	12
	ediction of Culprit Lesion Coronary Artery Disease and 1-Year Major Adverse rdiovascular Events in Patients with Acute Stroke. 2016 , 7, 180-5	2
1588 Identifying stabl	le coronary plaques with OCT technology. 2016 , 2, 77-88	2
	cular Ultrasound in the Detection of Cardiovascular Disease in Diabetes and rome in Latin America. 2016 , 9, 1	
	hronic kidney disease with periprocedural myocardial injury after elective stent single center prospective cohort study. 2016 , 95, e5381	5
	-month versus 12-month dual antiplatelet therapy after drug-eluting stent meta-analysis and meta-regression. 2016 , 95, e5819	9
	vation Myocardial Infarction Due to Severe Ostial Left Main Stem Stenosis in a philitic Aortitis. 2016 , 54, 74-9	2
	mparison of drug-eluting versus bare-metal stenting in patients with non-ST ardial infarction. 2016 , 3, e000455	7
	Long-segment Stenting With Everolimus-eluting Bioresorbable Scaffolds Focusing of Overlapping Implantation. 2016 , 69, 1144-1151	1
	mplante de armazfi bioabsorbible de éverolimus en segmentos largos atendiendo colapamiento de armazones. 2016 , 69, 1144-1151	2

1580	Gua ESC 2016 sobre el diagnatico y tratamiento de la insuficiencia cardiaca aguda y craica. 2016 , 69, 1167.e1-1167.e85	91
1579	Are drug-eluting stents any better than bare metal? New evidence in non-ST-elevation acute coronary syndrome. 2016 , 3, e000536	
1578	[Transcatheter aortic valve implantation and internal carotid artery stenting in a 74-year-old female patient]. 2016 , 57, 1235-1242	
1577	Meta-Analysis of the Duration of Dual Antiplatelet Therapy in Patients Treated With Second-Generation Drug-Eluting Stents. 2016 , 117, 1714-23	46
1576	Cardiovascular PET-CT imaging: a new frontier?. 2016 , 71, 647-59	3
1575	Contemporary Reflections on the Safety of Long-Term Aspirin Treatment for the Secondary Prevention of Cardiovascular Disease. 2016 , 39, 715-27	8
1574	Direct oral anticoagulant use and stent thrombosis following an acute coronary syndrome: A potential new pharmacological option?. 2016 , 109, 359-69	О
1573	Optical Coherence Tomography in Grafts. 2016 , 539-554	
1572	Beyond Stenosis With Fractional Flow Reserve Via Computed Tomography and Advanced Plaque Analyses for the Diagnosis of Lesion-Specific Ischemia. 2016 , 32, 1315.e1-1315.e9	3
1571	Sex-Based Differences in Acute Coronary Syndromes: Insights From Invasive and Noninvasive Coronary Technologies. 2016 , 9, 451-64	24
1570	Management of stable angina: A commentary on the European Society of Cardiology guidelines. 2016 , 23, 1401-12	22
1569	Stress-induced ST elevation with or without concomitant ST depression is predictive of presence, location and amount of myocardial ischemia assessed by myocardial perfusion SPECT, whereas isolated stress-induced ST depression is not. 2016 , 49, 307-15	2
1568	Using bilateral internal thoracic arteries-just do it. 2016 , 152, 128-30	1
1567	Impact of severe lesion calcification on clinical outcome of patients with stable angina, treated with newer generation permanent polymer-coated drug-eluting stents: A patient-level pooled analysis from TWENTE and DUTCH PEERS (TWENTE II). 2016 , 175, 121-9	27
1566	Smoking Cessation and Health Economics. 2016 , 57, 67-9	1
1565	Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention. 2016 , 133, 2094-8	18
1564	Repeat revascularization: Percutaneous coronary intervention after coronary artery bypass graft surgery. 2016 , 17, 272-8	13
1563	First fusion and combined evaluation of 3D-CMR perfusion with 3D-MR coronary angiography. 2016 , 202, 62-3	4

1562	Optical frequency domain imaging vs. intravascular ultrasound in percutaneous coronary intervention (OPINION trial): Study protocol for a randomized controlled trial. 2016 , 68, 455-460	27
1561	Multiple arterial grafting: Please don't confuse me with the facts. 2016 , 152, 380-1	
1560	Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary PCI: An updated meta-analysis of 10,350 patients from five randomized clinical trials. 2016 , 5, 253-62	43
1559	Optimal antithrombotic treatment in patients with atrial fibrillation and coronary stents: an update. 2016 , 31, 356-65	1
1558	Can We Just Rely on Contrast?. 2016 , 32, 717-9	
1557	The Clinical Significance and Management Implications of Chronic Total Occlusion Associated With Surgical Coronary Artery Revascularization. 2016 , 32, 1286-1289	5
1556	Successful resolution of left ventricular thrombus with apixaban treatment. 2016 , 2, 57-58	13
1555	Evaluation of a 'color coding' system for the assessment of patients undergoing primary percutaneous coronary intervention. 2016 , 212, 371-6	3
1554	Does Uncontrolled Platelet Activation Promote Coronary Artery Disease?. 2016 , 9, 855-857	2
1553	Utilizing Post-Intervention Fractional Flow Reserve to Optimize Acute Results and the Relationship to Long-Term Outcomes. 2016 , 9, 1022-31	83
1552	Angiographic and Clinical Outcomes After Everolimus-Eluting Stenting for Unprotected Left Main Disease and High Anatomic Coronary Complexity. 2016 , 9, 1001-7	12
1551	N-terminal pro-B-type natriuretic peptide is associated with aortic stiffness in patients presenting with acute myocardial infarction. 2016 , 5, 560-567	10
1550	Optimal P2Y12 Inhibitor for Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: Network Meta-Analysis in the Data-Free Zone: Do You Believe in Magic?. 2016 , 9, 1047-50	2
1549	Drug-eluting balloons in the treatment of de-novo coronary lesions: a meta-analysis of randomized-controlled trials. 2016 , 27, 467-77	1
1548	Ethnic Differences in Coronary Revascularisation following an Acute Coronary Syndrome in New Zealand: A National Data-linkage Study (ANZACS-QI 12). 2016 , 25, 820-8	7
1547	Rationale and design of the Affordability and Real-world Antiplatelet Treatment Effectiveness after Myocardial Infarction Study (ARTEMIS): A multicenter, cluster-randomized trial of P2Y12 receptor inhibitor copayment reduction after myocardial infarction. 2016 , 177, 33-41	11
1546	Optical coherence tomography: an experimental validation for vascular imaging of saphenous vein bypass grafts. 2016 , 2, 025002	1
1545	Vein graft failure: from pathophysiology to clinical outcomes. 2016 , 13, 451-70	155

1544	Long-Term (â l 0 Years) Safety of Percutaneous Treatment of Unprotected Left Main Stenosis With Drug-Eluting Stents. 2016 , 118, 32-9	16
1543	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of	7751
1542	Impact of diabetes on immature platelets fraction and its relationship with platelet reactivity in patients receiving dual antiplatelet therapy. 2016 , 42, 245-53	24
1541	Coronary angiography and myocardial revascularization following the first acute myocardial infarction in Norway during 2001-2009: Analyzing time trends and educational inequalities using data from the CVDNOR project. 2016 , 212, 122-8	12
1540	All-comer treatment with bioresorbable vascular scaffold. 2016 , 128, 210-4	
1539	Cardiac Positron Emission Tomography: a Clinical Perspective. 2016 , 9, 1	1
1538	Predictive Value of Neutrophil Gelatinase-Associated Lipocalin for Contrast-Induced Acute Kidney Injury After Cardiac Catheterization: A Meta-analysis. 2016 , 32, 1033.e19-29	16
1537	Is Prolonged DAPT Apt or a Study in Zero-Sum Games?. 2016 , 9, 148-50	
1536	Shorter (âß months) vs. longer (âß2 months) dual antiplatelet therapy after second-generation drug-eluting stents implantation: a meta-analysis of randomized controlled trials. 2016 , 18, A54-A62	3
1535	Temporal Evolution of Myocardial Hemorrhage and Edema in Patients After Acute ST-Segment Elevation Myocardial Infarction: Pathophysiological Insights and Clinical Implications. 2016 , 5,	72
1534	Logistical and financial obstacles for endovascular therapy of acute stroke implementation. 2016 , 11, 502-8	3
1533	Current Risk Scores for the Establishment of the Best Myocardial Revascularization Methods. 2016 , 101-129	
1532	Early CABG Failure. 2016 , 131-138	
1531	Disease Progression After CABG. 2016 , 139-144	
1530	Multivessel Disease, Risk of Graft Failure. 2016 , 155-160	
1529	Early Postoperative Care After CABG. 2016 , 75-97	
1528	Deferred versus conventional stent implantation in patients with ST-segment elevation myocardial infarction (DANAMI 3-DEFER): an open-label, randomised controlled trial. 2016 , 387, 2199-206	101
1527	Primary angioplasty for STEMI: hard to improve upon. 2016 , 387, 2166-8	

1526	Vasculopathy: the CART (Cardiac Allograft Reparative Therapy) Prospective Multicenter Pilot Study. 2016 , 9, 40-8	7
1525	Fractional flow reserve implementation in daily clinical practice: A European survey. 2016 , 207, 206-7	9
1524	Diabetes Mellitus and Prevention of Late Myocardial Infarction After Coronary Stenting in the Randomized Dual Antiplatelet Therapy Study. 2016 , 133, 1772-82	36
1523	Contemporary use of ticagrelor in patients with acute coronary syndrome: insights from Swedish Web System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART). 2016 , 2, 5-12	30
1522	Validation of a P2Y-receptor specific whole blood platelet aggregation assay. 2016 , 27, 668-672	5
1521	Three-year efficacy and safety of new- versus early-generation drug-eluting stents for unprotected left main coronary artery disease insights from the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 trials. 2016 , 105, 575-84	15
1520	Revascularization in complex multivessel coronary artery disease after FREEDOM. Is there an indication for PCI and drug-eluting stents?. 2016 , 41, 224-32	2
1519	Revascularization for Silent Myocardial Ischemia. 2016 , 111-124	
1518	Long-Term Clinical Outcomes After Bioresorbable Vascular Scaffold Implantation for the Treatment of Coronary In-Stent Restenosis: A Multicenter Italian Experience. 2016 , 9, e003148	25
1517	One-year incidence and clinical impact of bleeding events in patients treated with prasugrel or clopidogrel after ST-segment elevation myocardial infarction. 2016 , 109, 337-47	7
1516	Periprocedural antithrombotic therapy during various types of percutaneous cardiovascular interventions. 2016 , 2, 131-40	15
1515	Novel Sirolimus-Coated Balloon Catheter: In Vivo Evaluation in a Porcine Coronary Model. 2016 , 9, e003543	37
1514	What is the optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent implantation?. 2016 , 73, e229-37	1
1513	Contrast-induced acute kidney injury in patients with non-ST-segment elevation myocardial infarction undergoing early versus delayed invasive strategy. 2016 , 203, 638-9	1
1512	Comparing Performance of Risk Scores for Combined Aortic Valve Replacement and Coronary Bypass Grafting Surgery. 2016 , 25, 1118-1123	10
1511	Treatment of Patients With Stable Ischemic Heart DiseaseReply. 2016 , 315, 1905-6	
1510	Revascularization in Patients With Multivessel Coronary Artery Disease and Severe Left Ventricular Systolic Dysfunction: Everolimus-Eluting Stents Versus Coronary Artery Bypass Graft Surgery. 2016 , 133, 2132-40	86
1509	Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Left Ventricular Dysfunction: Do We Have the Evidence?. 2016 , 133, 2125-7	1

1508	Drug coated balloon angioplasty in the treatment of peripheral artery disease. 2016 , 13, 569-82	5
1507	One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trial. 2016 , 31, 196-209	39
1506	Intravascular ultrasound-guided drug-eluting stent implantation: An updated meta-analysis of randomized control trials and observational studies. 2016 , 216, 133-9	55
1505	Duration of dual antiplatelet therapy after various drug-eluting stent implantation. 2016 , 215, 157-66	8
1504	Integrity([]) bare-metal coronary stent-induced platelet and endothelial cell activation results in a higher risk of restenosis compared to Xience([]) everolimus-eluting stents in stable angina patients. 2016 , 27, 410-9	6
1503	Surgical ventricular reconstruction for ischaemic heart failure: state of the art. 2016 , 18, E8-E14	11
1502	Should Chronic Total Occlusion Be Treated With Coronary Artery Bypass Grafting? Chronic Total Occlusion Should Be Treated With Coronary Artery Bypass Grafting. 2016 , 133, 1807-16	9
1501	Treatment of Patients With Stable Ischemic Heart Disease. 2016 , 315, 1904-5	
1500	Surgical Decision Making. 2016 ,	2
1499	The left atrial appendage: from embryology to prevention of thromboembolism. <i>European Heart Journal</i> , 2017 , 38, 877-887	41
1498	Treatment of Patients With Stable Ischemic Heart DiseaseReply. 2016 , 315, 1906-7	
1497	Diagnostic performance of cardiac imaging methods to diagnose ischaemia-causing coronary artery disease when directly compared with fractional flow reserve as a reference standard: a 9.5 meta-analysis. <i>European Heart Journal</i> , 2017 , 38, 991-998	134
1496	Treatment of Patients With Stable Ischemic Heart Disease. 2016 , 315, 1905	1
1495	Quantification of the Effect of Pressure Wire Drift on the Diagnostic Performance of Fractional Flow Reserve, Instantaneous Wave-Free Ratio, and Whole-Cycle Pd/Pa. 2016 , 9, e002988	34
1494	To Revascularise or Not To Revascularise, That Is the Question: the Diagnostic and Management Conundrum of Ischaemic Cardiomyopathy. 2016 , 18, 54	2
1493	Regarding article, "A multi-artery fractional flow reserve (FFR) approach for handling coronary stenosis-stenosis interaction in the multi-vessel disease (MVD) arena". 2016 , 214, 526-7	
1492	Low-Intensity Pulsed Ultrasound Enhances Angiogenesis and Ameliorates Left Ventricular Dysfunction in a Mouse Model of Acute Myocardial Infarction. 2016 , 36, 1220-9	45
1491	Predictive performance of adding platelet reactivity on top of CRUSADE score for 1-year bleeding risk in patients with acute coronary syndrome. 2016 , 42, 360-8	10

(2016-2016)

1490	Underuse of coronary intervention and its impact on mortality in the elderly with myocardial infarction. A propensity-matched analysis from the Hungarian Myocardial Infarction Registry. 2016 , 214, 485-90	6
1489	Das akute Koronarsyndrom âDefinition, Untersuchungskomponenten und Therapiepfade. 2016 , 44, 588-593	
1488	Baduanjin Exercise Prevents post-Myocardial Infarction Left Ventricular Remodeling (BE-PREMIER trial): Design and Rationale of a Pragmatic Randomized Controlled Trial. 2016 , 30, 315-22	12
1487	Safety and Efficacy of Bivalirudin in Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: From the REPLACE-2, ACUITY and HORIZONS-AMI Trials. 2016 , 118, 6-16	4
1486	Cardiac Magnetic Resonance Imaging Before Coronary Artery Bypass Graft Surgery: Is It Ready for Risk Stratification?. 2016 , 25, 535-7	
1485	First report of the point-of-care TEG: A technical validation study of the TEG-6S system. 2016 , 27, 642-649	101
1484	Cerebrovascular Events After No-Touch Off-Pump Coronary Artery Bypass Grafting, Conventional Side-Clamp Off-Pump Coronary Artery Bypass, and Proximal Anastomotic Devices: A Meta-Analysis. 2016 , 5,	36
1483	Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable-Polymer Everolimus-Eluting Stent for Percutaneous Coronary Revascularization: 2-Year Results of the BIOSCIENCE Trial. 2016 , 5, e003255	45
1482	Should a prolonged duration of dual anti-platelet therapy be recommended to patients with diabetes mellitus following percutaneous coronary intervention? A systematic review and meta-analysis of 15 studies. 2016 , 16, 161	13
1481	Anatomic or Functional Evaluation as an Initial Test for Stable Coronary Artery Disease: A Propensity Score Analysis. 2016 , 57, 1364-9	8
1480	Left Main Coronary Artery Disease: Secular Trends in Patient Characteristics, Treatments, and Outcomes. 2016 , 68, 1233-1246	107
1479	Fifteen-year trends in the management of cardiogenic shock and associated 1-year mortality in elderly patients with acute myocardial infarction: the FAST-MI programme. 2016 , 18, 1144-52	34
1478	[The heart team in planning and performance of revascularization : ESC guidelines versus clinical routine]. 2016 , 41, 562-565	5
1477	Impact of Chronic Total Occlusion of the Coronary Artery on Long-Term Prognosis in Patients With Ischemic Systolic Heart Failure: Insights From the COMMIT-HF Registry. 2016 , 9, 1790-7	26
1476	Survival After Varying Revascularization Strategies in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Coronary Artery Disease: A Pairwise and Network Meta-Analysis. 2016 , 9, 1765-76	45
1475	Percutaneous Coronary Intervention for Multivessel Disease and ST-Segment Elevation Myocardial Infarction: When, Not Whether. 2016 , 9, 1777-9	1
1474	Integrated Myocardial Perfusion Imaging Diagnostics Improve Detection of Functionally Significant Coronary Artery Stenosis by 13N-ammonia Positron Emission Tomography. 2016 , 9,	58
	Impact of Angiographic Result After Predilatation on Outcome After Drug-Coated Balloon	

1472	[Intracoronary administration of antithrombotic agents via a perfusion balloon catheter in patients with ST-segment elevation myocardial infarction presenting with massive intraluminal thrombus and failed aspiration]. 2016 , 65, 299-305	
1471	Epidemiological characteristics, management and early outcomes of acute coronary syndromes in Greece: The PHAETHON study. 2016 , 57, 157-166	23
1470	Pulmonary arterial hypertension and quality of life in cardiology. Do we really need more studies?. 2016 , 57, 215-215	2
1469	Targeting percutaneous cardiovascular interventions at all who will benefit the most: The reality of the Eastern European countries. 2016 , 217 Suppl, S47-8	
1468	Optical coherence tomography guided treatment of recurrent drug-eluting stent failure using drug-eluting balloon. 2016 , 221, 32-3	0
1467	Peri-procedural Myocardial Infarction: If You Don't Take a Temperature, You Can't Find a Fever. 2016 , 69, 725-9	
1466	Infarto de miocardio periintervencifi: si no se mira la temperatura, no se puede detectar la fiebre. 2016 , 69, 725-729	0
1465	Guã ESC 2016 sobre prevenciñ de la enfermedad cardiovascular en la prŷtica clñica. 2016 , 69, 939.e1-939.e87	10
1464	Optimizing prevention and guideline-concordant care in Montenegro. 2016 , 217 Suppl, S32-6	3
1463	[Choosing wisely together with the patient]. 2016 , 57, 540-50	О
1463 1462	[Choosing wisely together with the patient]. 2016, 57, 540-50 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. 2016, 50, e1-e88	589
	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with	
1462	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. 2016 , 50, e1-e88 A multidisciplinary telehealth program in patients with combined chronic obstructive pulmonary	589
1462 1461	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. 2016, 50, e1-e88 A multidisciplinary telehealth program in patients with combined chronic obstructive pulmonary disease and chronic heart failure: study protocol for a randomized controlled trial. 2016, 17, 462 Endoscopic vein harvest in patients at high risk for leg wound complications: A cost-benefit analysis	589
1462 1461 1460	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. 2016, 50, e1-e88 A multidisciplinary telehealth program in patients with combined chronic obstructive pulmonary disease and chronic heart failure: study protocol for a randomized controlled trial. 2016, 17, 462 Endoscopic vein harvest in patients at high risk for leg wound complications: A cost-benefit analysis of an initial experience. 2016, 44, 1606-1610 Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and	589 21 8
1462 1461 1460 1459	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. 2016, 50, e1-e88 A multidisciplinary telehealth program in patients with combined chronic obstructive pulmonary disease and chronic heart failure: study protocol for a randomized controlled trial. 2016, 17, 462 Endoscopic vein harvest in patients at high risk for leg wound complications: A cost-benefit analysis of an initial experience. 2016, 44, 1606-1610 Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. 2016, 182, 125-134 Factors associated with use of percutaneous coronary intervention among elderly patients presenting with ST segment elevation acute myocardial infarction (STEMI): Results from the	589 21 8
1462 1461 1460 1459 1458	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. 2016, 50, e1-e88 A multidisciplinary telehealth program in patients with combined chronic obstructive pulmonary disease and chronic heart failure: study protocol for a randomized controlled trial. 2016, 17, 462 Endoscopic vein harvest in patients at high risk for leg wound complications: A cost-benefit analysis of an initial experience. 2016, 44, 1606-1610 Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. 2016, 182, 125-134 Factors associated with use of percutaneous coronary intervention among elderly patients presenting with ST segment elevation acute myocardial infarction (STEMI): Results from the ISACS-TC registry. 2016, 217 Suppl, S21-6 Treatment of chronic total occlusions in native coronary arteries by drug-coated balloons without	589 21 8 84 9
1462 1461 1460 1459 1458	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. 2016, 50, e1-e88 A multidisciplinary telehealth program in patients with combined chronic obstructive pulmonary disease and chronic heart failure: study protocol for a randomized controlled trial. 2016, 17, 462 Endoscopic vein harvest in patients at high risk for leg wound complications: A cost-benefit analysis of an initial experience. 2016, 44, 1606-1610 Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. 2016, 182, 125-134 Factors associated with use of percutaneous coronary intervention among elderly patients presenting with ST segment elevation acute myocardial infarction (STEMI): Results from the ISACS-TC registry. 2016, 217 Suppl, S21-6 Treatment of chronic total occlusions in native coronary arteries by drug-coated balloons without stenting - A feasibility and safety study. 2016, 225, 262-267 Chronic Kidney Disease in the Second-Generation Drug-Eluting Stent Era: Pooled Analysis of the	589 21 8 84 9

1454 [Coronary interventions: Current developments for improved long-term results]. **2016**, 57, 832-43

1453	Quick Evidence Synopsis: Coronary Artery Revascularization in Patients with Acute Coronary Syndrome and Comorbid Renal Disease. 2016 , 34, 609-613	
1452	Complications of Percutaneous Coronary Intervention. 2016,	3
1451	Peri-angiography Hemofiltration to Reduce Mortality. 2016 , 73-80	
1450	Incidence, feasibility and outcome of percutaneous coronary intervention after transcatheter aortic valve implantation with a self-expanding prosthesis. Results from a single center experience. 2016 , 17, 391-8	31
1449	[Not Available]. 2016 , 48 Suppl 1, 4-26	5
1448	Reducing Microvascular Dysfunction in Revascularized Patients with ST-Elevation Myocardial Infarction by Off-Target Properties of Ticagrelor versus Prasugrel. Rationale and Design of the REDUCE-MVI Study. 2016 , 9, 249-256	12
1447	Does thrombo-aspiration still have a place in the treatment of myocardial infarction?. 2016 , 16, 97	5
1446	Coronary revascularization in diabetic patients with chronic kidney disease. <i>European Heart Journal</i> , 2016 , 37, 3448-3451	5
1445	Role of New Antiplatelet Drugs on Cardiovascular Disease: Update on Cangrelor. 2016 , 18, 66	6
1444	Optimal Medical Therapy in the Prognosis of Coronary Artery Disease. 2016 , 9, 1973-4	
1443	Safety of 6-month duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndromes: Rationale and design of the Smart Angioplasty Research Team-safety of 6-month duration of Dual Antiplatelet Therapy after percutaneous	7
1442	Coronary CTA and percutaneous coronary intervention - A symbiosis waiting to happen. 2016 , 10, 384-5	8
1441	Trends in cardiac anaesthesia. 2016 , 9, 35-42	O
1440	Treatment of Higher-Risk Patients With an Indication for Revascularization: Evolution Within the Field of Contemporary Percutaneous Coronary Intervention. 2016 , 134, 422-31	108
1439	Validation of Three Platelet Function Tests for Bleeding Risk Stratification During Dual Antiplatelet Therapy Following Coronary Interventions. 2016 , 39, 385-90	10
1438	Individual Long-Term Mortality Prediction Following Either Coronary Stenting or Bypass Surgery in Patients With Multivessel and/or Unprotected Left Main Disease: An External Validation of the SYNTAX Score II Model in the 1,480 Patients of the BEST and PRECOMBAT Randomized Controlled	33
1437	Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition). 2016 , 134, 723-33	23

1436	Reframing the association and significance of co-morbidities in heart failure. 2016 , 18, 744-58		116
1435	Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients With and Without Acute Coronary Syndrome: A Systematic Review of Randomized Controlled Trials. 2016 , 91, 1084-93		5
1434	[Chronic coronary occlusions: When and how should revascularization be performed?]. 2016 , 41, 585-590		0
1433	Non-vitamin K oral anticoagulant treatment in elderly patients with atrial fibrillation and coronary heart disease. 2016 , 222, 1079-1083		9
1432	Antithrombotic therapy for secondary prevention of atherothrombotic events in cerebrovascular disease. 2016 , 13, 609-22		17
1431	Preclinical evaluation of a novel polyphosphazene surface modified stent. 2016 , 222, 217-225		19
1430	Standardization of Fractional Flow Reserve Measurements. 2016 , 68, 742-53		106
1429	1-Year Outcomes With Intracoronary Abciximab in Diabetic Patients Undergoing Primary Percutaneous Coronary Intervention. 2016 , 68, 727-38		5
1428	Cardiac CT for the Interventional Cardiologist. 2016 , 2, 13-24		
1427	Left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation: indications diversity and future perspectives. 2016 , 2, 32-36		
1426	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of		4036
1425	the ESC. 2016 , 18, 891-975 "Smoker's paradox" in patients with cardiogenic shock complicating myocardial infarction - A substudy of the IABP-SHOCK II-trial and registry. 2016 , 222, 775-779		10
1424	[Bleeding in patients receiving dual antiplatelet therapy after acute coronary syndrome - significance, prevention and interdisciplinary management]. 2016 , 141, 1107-11		2
1423	Gender-related differences in elderly patients with myocardial infarction in a European Centre. 2016 , 46, 60-9		7
1422	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>European Heart Journal</i> , 2016 , 37, 2893-2962	;	4465
1421	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. 2016 , 18, 1609-1678		1293
1420	Primary percutaneous coronary intervention in octogenarians. 2016 , 222, 1129-1135		7
1419	Management of bleeding in vascular surgery. 2016 , 117 Suppl 2, ii85-ii94		16

(2016-2016)

1418	2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). European Heart Journal, 2016,	1249
1417	37, 2768-2801 PCI Strategies in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Coronary Artery Disease. 2016 , 68, 1066-81	41
1416	Outcomes After Percutaneous Coronary Intervention or Bypass Surgery in Patients With Unprotected Left Main Disease. 2016 , 68, 999-1009	79
1415	Myocardial Revascularization for Left Main Coronary Artery Disease: A Step Toward Individualized Treatment Selection. 2016 , 68, 1010-3	2
1414	New antiplatelet drugs and new oral anticoagulants. 2016 , 117 Suppl 2, ii74-ii84	30
1413	Effects of rhBNP after PCI on non-invasive hemodynamic in acute myocardial infarction patients with left heart failure. 2016 , 9, 791-5	9
1412	Applicability of the COURAGE, BARI 2D, and FREEDOM Trials to Contemporary Practice. 2016, 68, 996-8	9
1411	Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have	58
1410	Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF-TIMI48 Trial. 2016 , 5,	79
1409	[Immediate multivessel PCI in patients with ACS : Is less more?]. 2016 , 41, 566-571	1
1408	Intracoronary Bivalirudin Bolus in ST-Elevation Myocardial Infarction Patients Treated with Primary Angioplasty: Theoretical Bases, Clinical Experience, and Future Applications. 2016 , 16, 391-397	1
1407	No benefit of additional treatment with exenatide in patients with an acute myocardial infarction. 2016 , 220, 809-14	28
1406	Prevention of Contrast-Induced Acute Kidney Injury: an Update. 2016 , 30, 515-524	28
1405	FFR prediction model based on conventional quantitative coronary angiography and the amount of myocardium subtended by an intermediate coronary artery stenosis. 2016 , 223, 340-344	7
1404	Soluble adhesion molecules in patients with acute coronary syndrome after percutaneous coronary intervention with drug-coated balloon, drug-eluting stent or bare metal stent. 2016 , 95, 20-23	2
1403	Usefulness of the monocyte-to-high-density lipoprotein cholesterol ratio to predict bare metal stent restenosis. 2016 , 10, 959-66	30
1402	Predischarge screening for chronic obstructive pulmonary disease in patients with acute coronary syndrome and smoking history. 2016 , 222, 806-812	16
1401	Phosphate- or Citrate-Buffered Tirofiban Versus Unfractionated Heparin and its Impact on Thrombocytopenia and Clinical Outcomes in Patients With Acute Coronary Syndrome: A Post Hoc Analysis From the PRISM Trial. 2016 , 9, 1667-76	3

1400	Circulating Microparticles Decrease After Cardiac Stress in Patients With Significant Coronary Artery Stenosis. 2016 , 39, 570-577	8
1399	The role of angiographic follow-up after percutaneous coronary intervention. 2016 , 222, 911-920	5
1398	Medication adherence and prognosis in elderly patients undergoing percutaneous coronary intervention. 2016 , 222, 881	1
1397	Intraindividual Comparison of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Drug-Eluting Metallic Stents. 2016 , 9,	2
1396	Comparison of the Effects of Incomplete Revascularization on 12-Month Mortality in Patients . 2016 , 118, 1164-1170	10
1395	How abciximab might be clinically useful. 2016 , 222, 1074-1078	9
1394	Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints, and data collection requirements for clinical studies. 2017 , 19, 4-15	88
1393	The Course of Ischemic Mitral Regurgitation in Acute Myocardial Infarction After Primary Percutaneous Coronary Intervention: From Emergency Room to Long-Term Follow-Up. 2016 , 9, e004841	28
1392	Preoperative platelet function predicts perioperative bleeding complications in ticagrelor-treated cardiac surgery patients: a prospective observational study. 2016 , 117, 309-15	58
1391	Discordance Between Resting and Hyperemic Indices of Coronary Stenosis Severity: The VERIFY 2 Study (A Comparative Study of Resting Coronary Pressure Gradient, Instantaneous Wave-Free Ratio and Fractional Flow Reserve in an Unselected Population Referred for Invasive Angiography). 2016 ,	47
1390	[Anticoagulation and new therapeutic options in atrial fibrillation]. 2016 , 141, 1618-1623	О
1389	Impact of Diabetes Mellitus on Intravascular Ultrasound-Guided Provisional Stenting in Coronary Bifurcation Lesions J-REVERSE Sub-Study. 2016 , 29, 576-587	1
1388	Factors Affecting Platelet Reactivity 2 Hours After P2YâBlReceptor Antagonist Loading in Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction - Impact of Pain-to-Loading Time. 2016 , 80, 442-9	10
1387	Clinical Feasibility of Simultaneous Acquisition Rest (99m)Tc/Stress (201)Tl Dual-Isotope Myocardial Perfusion Single-Photon Emission Computed Tomography With Semiconductor Camera. 2016 , 80, 689-95	21
1386	Screening of Coronary Artery Disease in Diabetic Patients: Who and How?. 2016 , 80, 543	
1385	Is Bilateral Internal Mammary Arterial Grafting Beneficial for Patients Aged 75 Years or Older?. 2016 , 80, 1756-63	16
1384	Inter-Facility Transfer vs. Direct Admission of Patients With ST-Segment Elevation Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. 2016 , 80, 1764-72	16
1383	Optical Coherence Tomography of De Novo Lesions and In-Stent Restenosis in Coronary Saphenous Vein Grafts (OCTOPUS Study). 2016 , 80, 1804-11	4

1382	Long-Term Follow-Up of Patients With Previous Coronary Artery Bypass Grafting Undergoing Percutaneous Coronary Intervention for Chronic Total Occlusion. 2016 , 118, 1641-1646	20
1381	The International Survey of Acute Coronary Syndromes in Transitional Countries (ISACS-TC): 2010-2015. 2016 , 217 Suppl, S1-6	12
1380	Proton Pump Inhibitors in Cardiovascular Disease: Drug Interactions with Antiplatelet Drugs. 2017 , 906, 325-350	2
1379	Empfehlungen zum hmodynamischen Monitoring in der internistischen Intensivmedizin. 2016 , 10, 149-169	12
1378	Fractional Flow Reserve-Guided Deferred Versus Complete Revascularization in Patients With Diabetes Mellitus. 2016 , 118, 1293-1299	14
1377	Diagnosis and pharmacological management of stable angina. 2016 , 27, 27-33	1
1376	Risk of bleeding after hospitalization for a serious coronary event: a retrospective cohort study with nested case-control analyses. 2016 , 16, 164	8
1375	Impact of bivalirudin on mortality and bleeding complications in acute coronary syndrome patients undergoing invasive revascularization: A real world experience. 2016 , 128, 906-915	1
1374	The 3 R's: The radial artery, the right internal thoracic artery, and the race for the second best. 2016 , 152, 1092-4	2
1373	Extracorporeal life support during cardiac arrest and cardiogenic shock: a systematic review and meta-analysis. 2016 , 42, 1922-1934	256
1373 1372		256 9
	meta-analysis. 2016 , 42, 1922-1934 Impact of systolic blood pressure on hemorrhagic stroke in patients with coronary artery disease	
1372	Impact of systolic blood pressure on hemorrhagic stroke in patients with coronary artery disease during anti-platelet therapy: The Japanese Coronary Artery Disease (JCAD) study. 2016, 224, 112-113 Predictors of in-hospital mortality among cardiogenic shock patients. Prognostic and therapeutic implications. 2016, 224, 114-118 Periprocedural platelet inhibition with cangrelor in P2Y-inhibitor nate patients with acute coronary syndromes - A matched-control pharmacodynamic comparison in real-world patients. 2016, 223, 848-851	9
1372	Impact of systolic blood pressure on hemorrhagic stroke in patients with coronary artery disease during anti-platelet therapy: The Japanese Coronary Artery Disease (JCAD) study. 2016 , 224, 112-113 Predictors of in-hospital mortality among cardiogenic shock patients. Prognostic and therapeutic implications. 2016 , 224, 114-118 Periprocedural platelet inhibition with cangrelor in P2Y-inhibitor nate patients with acute coronary	9
1372 1371 1370	Impact of systolic blood pressure on hemorrhagic stroke in patients with coronary artery disease during anti-platelet therapy: The Japanese Coronary Artery Disease (JCAD) study. 2016 , 224, 112-113 Predictors of in-hospital mortality among cardiogenic shock patients. Prognostic and therapeutic implications. 2016 , 224, 114-118 Periprocedural platelet inhibition with cangrelor in P2Y-inhibitor nawe patients with acute coronary syndromes - A matched-control pharmacodynamic comparison in real-world patients. 2016 , 223, 848-851 Prospective randomized comparison of clinical and angiographic outcomes between everolimus-eluting vs. zotarolimus-eluting stents for treatment of coronary restenosis in	9 10 11
1372 1371 1370 1369	Impact of systolic blood pressure on hemorrhagic stroke in patients with coronary artery disease during anti-platelet therapy: The Japanese Coronary Artery Disease (JCAD) study. 2016, 224, 112-113 Predictors of in-hospital mortality among cardiogenic shock patients. Prognostic and therapeutic implications. 2016, 224, 114-118 Periprocedural platelet inhibition with cangrelor in P2Y-inhibitor nawe patients with acute coronary syndromes - A matched-control pharmacodynamic comparison in real-world patients. 2016, 223, 848-851 Prospective randomized comparison of clinical and angiographic outcomes between everolimus-eluting vs. zotarolimus-eluting stents for treatment of coronary restenosis in drug-eluting stents: intravascular ultrasound volumetric analysis (RESTENT-ISR trial). European	9 10 11
1372 1371 1370 1369	Impact of systolic blood pressure on hemorrhagic stroke in patients with coronary artery disease during anti-platelet therapy: The Japanese Coronary Artery Disease (JCAD) study. 2016, 224, 112-113 Predictors of in-hospital mortality among cardiogenic shock patients. Prognostic and therapeutic implications. 2016, 224, 114-118 Periprocedural platelet inhibition with cangrelor in P2Y-inhibitor nawe patients with acute coronary syndromes - A matched-control pharmacodynamic comparison in real-world patients. 2016, 223, 848-851 Prospective randomized comparison of clinical and angiographic outcomes between everolimus-eluting vs. zotarolimus-eluting stents for treatment of coronary restenosis in drug-eluting stents: intravascular ultrasound volumetric analysis (RESTENT-ISR trial). European Diabetes and Heart Failure: Sugared Words Prove Bitter. 2016, 68, 1417-1419 Prise en charge thfapeutique de lâBnvrysme de lâBorte abdominale. 2016, 2016, 6-12	9 10 11

1364	Impact of Early Coronary Revascularization on Long-Term Outcomes in Patients With Myocardial Ischemia on Dobutamine Stress Echocardiography. 2016 , 118, 635-40		5
1363	Impact of functional focal versus diffuse coronary artery disease on bypass graft patency. 2016 , 222, 16-21		18
1362	Everolimus-Eluting Stents in Patients With Bare-Metal and Drug-Eluting In-Stent Restenosis: Results From a Patient-Level Pooled Analysis of the RIBS IV and V Trials. 2016 , 9,		17
1361	Duration of Triple Antithrombotic Therapy and Outcomes Among Patients Undergoing Percutaneous Coronary Intervention. 2016 , 9, 1473-83		20
1360	Exercise training-induced different improvement profile of endothelial progenitor cells function in mice with or without myocardial infarction. 2016 , 221, 335-41		11
1359	In-Stent Restenosis? The Raiders of the Magic Remedy. 2016 , 9,		6
1358	Resolving the paradox of randomised controlled trials and observational studies comparing multi-vessel angioplasty and culprit only angioplasty at the time of STEMI. 2016 , 222, 1-8		10
1357	Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry. <i>European Heart Journal</i> , 2016 , 37, 3335-3342	9.5	109
1356	[Recommendations of the ESC guidelines regarding cardiovascular imaging]. 2016, 41, 362-70		
1355	Optimisation of percutaneous coronary intervention: indispensables for bioresorbable scaffolds. 2016 , 14, 1053-70		2
1354	Does Platelet Reactivity Predict Bleeding in Patients Needing Urgent Coronary Artery Bypass Grafting During Dual Antiplatelet Therapy?. 2016 , 102, 2010-2017		28
1353	High platelet reactivity after P2Y12-inhibition in patients with atrial fibrillation and coronary stenting. 2016 , 42, 558-65		1
1352	Dedicated CTO-PCI Centres: 'If you Build it they will Come'. 2016 , 25, 637-8		
1351	Impact of Operator Experience and Volume on Outcomes After Left Main Coronary Artery Percutaneous Coronary Intervention. 2016 , 9, 2086-2093		64
1350	Platelet inhibition and bleeding complications in cardiac surgery: A review. 2016 , 50, 349-354		7
1349	New concepts for anticoagulant therapy in persons with hemophilia. 2016 , 128, 2471-2474		25
1348	Perioperative management of dual anti-platelet therapy. 2016 , 44, 237-241		2
1347	Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. <i>European Heart Journal</i> , 2017 , 38, 804-810	9.5	114

(2016-2016)

1346	bivalirudin in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Insights from the ORBI registry. 2016 , 109, 696-707	3
1345	The Influence of Lesion Location on the Diagnostic Accuracy of Adenosine-Free Coronary Pressure Wire Measurements. 2016 , 9, 2390-2399	54
1344	Temporal Trends in Predictors of Early and Late Mortality After Emergency Coronary Artery Bypass Grafting for Cardiogenic Shock Complicating Acute Myocardial Infarction. 2016 , 134, 1224-1237	26
1343	Surgical Management of Infective Endocarditis Complicated by Embolic Stroke: Practical Recommendations for Clinicians. 2016 , 134, 1280-1292	37
1342	Risk and Benefits of Triple Therapy in Patients Undergoing Coronary Stent Implantation Requiring Oral Anticoagulation: A Meta-Analysis of 16 Studies. 2016 , 30, 611-622	8
1341	Percutaneous coronary intervention for chronic total occlusion improved prognosis in patients with renal insufficiency at high risk of contrast-induced nephropathy. 2016 , 6, 21426	4
1340	Comparative Prognostic Utility of Indexes of Microvascular Function Alone or in Combination in Patients With an Acute ST-Segment-Elevation Myocardial Infarction. 2016 , 134, 1833-1847	89
1339	CMR First-Pass Perfusion for Suspected Inducible Myocardial Ischemia. 2016 , 9, 1338-1348	44
1338	[National disease management guidelines (NVL) for chronic CAD : What is new, what is particularly important?]. 2016 , 41, 537-60	1
1337	Coronary and cerebrovascular interventions. <i>European Heart Journal</i> , 2016 , 37, 3061-3063 9.5	
1337 1336	Coronary and cerebrovascular interventions. <i>European Heart Journal</i> , 2016 , 37, 3061-3063 9.5 Randomised trials in left main disease: a NOBLE effort. 2016 , 388, 2715-2716	6
		6
1336	Randomised trials in left main disease: a NOBLE effort. 2016 , 388, 2715-2716	
1336 1335	Randomised trials in left main disease: a NOBLE effort. 2016 , 388, 2715-2716 Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease. 2016 , 375, 2223-2235	603
1336 1335 1334	Randomised trials in left main disease: a NOBLE effort. 2016 , 388, 2715-2716 Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease. 2016 , 375, 2223-2235 Defibrillators: Selecting the Right Device for the Right Patient. 2016 , 134, 1390-1404 Novel cardioprotective and regenerative therapies in acute myocardial infarction: a review of	603
1336 1335 1334 1333	Randomised trials in left main disease: a NOBLE effort. 2016 , 388, 2715-2716 Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease. 2016 , 375, 2223-2235 Defibrillators: Selecting the Right Device for the Right Patient. 2016 , 134, 1390-1404 Novel cardioprotective and regenerative therapies in acute myocardial infarction: a review of recent and ongoing clinical trials. 2016 , 12, 655-672	603
1336 1335 1334 1333	Randomised trials in left main disease: a NOBLE effort. 2016, 388, 2715-2716 Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease. 2016, 375, 2223-2235 Defibrillators: Selecting the Right Device for the Right Patient. 2016, 134, 1390-1404 Novel cardioprotective and regenerative therapies in acute myocardial infarction: a review of recent and ongoing clinical trials. 2016, 12, 655-672 Coronary Artery Chronic Total Occlusion. 2016, 1, 325-335 Increased von Willebrand factor, P-selectin and fibrin content in occlusive thrombus resistant to	603 22 30

1328	Transition between ticagrelor and two different doses of clopidogrel at hospital discharge in patients with acute coronary syndrome submitted to percutaneous coronary intervention. 2016 , 24, 30-34	
1327	Five-year outcome of consecutive unprotected left main percutaneous coronary interventions. 2016 , 71, 654-662	
1326	Non-invasive versus invasive management in patients with prior coronary artery bypass surgery with a non-ST segment elevation acute coronary syndrome: study design of the pilot randomised controlled trial and registry (CABG-ACS). 2016 , 3, e000371	7
1325	Evaluation of computed tomography in patients with atypical angina or chest pain clinically referred for invasive coronary angiography: randomised controlled trial. 2016 , 355, i5441	53
1324	Echokardiografie als Gatekeeper bei KHK. 2016 , 5, 399-403	
1323	Wie lange duale antithrombozyt î e Therapie bei koronaren Risikopatienten?. 2016 , 5, 362-366	
1322	Myokardszintigrafie: aktueller Stand. 2016 , 5, 410-416	
1321	ACP Journal Club. Review: In patients with previous MI, long-term DAPT reduces CV events and increases major bleeding. 2016 , 164, JC9	
1320	Staged re-evaluation of non-culprit lesions in ST segment elevation myocardial infarction: a retrospective study. 2016 , 3, e000427	6
1319	Assessment of Left Ventricular Mechanics in Patients with Ischemic Heart Disease. 2016 , 79, 01027	
1318	Revascularisation of patients with end-stage renal disease on chronic haemodialysis: bypass surgery versus PCI-analysis of routine statutory health insurance data. 2016 , 3, e000464	6
1317	Double guide double wrist 5F left coronary artery transradial percutaneous coronary intervention and the X-Kiss technique. 2016 , 18, 45-52	1
1316	Sulodexide Protects Contrast-Induced Nephropathy in Sprague-Dawley Rats. 2016 , 40, 621-632	18
1315	(82)Rb PET imaging of myocardial blood flow-have we achieved the 4 "R"s to support routine use?. 2016 , 6, 69	3
1314	Renal insufficiency and left main coronary artery disease: reconsidering coronary intervention and bypass surgery. 2016 , 27, 529-31	
1313	Symptoms and delay times during myocardial infarction in 694 patients with and without diabetes; an explorative cross-sectional study. 2016 , 16, 108	9
1312	Impact of impaired fractional flow reserve after coronary interventions on outcomes: a systematic review and meta-analysis. 2016 , 16, 177	22
1311	Type 2 diabetes compromises the value of non-invasively measured augmentation index in predicting the severity of coronary artery disease: a hospital-based observational study. 2016 , 16, 216	2

1310	Comparing the adverse clinical outcomes associated with fraction flow reserve-guided versus angiography-guided percutaneous coronary intervention: a systematic review and meta-analysis of randomized controlled trials. 2016 , 16, 249	4
1309	Platelet aggregation and risk of stent thrombosis or bleeding in interventionally treated diabetic patients with acute coronary syndrome. 2016 , 16, 252	7
1308	What happens to work capacity after coronary revascularization?. 2017, 3, 95-96	
1307	[Revascularization therapy]. 2016, 41, 561	
1306	Assessment of Cardiac Device Position on Supine Chest Radiograph in the ICU: Introduction and Applicability of the Aortic Valve Location Ratio. 2016 , 44, e957-63	2
1305	Efficacy of blocker therapy for secondary prevention for patients undergoing coronary artery bypass grafting surgery. 2016 , 31, 654-661	2
1304	Prevalence of Sleep-Disordered Breathing and Patient Characteristics in a Coronary Artery Disease Cohort Undergoing Cardiovascular Rehabilitation. 2016 , 36, 421-429	32
1303	The effect of a dual or a triple antithrombotic therapy with apixaban on thrombus formation in vivo and in an ex vivo perfusion chamber model: An open-label, controlled, sequential study. 2016 , 95, e4145	1
1302	Total revascularization for an epsilon right coronary artery and severe left main disease combined with profound cardiogenic shock: A case report. 2016 , 95, e5667	1
1301	Outcomes of DES in Diabetic and Nondiabetic Patients with Complex Coronary Artery Disease after Risk Stratification by the SYNTAX Score. 2016 , 10, 103-10	2
1300	Predictors of restenosis following contemporary subintimal tracking and reentry technique: The importance of final TIMI flow grade. 2016 , 87, 884-92	24
1299	Two-year results and subgroup analyses of the PEPCAD China in-stent restenosis trial: A prospective, multicenter, randomized trial for the treatment of drug-eluting stent in-stent restenosis. 2016 , 87 Suppl 1, 624-9	27
1298	Evaluation of the efficacy and safety of dual antiplatelet therapy with or without warfarin in patients with a clinical indication for DAPT and chronic anticoagulation: A meta-analysis of observational studies. 2016 , 88, E12-22	17
1297	Impact of complete revascularization in patients with ST-elevation myocardial infarction: analysis of a 10-year all-comers prospective registry. 2016 , 27, 122-7	4
1296	Confounders of Cardioprotection by Remote Ischemic Preconditioning in Patients Undergoing Coronary Artery Bypass Grafting. 2016 , 133, 128-33	41
1295	Which long-term antiplatelet regimen for patients with acute coronary syndromes?. 2016 , 30, 333-8	
1294	Difficult Decisions in Cardiothoracic Surgery: Acute Cardiogenic Shock. 2016 , 165-175	
1293	External validity of the "all-comers" design: insights from the BIOSCIENCE trial. 2016 , 105, 744-54	10

Antikoagulanzien und Thrombozytenaggregationshemmer bei endoskopischen Interventionen. **2016**, 11, 137-149

1291	Thrombozytenfunktion. 2016 , 12, 102-108	
1290	Living Donation Mitigates Poorer Outcomes in Marginal Recipients. 2016 , 3, 121-138	3
1289	Comparison of Different Risk Scores for Predicting Contrast Induced Nephropathy and Outcomes After Primary Percutaneous Coronary Intervention in Patients With ST Elevation Myocardial Infarction. 2016 , 117, 1896-903	17
1288	Extended-release acetylsalicylic acid for secondary prevention of stroke and cardiovascular events. 2016 , 14, 779-91	2
1287	Coronary Artery Bypass Graft Surgery and Percutaneous Coronary Interventions in Patients With Unprotected Left Main Coronary Artery Disease. 2016 , 9, 1102-11	28
1286	A Simple, Effective, and Durable Treatment Choice for Left Main Coronary Artery Disease: Stents or Surgery?. 2016 , 9, 1112-4	
1285	Biolimus-A9 polymer-free coated stent in high bleeding risk patients with acute coronary syndrome: a Leaders Free ACS sub-study. <i>European Heart Journal</i> , 2017 , 38, 961-969	45
1284	Clinical, angiographic and procedural characteristics of longitudinal stent deformation. 2016 , 32, 1163-70	13
1283	Percutaneous Coronary Interventions for the Treatment of Stenoses in Small Coronary Arteries: A Network Meta-Analysis. 2016 , 9, 1324-34	44
1282	Drug-Eluting Balloons or Stents for Bare-Metal Stent Restenosis. 2016 , 9, 1256-1258	2
1281	Dual antiplatelet therapy after coronary stenting. 2016 , 17, 1775-87	9
1280	Cardiac SPECT/CCTA hybrid imaging: One answer to two questions?. 2016 , 41, 391-7	5
1279	Prevention of Contrast-Induced Renal Failure for the Interventional Cardiologist. 2016 , 9,	2
1278	Long-Term Results of Everolimus-Eluting Stents Versus Drug-Eluting Balloons in Patients With Bare-Metal In-Stent Restenosis: 3-Year Follow-Up of the RIBS V Clinical Trial. 2016 , 9, 1246-1255	37
1277	Frontiers of interventional cardiology: plaque imaging, thrombus load, and bifurcation lesions. European Heart Journal, 2016 , 37, 1861-4 9-5	1
1276	Revascularization Strategies in Patients with Diabetes Mellitus and Acute Coronary Syndrome. 2016 , 18, 79	8
1275	Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: Meta-analysis of randomized controlled trials. 2016 , 220, 895-900	7

1274	[Diamond-Forrester and cardiac CT : Is there a need to redefine the pretest probability of coronary artery disease?]. 2016 , 41, 371-5	3
1273	Long-Term Mortality After Coronary Revascularization in Nondiabetic Patients With Multivessel Disease. 2016 , 68, 29-36	34
1272	Multivessel CAD in Nondiabetic Patients: To Operate or to Dilate?. 2016 , 68, 37-9	
1271	Effect of Post-Primary Percutaneous Coronary Intervention Bivalirudin Infusion on Acute Stent Thrombosis: Meta-Analysis of Randomized Controlled Trials. 2016 , 9, 1313-20	16
1270	Expert position paper on prolonged dual antiplatelet therapy in secondary prevention following myocardial infarction. 2016 , 128, 450-7	2
1269	Meta-Analysis of the Prognostic Impact of Anemia in Patients Undergoing Percutaneous Coronary Intervention. 2016 , 118, 610-20	45
1268	Is the Risk of Wound Infection Related to Bilateral Internal Thoracic Artery Graft Potentiated by Age?. 2016 , 102, 1239-44	O
1267	Paclitaxel-coated balloon exerts late vessel healing and enlargement: A documented phenomenon with optical coherence tomography analysis. 2016 , 203, 551-2	12
1266	Comparison of drug-eluting balloon versus drug-eluting stent treatment of drug-eluting stent in-stent restenosis: A meta-analysis of available evidence. 2016 , 218, 126-135	16
1265	Toma de decisiones por el equipo cardiaco en Espa â : ¿hay margen de mejor॰?. 2016 , 69, 533-534	
1264	Bioresorbable vascular scaffold overlap evaluation with optical coherence tomography after implantation with or without enhanced stent visualization system (WOLFIE study): a two-centre prospective comparison. 2016 , 32, 211-223	13
1263	Nuclear Cardiology in the Management of Patients with Heart Failure. 2016 , 9, 1	7
1262	Radiation Dose Reduction from Radionuclide Myocardial Perfusion Imaging. 2016 , 9, 1	О
1261	Unwarranted variation of coronary stent choice in The Netherlands. 2016 , 24, 108-9	1
1260	CASE 11-2016 Perioperative Coronary Thrombosis in a Patient With Multiple Second-Generation Drug-Eluting Stents: Is It Time for a Paradigm Shift?. 2016 , 30, 1698-1708	1
1259	Excessively High Hydration Volume May Not Be Associated With Decreased Risk of Contrast-Induced Acute Kidney Injury After Percutaneous Coronary Intervention in Patients With Renal Insufficiency. 2016 , 5,	28
1258	Association between publication of appropriate use criteria and the temporal trends in diagnostic angiography in stable coronary artery disease: A population-based study. 2016 , 175, 153-9	13
1257	Treatment variation in stent choice in patients with stable or unstable coronary artery disease. 2016 , 24, 110-9	4

1256	Coronary Artery Bypass Grafting Versus Drug-Eluting Stents Implantation for Previous Myocardial Infarction. 2016 , 118, 17-22	11
1255	Implementation and consistency of Heart Team decision-making in complex coronary revascularisation. 2016 , 206, 37-41	25
1254	Stent Thrombosis With Drug-Eluting Stents and Bioresorbable Scaffolds: Evidence From a Network Meta-Analysis of 147 Trials. 2016 , 9, 1203-1212	88
1253	Heart Team Decision-making in Spain: Is There Room for Improvement?. 2016 , 69, 533-4	
1252	Impaired biological response to aspirin in therapeutic hypothermia comatose patients resuscitated from out-of-hospital cardiac arrest. 2016 , 105, 16-21	9
1251	Optical coherence tomography: A pathway from research to clinical practice. 2016 , 17, 71-3	
1250	No reflow phenomenon in percutaneous coronary interventions in ST-segment elevation myocardial infarction. 2016 , 68, 539-51	53
1249	64 slice-coronary computed tomography sensitivity and specificity in the evaluation of coronary artery bypass graft stenosis: A meta-analysis. 2016 , 216, 52-7	28
1248	6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial. 2016 , 9, 1438-46	82
1247	Heart Team Decision-making in Spain: Is There Room for Improvement? Response. 2016 , 69, 534-5	1
1246	The use of paclitaxel coated balloon (PCB) in acute coronary syndrome of small vessel de novo lesions: an analysis of a prospective 'real world' registry. 2016 , 5, 373	5
1245	Is There a Role for Cardiac Rehabilitation After Coronary Artery Bypass Grafting? There is No Role for Cardiac Rehabilitation After Coronary Artery Bypass Grafting. 2016 , 133, 2538-43	9
1244	Drug Interaction Between Clopidogrel and Ranitidine or Omeprazole in Stable Coronary Artery Disease: A Double-Blind, Double Dummy, Randomized Study. 2016 , 16, 275-284	12
1243	Is There a Role for Cardiac Rehabilitation After Coronary Artery Bypass Grafting? Treatment After Coronary Artery Bypass Surgery Remains Incomplete Without Rehabilitation. 2016 , 133, 2529-37	22
1242	Efficacy and safety of prolonged dual antiplatelet therapy: a meta-analysis of 15 randomized trials enrolling 85 265 patients. 2016 , 2, 218-28	9
1241	Prognostic impact of percutaneous coronary intervention in stable coronary disease. 2016 , 2, 1-3	1
1240	Impacto presupuestario del uso de un contraste isoosmolar frente a contrastes de baja osmolaridad en pacientes con alto riesgo de nefropat\(\textit{a}\) inducida por contraste en el entorno hospitalario espa\(\theta\)l. 2016 , 13, 17-24	
1239	Comparison of a rapid point-of-care and two laboratory-based CYP2C19*2 genotyping assays for personalisation of antiplatelet therapy. 2016 , 38, 414-20	13

1238	Ticagrelor versus prasugrel in patients with high on-clopidogrel treatment platelet reactivity after PCI: The ISAR-ADAPT-PF study. 2016 , 27, 796-804		9
1237	Is it time to take bare metal stents off the catheter laboratory shelf?. <i>European Heart Journal</i> , 2016 , 37, 3372-3375	9.5	10
1236	State of the art in coronary revascularization: Everolimus eluting stents versus multiple arterial grafting. 2016 , 219, 345-9		5
1235	Transfemoral approach with systematic use of FemoSealâ&losure device compared to transradial approach in primary angioplasty. 2016 , 87, 849-54		9
1234	A novel drug-coated scoring balloon for the treatment of coronary in-stent restenosis: Results from the multi-center randomized controlled PATENT-C first in human trial. 2016 , 88, 51-9		22
1233	Upstream clopidogrel, prasugrel, or ticagrelor for patients treated with primary angioplasty: Results of an angiographic randomized pilot study. 2016 , 87, 1187-93		3
1232	Opportunities for improvement in anti-thrombotic therapy and other strategies for the management of acute coronary syndromes: Insights from EPICOR, an international study of current practice patterns. 2016 , 5, 3-12		36
1231	Drug-coated balloon treatment for lower extremity vascular disease intervention: an international positioning document. <i>European Heart Journal</i> , 2016 , 37, 1096-103	9.5	56
1230	Complete and incomplete revascularization: Whose definition is it anyway?. 2016 , 23, 556-9		1
1229	Influence of coronary spasm on long term outcomes. 2016 , 202, 252		1
1228	Kounis syndrome: A concise review with focus on management. 2016 , 30, 7-10		71
1227	Quality markers in cardiology: measures of outcomes and clinical practicea perspective of the Spanish Society of Cardiology and of Thoracic and Cardiovascular Surgery. <i>European Heart Journal</i> , 2016 , 37, 12-23	9.5	10
1226	Myocardial Hemorrhage After Acute Reperfused ST-Segment-Elevation Myocardial Infarction: Relation to Microvascular Obstruction and Prognostic Significance. 2016 , 9, e004148		111
1225	Coronary intervention in 2015: Improvement of long-term outcomes after PCI. 2016 , 13, 69-70		
1224	Significance of Baseline Diagnosis and Medical Therapy in Patients Undergoing Coronary Artery Bypass Graft Surgery. 2016 , 101, 831-2		2
1223	Bridge therapy or standard treatment for urgent surgery after coronary stent implantation: Analysis of 314 patients. 2016 , 80, 85-90		16
1222	Dual Antiplatelet Therapy in Patients with Stable Ischemic Heart Disease. 2016 , 18, 5		3
1221	The challenge for predicting bleeding events by assessing platelet reactivity following coronary stenting. 2016 , 207, 128-31		4

1220	Incidence and Predictors of Cardiomyocyte Injury in Elective Coronary Angiography. 2016 , 129, 537.e1-8	3
1219	Temporal trends in the treatment and outcomes of elderly patients with acute coronary syndrome. European Heart Journal, 2016 , 37, 1304-11 9.5	65
1218	Mechanisms of Very Late Drug-Eluting Stent Thrombosis Assessed by Optical Coherence Tomography. 2016 , 133, 650-60	200
1217	Effect of Preoperative Aspirin Replacement With Enoxaparin in Patients Undergoing Primary Isolated On-Pump Coronary Artery Bypass Grafting. 2016 , 117, 563-570	13
1216	Significance of Intermediate Values of Fractional Flow Reserve in Patients With Coronary Artery Disease. 2016 , 133, 502-8	87
1215	Invasive versus conservative strategy in patients aged 80 years or older with non-ST-elevation myocardial infarction or unstable angina pectoris (After Eighty study): an open-label randomised controlled trial. 2016 , 387, 1057-1065	232
1214	Impact of routine manual aspiration thrombectomy on outcomes of patients undergoing primary percutaneous coronary intervention for acute myocardial infarction: A meta-analysis. 2016 , 204, 189-95	15
1213	Efficacy and Safety of Available Protocols for Aspirin Hypersensitivity for Patients Undergoing Percutaneous Coronary Intervention: A Survey and Systematic Review. 2016 , 9, e002896	22
1212	Multi-vessel revascularization in ST-segment elevation myocardial infarction: where do we stand?. European Heart Journal, 2016 , 37, 217-20	4
1211	Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB 9.5 ST-segment elevation myocardial infarction-TROFI II trial. <i>European Heart Journal</i> , 2016 , 37, 229-40	159
121 0	Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: conceptual evolution based on emerging evidence. <i>European Heart Journal</i> , 2016 , 37, 353-64	47
1209	Occurrence, causes, and outcome after switching from ticagrelor to clopidogrel in a real-life scenario: data from a prospective registry. 2016 , 27, 484-7	26
1208	Percutaneous coronary interventions and antiplatelet therapy in renal transplant recipients. 2016 , 10, 86-97	3
1207	In-Stent Restenosis: Pathophysiology and Treatment. 2016 , 18, 10	15
1206	Clopidogrel Versus Aspirin as an Antiplatelet Monotherapy After 12-Month Dual-Antiplatelet Therapy in the Era of Drug-Eluting Stents. 2016 , 9, e002816	34
1205	Contrast-Induced Acute Kidney Injury: An Update. 2016 , 30, 215-28	50
1204	Single-Staged Compared With Multi-Staged PCI in Multivessel NSTEMI Patients: The SMILE Trial. 2016 , 67, 264-72	74
1203	Thrombus Aspiration in Patients With ST-Segment Elevation Myocardial Infarction Presenting Late After Symptom Onset. 2016 , 9, 113-22	32

1202	multicenter European study: a report of the prevention of late stent thrombosis. A interdisciplinary global European effort consortium. <i>European Heart Journal</i> , 2016 , 37, 1538-49	9.5	99
1201	Mechanisms of stent thrombosis analysed by optical coherence tomography: insights from the national PESTO French registry. <i>European Heart Journal</i> , 2016 , 37, 1208-16	9.5	185
1200	Comparative effect on platelet function of a fixed-dose aspirin and clopidogrel combination versus separate formulations in patients with coronary artery disease: A phase IV, multicenter, prospective, 4-week non-inferiority trial. 2016 , 202, 331-5		3
1199	Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials. 2016 , 387, 537-544		266
1198	Prognostic significance of infarct core pathology revealed by quantitative non-contrast in comparison with contrast cardiac magnetic resonance imaging in reperfused ST-elevation myocardial infarction survivors. <i>European Heart Journal</i> , 2016 , 37, 1044-59	9.5	81
1197	Factors Associated With Infarct-Related Artery Patency Before Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction (from the FAST-MI 2010 Registry). 2016 , 117, 17-21		12
1196	Risk of Adverse Cardiac and Bleeding Events Following Cardiac and Noncardiac Surgery in Patients With Coronary Stent: How Important Is the Interplay Between Stent Type and Time From Stenting to Surgery?. 2016 , 9, 39-47		26
1195	Prevention of Contrast-Induced Nephropathy by Central Venous Pressure-Guided Fluid Administration in Chronic Kidney Disease and Congestive Heart Failure Patients. 2016 , 9, 89-96		58
1194	Predicting ischemic mitral regurgitation in patients with acute ST-elevation myocardial infarction: Does time to reperfusion really matter and what is the role of collateral circulation?. 2016 , 203, 667-71		8
1193	Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: Which Regimen and for How Long?. 2016 , 67, 208-11		
1192	Impact of intracoronary adenosine administration during primary PCI: A meta-analysis. 2016 , 203, 1032-	41	27
1191	Stent thrombosis after primary percutaneous coronary intervention in comatose survivors of out-of-hospital cardiac arrest: Are the new P2Y12 inhibitors really more effective than clopidogrel?. 2016 , 98, 73-8		25
1190	An updated comprehensive meta-analysis of bivalirudin vs heparin use in primary percutaneous coronary intervention. 2016 , 171, 14-24		38
1189	Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. <i>European Heart Journal</i> , 2016 , 37, 2465-74	9.5	287
1188	Revascularization in stable coronary artery disease: a combined perspective from an interventional cardiologist and a cardiac surgeon. <i>European Heart Journal</i> , 2016 , 37, 1873-82	9.5	13
1187	[Thrombus aspiration in patients with acute myocardial infarction: Scientific evidence and guideline recommendations]. 2016 , 41, 591-598		4
1186	Balancing idealism with realism to safeguard the welfare of patients: The importance of Heart Team led decision-making in patients with complex coronary artery disease. 2016 , 68, 1-5		2
1185	Prediction of Outcomes in Patients with Chronic Ischemic Cardiomyopathy by Layer-Specific Strain Echocardiography: A Proof of Concept. 2016 , 29, 412-20		35

1184	Targeting thrombin long-term after an acute coronary syndrome: Opportunities and challenges. 2016 , 81, 1-14	6
1183	Clinical Outcome of First- vs Second-Generation DES According to DAPT Duration: Results of ARCTIC-Generation. 2016 , 39, 192-200	6
1182	Workstation-Based Calculation of CTA-Based FFR for Intermediate Stenosis. 2016 , 9, 690-9	76
1181	A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study. 2016 , 174, 120-8	22
1180	Advanced age and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor. 2016 , 14, 57-64	45
1179	Dual Antiplatelet Therapy Duration: A Review of Current Available Evidence. 2016 , 38, 961-73	1
1178	Comparison of Outcome of Patients With ST-Segment Elevation Myocardial Infarction and Complete Versus Incomplete ST-Resolution Before Primary Percutaneous Coronary Intervention. 2016 , 117, 1735-40	9
1177	Drug-Coated Balloon for Instent Restenosis in Patients at High Risk: Another Brick in the Wall of the Challenging Settings for Interventionists. 2016 , 117, 1859-61	1
1176	A case report of the new Polyzeneak COBRA PzFakNanocoated Coronary Stent System (NCS): Addressing an unmet clinical need. 2016 , 17, 209-11	8
1175	Left Main Stenting in Comparison With Surgical Revascularization: 10-Year Outcomes of the (Left Main Coronary Artery Stenting) LE MANS Trial. 2016 , 9, 318-327	93
1174	No More Debate Over Left Main Stenting Versus Bypass Surgery. 2016 , 9, 328-330	1
1173	Percutaneous treatment of left main and non-left main bifurcation coronary lesions using drug-eluting stents. 2016 , 14, 229-43	2
1172	Six Versus 12 Months of Dual Antiplatelet Therapy After Implantation of Biodegradable Polymer Sirolimus-Eluting Stent: Randomized Substudy of the I-LOVE-IT 2 Trial. 2016 , 9, e003145	91
1171	Defining a Role for Prasugrel in Patients With Stable Coronary Artery Disease Undergoing Ad Hoc Percutaneous Coronary Intervention. 2016 , 9, 228-230	1
1170	Gender Differences in Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy. 2016 , 30, 143-50	15
1169	Polymer-Free Biolimus A9-Coated Stents in the Treatment of De Novo Coronary Lesions: 4- and 12-Month Angiographic Follow-Up and Final 5-Year Clinical Outcomes of the Prospective, Multicenter BioFreedom FIM Clinical Trial. 2016 , 9, 51-64	55
1168	Contrast-induced nephropathy following angiography and cardiac interventions. 2016 , 102, 638-48	108
1167	Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: A Tale of 2 Decades With New Perspectives in the Era of New-Generation Drug-Eluting Stents. 2016 , 9, e003587	8

1166	Bioresorbable Scaffold vs. Second Generation Drug Eluting Stent in Long Coronary Lesions requiring Overlap: A Propensity-Matched Comparison (the UNDERDOGS study). 2016 , 208, 40-5		27
1165	Response to Letters Regarding Article, "Efficacy of Long-Term Blocker Therapy for Secondary Prevention of Long-Term Outcomes After Coronary Artery Bypass Grafting Surgery". 2016 , 133, e394-5		
1164	Diabetespatienten mit kardiovaskul î er Erkrankung. 2016 , 12, 49-68		2
1163	Optical coherence tomography (OCT) evaluation of intermediate coronary lesions in patients with NSTEMI. 2016 , 17, 113-8		13
1162	Left Main Percutaneous Coronary Intervention. 2016 , 5, 125-134		1
1161	Antiplatelet Therapy in Percutaneous Coronary Intervention. 2016 , 5, 221-237		5
1160	Risk Stratification for Percutaneous Coronary Intervention. 2016 , 5, 249-257		5
1159	Percutaneous Coronary Intervention for Bifurcation Lesions. 2016 , 5, 153-175		3
1158	Impact of Right Atrial Pressure on Fractional Flow Reserve Measurements: Comparison of Fractional Flow Reserve and Myocardial Fractional Flow Reserve in 1,600 Coronary Stenoses. 2016 , 9, 453-9		36
1157	Aggressive hydraTion in patients with ST-Elevation Myocardial infarction undergoing Primary percutaneous coronary intervention to prevenT contrast-induced nephropathy (ATTEMPT): Study design and protocol for the randomized, controlled trial, the ATTEMPT, RESCIND 1 (First study for		15
1156	Usefulness of the CHA2DS2-VASC Score to Predict Adverse Outcomes in Patients Having Percutaneous Coronary Intervention. 2016 , 117, 1433-8		26
1155	Unprotected Left Main Disease: Indications and Optimal Strategies for Percutaneous Intervention. 2016 , 18, 19		2
1154	Intracoronary imaging of coronary atherosclerosis: validation for diagnosis, prognosis and treatment. <i>European Heart Journal</i> , 2016 , 37, 524-35a-c	9.5	67
1153	What is the role of coronary angioplasty and stenting in stable angina?. 2016 , 352, i205		7
1152	Same-day transfer for the invasive strategy of patients with non-ST-segment elevation acute coronary syndrome admitted to spoke hospitals: Data from the Emilia-Romagna Regional Network. 2016 , 5, 428-434		7
1151	Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI. 2016 , 67, 603-613		32
1150	Histopathological thrombus analysis in patients with stent thrombosis: what are the missing pieces in the puzzle?. <i>European Heart Journal</i> , 2016 , 37, 1550-2	9.5	0
1149	Simultaneous coronary and carotid revascularisation. 2016 , 58, e234-e237		

1148	Gua ESC 2015 sobre el tratamiento de pacientes con arritmiasventriculares y prevencia de la muerte sbita cardiaca. 2016 , 69, 176.e1-176.e77	11
1147	Developing drugs for use before, during and soon after percutaneous coronary intervention. 2016 , 17, 803-18	9
1146	Periprocedural effects of statins on the incidence of contrast-induced acute kidney injury: A systematic review and trial sequential analysis. 2016 , 206, 143-52	21
1145	Temporal changes in the current practice of primary angioplasty: a real life experience of a single high-volume center. 2016 , 17, 5-9	2
1144	Impact of Diabetic Status on Outcomes After Revascularization With Drug-Eluting Stents in Relation to Coronary Artery Disease Complexity: Patient-Level Pooled Analysis of 6081 Patients. 2016 , 9, e003255	66
1143	Traitements antiplaquettaire et anticoagulant des syndromes coronariens aigus. 2016 , 25, 155-167	
1142	Optimal duration of dual antiplatelet therapy after second-generation drug-eluting stent implantation in patients with diabetes: The SECURITY (Second-Generation Drug-Eluting Stent Implantation Followed By Six- Versus Twelve-Month Dual Antiplatelet Therapy)-diabetes substudy. 2016 , 207, 168-76	16
1141	Long-Term Outcome of Incomplete Revascularization After Percutaneous Coronary Intervention in SCAAR (Swedish Coronary Angiography and Angioplasty Registry). 2016 , 9, 207-215	33
1140	The Role of Manual Aspiration Thrombectomy in Patients Undergoing Primary Percutaneous Coronary Intervention for STEMI. 2016 , 18, 30	1
1139	Remote ischaemic conditioning and healthcare system delay in patients with ST-segment elevation myocardial infarction. 2016 , 102, 1023-8	25
1138	Antikoagulation und perioperatives Bridging. 2016 , 10, 59-72	1
1137	Risk and timing of recurrent ischemic events among patients with stable ischemic heart disease, non-ST-segment elevation acute coronary syndrome, and ST-segment elevation myocardial infarction. 2016 , 175, 56-65	42
1136	Bivalirudin versus heparin in non-ST and ST-segment elevation myocardial infarction-a registry-based randomized clinical trial in the SWEDEHEART registry (the VALIDATE-SWEDEHEART trial). 2016 , 175, 36-46	28
1135	Biomarker evaluation as a potential cause of gender differences in obesity paradox among patients with STEMI. 2016 , 17, 88-94	4
1134	Escalation of therapy without evidence: a "may" does not imply a "should"!. 2016 , 42, 485-487	1
1133	Controversies in the treatment of patients with STEMI and multivessel disease: is it time for PCI of all lesions?. 2016 , 105, 467-70	8
1132	[Contrast-induced nephropathy: An update]. 2016 , 65, 87-94	2
1131	Bioresorbable Vascular Scaffold Technology Benefits From Healthy Skepticism. 2016 , 67, 932-935	10

1130	Aspirin desensitization in patients with acute coronary syndrome. 2016 , 40, 452-4		4
1129	Bivalirudin, glycoprotein inhibitor, and heparin use and association with outcomes of primary percutaneous coronary intervention in the United Kingdom. <i>European Heart Journal</i> , 2016 , 37, 1312-20	9.5	19
1128	The ENCOURAGE mortality risk score and analysis of long-term outcomes after VA-ECMO for acute myocardial infarction with cardiogenic shock. 2016 , 42, 370-378		240
1127	Intracoronary Imaging in the Detection of Vulnerable Plaques. 2016 , 18, 28		21
1126	Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?: A Pre-Specified Analysis From the ZEUS Trial. 2016 , 9, 426-36		99
1125	Disappointing Results, But We Must Carry On. 2016 , 9, 352-354		2
1124	Can't Bare It Any Longer. 2016 , 9, 437-9		1
1123	Anticoagulation in coronary intervention. European Heart Journal, 2016, 37, 3376-3385	9.5	27
1122	Coronary Flow Reserve and Microcirculatory Resistance in Patients With Intermediate Coronary Stenosis. 2016 , 67, 1158-1169		175
1121	The Use of Echocardiography in Certified Chest Pain Units: Results from the German Chest Pain Unit Registry. 2016 , 134, 75-83		9
1120	Provisional vs. two-stent technique for unprotected left main coronary artery disease after ten years follow up: A propensity matched analysis. 2016 , 211, 37-42		41
1119	Thrombus aspiration in acute myocardial infarction. 2016 , 13, 418-28		27
1118	Imaging- and physiology-guided percutaneous coronary intervention without contrast administration in advanced renal failure: a feasibility, safety, and outcome study. <i>European Heart Journal</i> , 2016 , 37, 3090-3095	9.5	110
1117	Multivessel versus culprit lesion only percutaneous revascularization plus potential staged revascularization in patients with acute myocardial infarction complicated by cardiogenic shock: Design and rationale of CULPRIT-SHOCK trial. 2016 , 172, 160-9		75
1116	Risk of Myocardial Infarction in Patients with Long-Term Non-Vitamin K Antagonist Oral Anticoagulant Treatment. 2016 , 58, 483-94		20
1115	MRI in the assessment of ischaemic heart disease. 2016 , 102, 239-52		17
1114	Addition of cilostazol to aspirin therapy for secondary prevention of cardiovascular and cerebrovascular disease in patients undergoing percutaneous coronary intervention: A randomized, open-label trial. 2016 , 173, 134-42		12
1113	NADPH oxidase 4 protects against development of endothelial dysfunction and atherosclerosis in LDL receptor deficient mice. <i>European Heart Journal</i> , 2016 , 37, 1753-61	9.5	79

1112	Enhancement patterns detected by multidetector computed tomography are associated with microvascular obstruction and left ventricular remodelling in patients with acute myocardial infarction. <i>European Heart Journal</i> , 2016 , 37, 684-92	9.5	15
1111	Risk stratification of patients undergoing medical therapy after coronary angiography. <i>European Heart Journal</i> , 2016 , 37, 3103-3110	9.5	6
1110	Causes of Death Following PCI Versus CABG in Complex CAD: 5-Year Follow-Up of SYNTAX. 2016 , 67, 42-55		70
1109	Perfusion dyssynchrony analysis. 2016 , 17, 1414-1423		6
1108	Comparison of the Efficacy of Everolimus-Eluting Stents Versus Drug-Eluting Balloons in Patients With In-Stent Restenosis (from the RIBS IV and V Randomized Clinical Trials). 2016 , 117, 546-554		19
1107	Pre-treatment with P2Y12 inhibitors in ACS patients: who, when, why, and which agent?. <i>European Heart Journal</i> , 2016 , 37, 1284-95	9.5	38
1106	Heparin Versus Bivalirudin Monotherapy in the Setting of Primary Percutaneous Coronary Intervention for Patients With ST-Segment Elevation Myocardial Infarction. 2016 , 50, 141-51		1
1105	Transatlantic Comparison of ST-Segment Elevation Myocardial Infarction Guidelines: Insights From the United States and Europe. 2016 , 67, 216-229		19
1104	Randomized Comparison of Different Thienopyridine Loading Strategies in Patients Undergoing Elective Coronary Intervention: The ExcelsiorLOAD Trial. 2016 , 9, 219-227		15
1103	Association of Dialysis Duration with Outcomes after Transplantation in a Japanese Cohort. 2016 , 11, 497-504		29
1102	Long-term EXAMINATION of drug-eluting stents in acute myocardial infarction. 2016 , 387, 316-318		1
1101	Stent collapse after guide extension catheter collision. Signature procedural finding by optical coherence tomography. 2016 , 202, 488-9		O
1100	Impact of statin non-adherence on in-stent restenosis following bare-metal stent implantation. 2016 , 203, 529-31		6
1099	Treatment of drug-eluting stents in-stent restenosis with paclitaxel-coated balloon angioplasty: Insights from the French "real-world" prospective GARO Registry. 2016 , 203, 690-6		7
1098	Medical Therapy With Versus Without Revascularization in Stable Patients With Moderate and Severe Ischemia: The Case for Community Equipoise. 2016 , 67, 81-99		70
1097	Comparison of Fractional Flow Reserve Based on Computational Fluid Dynamics Modeling Using Coronary Angiographic Vessel Morphology Versus Invasively Measured Fractional Flow Reserve. 2016 , 117, 29-35		46
1096	Predictors of high on-clopidogrel platelet reactivity in patients with acute coronary syndrome. 2016 , 27, 159-67		7
1095	Magnesium stent scaffolds: DREAMS become reality. 2016 , 387, 3-4		18

Duration of dual antiplatelet therapy following drug-eluting coronary stents: Longer or shorter?. **2016**, 202, 936-7

1093	Interventional cardiology: Treating nonischaemic stable CAD lesionssafe to DEFER?. 2016 , 13, 7-8		
1092	Usefulness of Intra-aortic Balloon Pump Counterpulsation. 2016 , 117, 469-76		40
1091	Appropriateness of percutaneous revascularization of coronary chronic total occlusions: an overview. European Heart Journal, 2016, 37, 2692-700	9.5	67
1090	Discontinuation of P2Y12 antagonists before coronary bypass surgery: is 5 days really required?. <i>European Heart Journal</i> , 2016 , 37, 198-9	9.5	6
1089	Update on oral antithrombotic therapy for secondary prevention following non-ST segment elevation myocardial infarction. 2016 , 26, 321-34		3
1088	Healing after coronary artery dissection: The effect of a drug coated balloon angioplasty in a bifurcation lesion. A lesson from intravascular ultrasound analysis. 2016 , 203, 298-300		6
1087	Clinical outcomes in patients with ST-segment elevation myocardial infarction treated with everolimus-eluting stents versus bare-metal stents (EXAMINATION): 5-year results of a randomised trial. 2016 , 387, 357-366		119
1086	Safety of percutaneous coronary intervention in patients with acute ischemic stroke/transient ischemic attack and acute coronary syndrome. 2016 , 105, 356-63		6
1085	Acute coronary syndrome (ACS) in patients with essential thrombocytemia (ET). What is the best treatment?. 2016 , 203, 225-7		6
1084	Intravenous Clopidogrel (MDCO-157) Compared with Oral Clopidogrel: The Randomized Cross-Over AMPHORE Study. 2016 , 16, 43-53		2
1083	Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial. 2016 , 202, 894-6		56
1082	Coronary artery disease: a dam in the river for ranolazine. 2016 , 387, 100-2		1
1081	Patients' attitude and knowledge about oral anticoagulation therapy: results of a self-assessment survey in patients with atrial fibrillation conducted by the European Heart Rhythm Association. 2016 , 18, 151-5		37
1080	Acute heart failure and cardiogenic shock: a multidisciplinary practical guidance. 2016 , 42, 147-63		113
1079	Comparison between drug-coated balloon angioplasty and second-generation drug-eluting stent placement for the treatment of in-stent restenosis after drug-eluting stent implantation. 2016 , 31, 140)5-11	8
1078	Current treatment of left main coronary artery disease. 2016 , 58, e328-e339		2
1077	Coronary artery bypass grafting-related bleeding complications in patients treated with ticagrelor or clopidogrel: a nationwide study. <i>European Heart Journal</i> , 2016 , 37, 189-97	9.5	121

1076	Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European	9.5	3850
1075	Society of Cardiology (ESC). European Heart Journal, 2016, 37, 267-315 Economic impact of contrast-induced acute kidney injury associated with invasive cardiology: role of iso-osmolar contrast media in Germany, Italy, Poland, and Spain. 2016, 19, 158-68		3
1074	Use and outcome of thrombus aspiration in patients with primary PCI for acute ST-elevation myocardial infarction: results from the multinational Euro Heart Survey PCI Registry. 2016 , 31, 1438-45		5
1073	The impact of dual antiplatelet therapy duration on primary composite endpoint after drug-eluting stent implantation: A meta-analysis of 10 randomized trials. 2016 , 202, 504-6		1
1072	Role of intra-aortic balloon pump counterpulsation in the treatment of acute myocardial infarction complicated by cardiogenic shock: Evidence from the Portuguese nationwide registry. 2016 , 5, 23-31		10
1071	Evaluation of the short- and long-term safety and therapy outcomes of the everolimus-eluting bioresorbable vascular scaffold system in patients with coronary artery stenosis: Rationale and design of the German-Austrian ABSORB RegistRy (GABI-R). 2016 , 17, 34-7		19
1070	Impact of incomplete revascularization of coronary artery disease on long-term cardiac outcomes. Retrospective comparison of angiographic and myocardial perfusion imaging criteria for completeness. 2016 , 23, 546-55		9
1069	STEMI patients and nonculprit lesions: To treat or not to treat? and when? A review of most recent literature. 2016 , 87, 1258-68		6
1068	Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial. 2016 , 387, 31-9		224
1067	Off-pump coronary artery bypass grafting improves short-term outcomes in high-risk patients compared with on-pump coronary artery bypass grafting: Meta-analysis. 2016 , 151, 60-77.e1-58		122
1066	Switching P2Y12-receptor inhibitors in patients with coronary artery disease. 2016 , 13, 11-27		127
1065	Differences between automatically detected and steady-state fractional flow reserve. 2016 , 105, 127-3-	4	7
1064	Optimal Duration of Dual Antiplatelet Therapy After DES Implantation: A Meta-Analysis of 11 Randomized Trials. 2016 , 67, 224-38		19
1063	Optimal timing of initiation of oral P2Y12-receptor antagonist therapy in patients with non-ST elevation acute coronary syndromes. Lessons learnt from the ACCOAST-trial. 2016 , 5, 282-8		3
1062	Glycoprotein IIb/IIIa inhibitors: The resurgence of tirofiban. 2016 , 78, 10-6		39
1061	Contrast-Induced Nephropathy: From Pathophysiology to Preventive Strategies. 2016 , 32, 247-55		144
1060	THE STORM (acute coronary Syndrome in paTients end Of life and Risk assesMent) study. 2016 , 33, 10-6		15
1059	Complete myocardial revascularization confers a larger clinical benefit when performed with state-of-the-art techniques in high-risk patients with multivessel coronary artery disease: A meta-analysis of randomized and observational studies. 2016 , 87, 3-12		43

1058	Bilateral internal thoracic artery grafting in octogenarians: where are the benefits?. 2016 , 31, 702-12	23
1057	Impact of preoperative use of P2Y12 receptor inhibitors on clinical outcomes in cardiac and non-cardiac surgery: A systematic review and meta-analysis. 2017 , 6, 753-770	40
1056	Antithrombotic therapy before, during and after emergency angioplasty for ST elevation myocardial infarction. 2017 , 6, 173-190	11
1055	Impact of multivessel coronary artery disease on reperfusion success in patients with ST-elevation myocardial infarction: A substudy of the AIDA STEMI trial. 2017 , 6, 592-600	11
1054	Short-term mechanical circulatory support with the Impella 5.0 device for cardiogenic shock at La Piti [*] Salp"triße. 2017 , 6, 87-92	31
1053	Impact of preoperative dual antiplatelet therapy on bleeding complications in patients with acute coronary syndromes who undergo urgent coronary artery bypass grafting. 2017 , 69, 156-161	9
1052	Clinical predictors of patient related delay in the VIENNA ST-elevation myocardial infarction network and impact on long-term mortality. 2017 , 6, 254-261	20
1051	Intravenous Enoxaparin Versus Unfractionated Heparin in Elderly Patients Undergoing Primary Percutaneous Coronary Intervention: An Analysis of the Randomized ATOLL Trial. 2017 , 68, 29-39	7
1050	Thrombus aspiration in non-ST-elevation myocardial infarction - 12-month clinical outcome of the randomised TATORT-NSTEMI trial. 2017 , 6, 10-17	12
1049	Coronary artery calcium score and N-terminal pro-B-type natriuretic peptide as potential gatekeepers for myocardial perfusion imaging. 2017 , 37, 710-716	1
1048	The wise radialist's guide to optimal transfemoral access: Selection, performance, and troubleshooting. 2017 , 89, 399-407	3
1047	[Computed tomography in patients with chronic stable angina: Fractional flow reserve measurement]. 2017 , 42, 51-57	7
1046	Utility of post-procedural anticoagulation after primary PCI for STEMI: insights from a pooled analysis of the HORIZONS-AMI and EUROMAX trials. 2017 , 6, 659-665	12
1045	Scalpels Versus Balloons in Failing Hearts: Case Closed?. 2017 , 68, 8-9	
1044	Prospective assessment of a palliative care tool to predict one-year mortality in patients with acute coronary syndrome. 2017 , 6, 272-279	8
1043	Systematic review of the clinical impact of dual antiplatelet therapy discontinuation after acute coronary syndromes. 2017 , 6, 522-531	4
1042	Global review of delay time in seeking medical care for chest pain: An integrative literature review. 2017 , 30, 13-20	25
1041	Editor's Choice-Acute versus subacute angiography in patients with non-ST-elevation myocardial infarction - the NONSTEMI trial phase I. 2017 , 6, 490-499	13

[Fractional flow reserve and instantaneous wave-free ratio for coronary artery stenosis in the catheterization laboratory: Practical Coronary artery stenosis in the catheterization laboratory (Practical Coronary artery stenosis)	
Reply to "Predictable Superiority of Everolimus-Eluting Stent C Patients with In-Stent Restenosis". 2017 , 120, e3	over Paclitaxel-Eluting Balloon in
1038 The value of local normal limits in quantitative Thallium-201 CZ	T MPI SPECT. 2017 , 24, 672-682
Detection of ischemia with early myocardial perfusion imaging 2017 , 24, 1157-1160	You see more if you watch before.
1036 [Current management of stable ischemic heart disease]. 2017 ,	43, 57-58
Coronary Artery Bypass Grafting Versus Percutaneous Coronar Ventricular Systolic Dysfunction: A Meta-Analysis. 2017 , 68, 19	
Five-year evolution of reperfusion strategies and early mortali elevation myocardial infarction in France. 2017 , 6, 573-582	y in patients with ST-segment 7
Impact of total stent length after cobalt chromium everolimus clinical outcomes. 2017 , 89, 207-216	eluting stent implantation on 3-year 8
Fractional flow reserve-guided coronary angioplasty using pact implantation: feasibility, safety and 6-month results by angiography. 2017 , 106, 18-27	
1031 Oral Antiplatelet Therapy in Coronary Disease. 2017 , 24, e744-	e750 2
	-
1030 Long (>12 Months) and Short (. 2017 , 24, e468-e476	6
1030 Long (>12 Months) and Short (. 2017 , 24, e468-e476 1029 Trends of percutaneous coronary intervention in Italy in the last	6
	6 t 10 years. 2017 , 18, 170-177
Trends of percutaneous coronary intervention in Italy in the last	6 t 10 years. 2017 , 18, 170-177 6 sk of coronary artery disease. 2017 ,
Trends of percutaneous coronary intervention in Italy in the last Coronary CT angiography in clinical triage of patients at high ris 51, 28-34 9-Month Clinical and Angiographic Outcomes of the COBRA Po	t 10 years. 2017, 18, 170-177 6 sk of coronary artery disease. 2017, 7 lyzene-F NanoCoated Coronary
Trends of percutaneous coronary intervention in Italy in the last Coronary CT angiography in clinical triage of patients at high ris 51, 28-34 9-Month Clinical and Angiographic Outcomes of the COBRA Postent System. 2017, 10, 160-167 Randomized Comparison of Oral P2Y-Receptor Inhibitor Loading	t 10 years. 2017, 18, 170-177 6 sk of coronary artery disease. 2017, 7 lyzene-F NanoCoated Coronary 29 drug-eluting stent implantation for
Trends of percutaneous coronary intervention in Italy in the last Coronary CT angiography in clinical triage of patients at high ris 51, 28-34 9-Month Clinical and Angiographic Outcomes of the COBRA Postent System. 2017, 10, 160-167 Randomized Comparison of Oral P2Y-Receptor Inhibitor Loadin Cangrelor: The ExcelsiorLOAD2 Trial. 2017, 10, 121-129 Predictors of long-term outcomes after bypass grafting versus	t 10 years. 2017, 18, 170-177 6 Sk of coronary artery disease. 2017, 7 lyzene-F NanoCoated Coronary 29 drug-eluting stent implantation for 185 4 Coppler strain and strain rate

	of suboptimal stent deployment using intravascular ultrasound and coronary pressure measurement. 2017 , 69, 613-618	8
	asociados a mortalidad a 30 d\u00e4s en pacientes mayores de 75 a\u00f3s llevados a cateterismo 2017 , 24, 327-333	2
	ular Ultrasound Predictors of Major Adverse Cardiovascular Events After Implantation of us-eluting Stents for Long Coronary Lesions. 2017 , 70, 88-95	2
	es de eventos cardiovasculares adversos mayores en la ecocardiografa intravascular tras te de stents liberadores de everolimus en lesiones coronarias largas. 2017 , 70, 88-95	11
	d y factibilidad de la intervencifi coronaria percutĝea ambulatoria en pacientes ados: datos de un registro multicĥtrico espa ô l. 2017 , 70, 535-542	5
	2016 sobre el diagn§tico y tratamiento de la fibrilaciß auricular, desarrollada en :iß con la EACTS. 2017 , 70, 50.e1-50.e84	6
1016 Cardiac R	emote Ischaemic Preconditioning: Mechanistic and Clinical Considerations. 2017 , 26, 545-553	5
	Please vs. Pantera Lux drug coated balloon angioplasty in real life: Results from the fDCB registry. 2017 , 231, 68-72	12
	versus conventional stent implantation in patients with acute ST-segment elevation al infarction: An updated meta-analysis of 10 studies. 2017 , 230, 509-517	7
	edural myocardial infarction during percutaneous coronary intervention in an academic entre in Johannesburg. 2017 , 230, 175-180	4
1012 multivess care for t	nd rationale of the COMPARE-ACUTE trial: Fractional flow reserve-guided primary sel percutaneous coronary intervention to improve guideline indexed actual standard of reatment of ST-elevation myocardial infarction in patients with multivessel coronary	9
Antithror	2017, 186, 21-28 nbotic treatment in anticoagulated atrial fibrillation patients undergoing percutaneous intervention. 2017, 40, 1-7	4
	platelet agents for the management of acute coronary syndromes: A review for nurses and althorace professionals. 2017 , 29, 104-115	1
	and Fall of Anticoagulation with Bivalirudin During Percutaneous Coronary Interventions: Article. 2017 , 6, 1-12	1
	t of correcting VerifyNow P2Y12 assay results for hematocrit in patients undergoing eous coronary interventions. 2017 , 15, 618-623	13
	l flow reserve and resting indices for coronary physiologic assessment: Practical guide, tricks. 2017 , 90, 598-611	3
	ss of Drug-Eluting Balloons for Bare-Metal and Drug-Eluting In-Stent Restenosis (from the nd V Randomized Trials). 2017 , 119, 983-990	13
	utcomes in myocardial infarction and multivessel disease after a cardiac rehabilitation ne: Partial versus complete revascularization. 2017 , 110, 234-241	

1004	Percutaneous revascularization of chronic total occlusions: Rationale, indications, techniques, and the cardiac surgeon's point of view. 2017 , 231, 90-96	16
1003	Effect of postprocedural full-dose infusion of bivalirudin on acute stent thrombosis in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Outcomes in a large real-world population. 2017 , 35, e12251	2
1002	Coronary Procedures After TAVI With the Self-Expanding Aortic Bioprosthesis Medtronic CoreValvea Not an Easy Matter. 2017 , 30, 56-62	36
1001	Survival Benefits of Invasive Versus Conservative Strategies in Heart Failure in Patients With Reduced Ejection Fraction and Coronary Artery Disease: A Meta-Analysis. 2017 , 10,	75
1000	Midterm and one-year outcome of amphilimus polymer free drug eluting stent in patients needing short dual antiplatelet therapy. Insight from the ASTUTE registry (AmphilimuS iTalian mUlticenTer rEgistry). 2017 , 231, 54-60	10
999	Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis 9.5 of six randomized trials and 11 473 patients. <i>European Heart Journal</i> , 2017 , 38, 1034-1043	110
998	First high-risk percutaneous coronary intervention under use of the iVAC2l system in Germany. 2017 , 13, 117-123	6
997	Cherry-Picking Historical Data to Legitimize Contemporary Practice: Should Diabetic Status Influence Decision-Making in Complex CAD?. 2017 , 69, 404-408	2
996	Treatment of coronary artery in-stent restenosis. 2017 , 15, 191-202	28
995	Percutaneous Coronary Intervention of Complex Calcified Lesions With Drug-Coated Balloon After Rotational Atherectomy. 2017 , 30, 139-146	24
994	Non-ST-Segment Elevation Acute Coronary Syndrome. 2017 , 1-29	1
993	Passagere Herzuntersttzungssysteme. 2017 , 20, 63-79	
992	Preprocedural C-Reactive Protein Predicts Outcomes after Primary Percutaneous Coronary Intervention in Patients with ST-elevation Myocardial Infarction a systematic meta-analysis. 2017 , 7, 41530	26
991	Efficacy and safety of a biodegradable polymer Cobalt-Chromium sirolimus-eluting stent (EXCROSSAL) in treating de novo coronary artery disease: A pooled analysis of the CREDIT II and CREDIT III trials. 2017 , 89, 512-519	4
990	Impact of six versus 12 months of dual antiplatelet therapy in patients with drug-eluting stent implantation after risk stratification with the residual SYNTAX score: Results from a secondary analysis of the I-LOVE-IT 2 trial. 2017 , 89, 565-573	10
989	Aspirin desensitization in patients with coronary artery disease: Cost savings. 2017 , 41, 446-447	2
988	Off-Hour Primary Percutaneous Coronary Angioplasty Does Not Affect Contrast-Induced Nephropathy in Patients With ST-Segment Elevation Myocardial Infarction. 2017 , 68, 807-815	5
987	Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy). 2017 , 135, 1720-1732	13

986	Antithrombotic therapy for patients with STEMI undergoing primary PCI. 2017, 14, 361-379	60
985	Mid- to long-term outcome of patients treated with everolimus-eluting bioresorbable vascular scaffolds: Data of the BVS registry GEtingen predominantly from ACS patients. 2017 , 234, 58-63	3
984	Risk stratification after acute coronary syndromes: Scores, scores and yet another score. 2017 , 36, 85-87	1
983	Canada Acute Coronary Syndrome Score: A Preprocedural Risk Score for Contrast-Induced Nephropathy After Primary Percutaneous Coronary Intervention. 2017 , 68, 782-789	7
982	Aspirin Desensitization in Patients With Coronary Artery Disease: Results of the Multicenter ADAPTED Registry (Aspirin Desensitization in Patients With Coronary Artery Disease). 2017 , 10,	23
981	Recent developments in the management of patients resuscitated from cardiac arrest. 2017 , 39, 97-107	14
980	Increased Radial Access Is Not Associated With Worse Femoral Outcomes for Percutaneous Coronary Intervention in the United Kingdom. 2017 , 10, e004279	24
979	Postoperative ischemic stroke and death prediction with CHADS-VASc score in patients having coronary artery bypass grafting surgery: A nationwide cohort study. 2017 , 241, 120-123	11
978	Left main coronary artery stenosis: severity evaluation and implications for management. 2017 , 15, 157-163	1
977	Association Between Early Q Waves and Reperfusion Success in Patients With ST-Segment-Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention: A Cardiac Magnetic Resonance Imaging Study. 2017 , 10,	8
976	Comparison of P2Y inhibitors for mortality and stent thrombosis in patients with acute coronary syndromes: Single center study of 10 793 consecutive 'real-world' patients. 2017 , 28, 767-773	13
975	Contemporary use of drug-coated balloons in coronary artery disease: Where are we now?. 2017 , 110, 259-272	20
974	Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. 2017 , 389, 1025-1034	543
973	Tailoring duration of DAPT with risk scores. 2017 , 389, 987-989	30
972	Meta-Analysis of the Optimal Percutaneous Revascularization Strategy in Patients With Acute Myocardial Infarction, Cardiogenic Shock, and Multivessel Coronary Artery Disease. 2017 , 119, 1525-1531	5
971	A risk scoring system to predict coronary stent thrombosis. 2017 , 33, 859-867	6
970	Deferred Versus Immediate Stenting in Patients With ST-Segment Elevation Myocardial Infarction: A Systematic Review and Meta-Analysis. 2017 , 6,	15
969	Defining optimal activated clotting time for percutaneous coronary intervention: A systematic review and Bayesian meta-regression. 2017 , 89, 351-366	12

968	Outcomes of Coronary Artery Bypass and Stents for Unprotected Left Main Coronary Stenosis. 2017 , 104, 630-637	6
967	Out-of-hospital cardiac arrest and stent thrombosis: Ticagrelor versus clopidogrel in patients with primary percutaneous coronary intervention under mild therapeutic hypothermia. 2017 , 114, 141-145	21
966	Editor's Choice-The organization of chest pain units: Position statement of the Acute Cardiovascular Care Association. 2017 , 6, 203-211	13
965	Effect of Ischemic Postconditioning During Primary Percutaneous Coronary Intervention for Patients With ST-Segment Elevation Myocardial Infarction: A Randomized Clinical Trial. 2017 , 2, 490-497	70
964	High Urine Output With Matched Hydration for CI-AKI Prevention: "Salus Per Aquam" (Health Through Water). 2017 , 10, 364-366	2
963	Determination of health anxiety, anxiety, and somatosensory amplification levels in individuals with normal coronary angiography. 2017 , 252, 114-117	5
962	Safety and Feasibility of Outpatient Percutaneous Coronary Intervention in Selected Patients: A Spanish Multicenter Registry. 2017 , 70, 535-542	3
961	A prospective, randomized, open-label trial of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction: Rationale and design of the "DAPT-STEMI trial". 2017 , 188, 11-17	12
960	Preoperative intra-aortic balloon pump use in high-risk patients prior to coronary artery bypass graft surgery decreases the risk for morbidity and mortality-A meta-analysis of 9,212 patients. 2017 , 32, 177-185	25
959	Intracoronary Imaging. 2017 , 103, 708-725	5
959 958	Intracoronary Imaging. 2017, 103, 708-725 Intracoronary optical coherence tomography: Clinical and research applications and intravascular imaging software overview. 2017, 89, 679-689	5
	Intracoronary optical coherence tomography: Clinical and research applications and intravascular	
958	Intracoronary optical coherence tomography: Clinical and research applications and intravascular imaging software overview. 2017 , 89, 679-689 Assessment of myocardial ischemia by strain dobutamine stress echocardiography and cardiac	14
958 957	Intracoronary optical coherence tomography: Clinical and research applications and intravascular imaging software overview. 2017 , 89, 679-689 Assessment of myocardial ischemia by strain dobutamine stress echocardiography and cardiac magnetic resonance perfusion imaging before and after coronary artery bypass grafting. 2017 , 34, 557-566	14 5
958 957 956	Intracoronary optical coherence tomography: Clinical and research applications and intravascular imaging software overview. 2017 , 89, 679-689 Assessment of myocardial ischemia by strain dobutamine stress echocardiography and cardiac magnetic resonance perfusion imaging before and after coronary artery bypass grafting. 2017 , 34, 557-566 Bleeding associated with the management of acute coronary syndromes. 2017 , 103, 546-562	14 5 5
958 957 956 955	Intracoronary optical coherence tomography: Clinical and research applications and intravascular imaging software overview. 2017 , 89, 679-689 Assessment of myocardial ischemia by strain dobutamine stress echocardiography and cardiac magnetic resonance perfusion imaging before and after coronary artery bypass grafting. 2017 , 34, 557-566 Bleeding associated with the management of acute coronary syndromes. 2017 , 103, 546-562 Coronary revascularisation in the elderly. 2017 , 103, 316-324 Optimal duration of dual antiplatelet therapy after acute coronary syndromes and coronary	14 5 5
958 957 956 955 954	Intracoronary optical coherence tomography: Clinical and research applications and intravascular imaging software overview. 2017, 89, 679-689 Assessment of myocardial ischemia by strain dobutamine stress echocardiography and cardiac magnetic resonance perfusion imaging before and after coronary artery bypass grafting. 2017, 34, 557-566 Bleeding associated with the management of acute coronary syndromes. 2017, 103, 546-562 Coronary revascularisation in the elderly. 2017, 103, 316-324 Optimal duration of dual antiplatelet therapy after acute coronary syndromes and coronary stenting. 2017, 103, 871-884 Drug-eluting stents versus bare-metal stents in acute myocardial infarction with cardiogenic shock.	14 5 5 10

950	Percutaneous coronary intervention vs. cardiac surgery in diabetic patients. Where are we now and where should we be going?. 2017 , 58, 178-189	13
949	The development and mechanical characterisation of a novel reinforced venous conduit that mimics the mechanical properties of an arterial wall. 2017 , 71, 23-31	5
948	Meta-Analysis of Randomized Control Trials Comparing Drug-Eluting Stents Versus Coronary Artery Bypass Grafting for Significant Left Main Coronary Narrowing. 2017 , 119, 1338-1343	4
947	Everolimus- Versus Novolimus-Eluting Bioresorbable Scaffolds for the Treatment of Coronary Artery Disease: A Matched Comparison. 2017 , 10, 477-485	9
946	Antiplatelet Therapy After Implantation of Bioresorbable Vascular Scaffolds: A Review of the Published Data, Practical Recommendations, and Future Directions. 2017 , 10, 425-437	34
945	Can Functional Testing for Ischemia and Viability Guide Revascularization?. 2017 , 10, 354-364	13
944	Five-year clinical performance of a biodegradable polymer-coated biolimus-eluting stent in unselected patients. 2017 , 103, 111-116	8
943	Utilidad de EuroSCORE-II en pacientes con cardiopatā isqumica. 2017 , 24, 56-62	
942	Coronary bypass surgery versus stenting in multivessel disease involving the proximal left anterior descending coronary artery. 2017 , 103, 428-433	13
941	Optimal duration of dual antiplatelet therapy following percutaneous coronary intervention: protocol for an umbrella review. 2017 , 7, e015421	2
940	Stress Perfusion CMR in Patients With Known and Suspected CAD: Prognostic Value and Optimal Ischemic Threshold for Revascularization. 2017 , 10, 526-537	72
939	Fractional Flow Reserve-Guided Complete Revascularization Improves the Prognosis in Patients With ST-Segment-Elevation Myocardial Infarction and Severe Nonculprit Disease: A DANAMI 3-PRIMULTI Substudy (Primary PCI in Patients With ST-Elevation Myocardial Infarction and	29
938	Comparison of Iodixanol and Iopromide in Patients With Renal Insufficiency and Congestive Heart Failure Undergoing Coronary Angiography by Hemodynamic Monitoring. 2017 , 68, 907-913	3
937	Correlation between Angiographic and Physiologic Evaluation of Coronary Artery Narrowings in Patients With Aortic Valve Stenosis. 2017 , 120, 106-110	15
936	[Coronary artery disease: Interventional and operative therapeutic options after cardiac arrest]. 2017 , 42, 138-150	1
935	Comparison of ESC and ACC/AHA guidelines for myocardial revascularization. 2017, 24, 1046-1053	14
934	Long-term follow-up of first generation versus new-generation drug-eluting stents in three-vessel coronary artery disease. 2017 , 18, 492-496	5
933	Previous hypertensive hemorrhage increases the risk for bleeding and ischemia for PCI patients on dual antiplatelet therapy. 2017 , 39, 516-520	O

932	Quality of life following coronary artery bypass graft surgery vs. percutaneous coronary intervention in diabetics with multivessel disease: a five-year registry study. 2017 , 3, 216-223	6
931	Prognosis of complete versus incomplete revascularisation of patients with STEMI with multivessel coronary artery disease: an observational study. 2017 , 4, e000541	7
930	[Secondary prevention after myocardial infarction with prolonged dual anti-platelet therapy (DAPT). A new therapeutic concept]. 2017 , 159, 49-52	
929	Cardiological Society of India: Position statement for the management of ST elevation myocardial infarction in India. 2017 , 69 Suppl 1, S63-S97	30
928	Angiographic Follow-Up in Patients With Coronary Artery Disease: Is There a Window to Be Definitively Closed?. 2017 , 10, 843-844	О
927	Real-world use of ticagrelor and prasugrel in patients with NSTEMI undergoing percutaneous coronary intervention. 2017 , 18, 450-451	4
926	Contemporary practice and outcomes of an elderly cohort of Japanese patients with non-ST-elevation acute coronary syndrome in the era of routine early invasive strategy. 2017 , 240, 49-54	2
925	The European Association of Preventive Cardiology Exercise Prescription in Everyday Practice and Rehabilitative Training (EXPERT) tool: A digital training and decision support system for optimized exercise prescription in cardiovascular disease. Concept, definitions and construction methodology.	84
924	Impact of Mild-to-Moderate Chronic Kidney Disease on One Year Outcomes after Percutaneous Coronary Intervention. 2017 , 137, 23-28	3
923	Intravascular Ultrasound Guidance Is Associated With Better Outcome in Patients Undergoing Unprotected Left Main Coronary Artery Stenting Compared With Angiography Guidance Alone. 2017 , 10,	57
922	Optical Coherence Tomography Findings in Patients With Stent Thrombosis. 2017 , 70, 1050-1058	1
921	[Initial management of ST-elevation myocardial infarction in 2014: From guidelines to practices, survey of 176 French interventional cardiologists]. 2017 , 66, 184-189	
920	Patterns and associations between DAPT cessation and 2-year clinical outcomes in left main/proximal LAD versus other PCI: Results from the Patterns of Non-Adherence to Dual Antiplatelet Therapy in Stented Patients (PARIS) registry. 2017 , 243, 132-139	8
919	Geographical Difference of the Interaction of Sex With Treatment Strategy in Patients With Multivessel Disease and Left Main Disease: A Meta-Analysis From SYNTAX (Synergy Between PCI With Taxus and Cardiac Surgery), PRECOMBAT (Bypass Surgery Versus Angioplasty Using	24
918	Perioperative Management of Dual-Antiplatelet Therapy in Patients With New-Generation Drug-Eluting Metallic Stents and Bioresorbable Vascular Scaffolds Undergoing Elective Noncardiac Surgery. 2017 , 31, 1857-1864	6
917	Effect of stenosis eccentricity on the functionality of coronary bifurcation lesions-a numerical study. 2017 , 55, 2079-2095	5
916	Thirty-Year Mortality After Coronary Artery Bypass Graft Surgery: A Danish Nationwide Population-Based Cohort Study. 2017 , 10, e002708	31
915	Is the Future of Coronary Arterial Revascularization a Hybrid Approach?: The Canadian Experience Across Three Centers. 2017 , 12, 82-86	14

914	Fractional flow reserve in 2017: current data and everyday practice. 2017, 15, 457-472		3
913	Comparison of Outcomes of Coronary Artery Bypass Grafting Versus Drug-Eluting Stent Implantation in Patients With Severe Left Ventricular Dysfunction. 2017 , 120, 69-74		19
912	The Contribution of Individual Exercise Training Components to Clinical Outcomes in Randomised Controlled Trials of Cardiac Rehabilitation: A Systematic Review and Meta-regression. 2017 , 3, 19		39
911	Comparison of Outcome of Coronary Artery Bypass Grafting Versus Drug-Eluting Stent Implantation for Non-ST-Elevation Acute Coronary Syndrome. 2017 , 120, 380-386		35
910	Utility of stress perfusion-cardiac magnetic resonance in follow-up of patients undergoing percutaneous coronary interventions of the left main coronary artery. 2017 , 33, 1589-1597		1
909	Current Interventions for the Left Main Bifurcation. 2017 , 10, 849-865		34
908	Comparison of Ticagrelor Pharmacokinetics and Pharmacodynamics in STEMI and NSTEMI Patients (PINPOINT): protocol for a prospective, observational, single-centre study. 2017 , 7, e013218		8
907	Perioperative Statins Do Not Prevent Acute Kidney Injury After Cardiac Surgery: A Meta-analysis of Randomized Controlled Trials. 2017 , 31, 2086-2092		9
906	High Volume Nuklearkardiologie mit Cadmiumzinktellurid-(CZT) Technik. 2017, 40, 30-39		
905	Impact of the SYNTAX scores I and II in patients with diabetes and multivessel coronary disease: a pooled analysis of patient level data from the SYNTAX, PRECOMBAT, and BEST trials. <i>European Heart Journal</i> , 2017 , 38, 1969-1977	9.5	49
905 904	pooled analysis of patient level data from the SYNTAX, PRECOMBAT, and BEST trials. European	9.5	49
	pooled analysis of patient level data from the SYNTAX, PRECOMBAT, and BEST trials. <i>European Heart Journal</i> , 2017 , 38, 1969-1977	9.5	
904	pooled analysis of patient level data from the SYNTAX, PRECOMBAT, and BEST trials. <i>European Heart Journal</i> , 2017 , 38, 1969-1977 Antiplatelet treatments: recent evidence from randomized controlled trials. 2017 , 32, 356-362 Complete versus culprit-only revascularisation in ST elevation myocardial infarction with	9.5	4
904	pooled analysis of patient level data from the SYNTAX, PRECOMBAT, and BEST trials. <i>European Heart Journal</i> , 2017 , 38, 1969-1977 Antiplatelet treatments: recent evidence from randomized controlled trials. 2017 , 32, 356-362 Complete versus culprit-only revascularisation in ST elevation myocardial infarction with multi-vessel disease. 2017 , 5, CD011986	9.5	13
904 903 902	pooled analysis of patient level data from the SYNTAX, PRECOMBAT, and BEST trials. <i>European Heart Journal</i> , 2017, 38, 1969-1977 Antiplatelet treatments: recent evidence from randomized controlled trials. 2017, 32, 356-362 Complete versus culprit-only revascularisation in ST elevation myocardial infarction with multi-vessel disease. 2017, 5, CD011986 Cardiogenic shock management: Still a challenge and a need for large-registry data. 2017, 110, 433-438 Actualidad en nefropata por medio de contraste. 2017, 14, 69-78	9.5	4 13 7
904 903 902 901	pooled analysis of patient level data from the SYNTAX, PRECOMBAT, and BEST trials. <i>European Heart Journal</i> , 2017, 38, 1969-1977 Antiplatelet treatments: recent evidence from randomized controlled trials. 2017, 32, 356-362 Complete versus culprit-only revascularisation in ST elevation myocardial infarction with multi-vessel disease. 2017, 5, CD011986 Cardiogenic shock management: Still a challenge and a need for large-registry data. 2017, 110, 433-438 Actualidad en nefropata por medio de contraste. 2017, 14, 69-78 Fractional flow reserve and pressure-bounded coronary flow reserve to predict outcomes in		4 13 7
904 903 902 901 900	pooled analysis of patient level data from the SYNTAX, PRECOMBAT, and BEST trials. European Heart Journal, 2017, 38, 1969-1977 Antiplatelet treatments: recent evidence from randomized controlled trials. 2017, 32, 356-362 Complete versus culprit-only revascularisation in ST elevation myocardial infarction with multi-vessel disease. 2017, 5, CD011986 Cardiogenic shock management: Still a challenge and a need for large-registry data. 2017, 110, 433-438 Actualidad en nefropatä por medio de contraste. 2017, 14, 69-78 Fractional flow reserve and pressure-bounded coronary flow reserve to predict outcomes in coronary artery disease. European Heart Journal, 2017, 38, 1980-1989 Der invasive Ischânienachweis âlFraktionelle Flussreserve (FFR) und Instantaneous Wave Free		4 13 7

896	Impact of point-of-care pre-procedure creatinine and eGFR testing in patients with ST segment elevation myocardial infarction undergoing primary PCI: The pilot STATCREAT study. 2017 , 240, 8-13	5
895	Cutoff Value and Long-Term Prediction of Clinical Events by FFR Measured Immediately After Implantation of a Drug-Eluting Stent in Patients With Coronary Artery Disease: 1- to 3-Year Results From the DKCRUSH VII Registry Study. 2017 , 10, 986-995	59
894	Percutaneous intervention versus coronary artery bypass graft surgery in left main coronary artery stenosis: a systematic review and meta-analysis. 2017 , 15, 84	13
893	Myocardial salvage after primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction presenting early versus late after symptom onset. 2017 , 33, 1571-1579	10
892	Coronary artery bypass graft surgery versus percutaneous coronary intervention with drug-eluting stents for left main coronary artery disease: A meta-analysis of randomized trials. 2017 , 241, 142-148	11
891	Should Fractional Flow Reserve Be Measured After Stent Deployment? Routinely? Ever?. 2017 , 10, 996-998	2
890	Atrial Fibrillation and Percutaneous Coronary Intervention. 2017,	
889	Interventional therapies in acute myocardial infarction complicated by cardiogenic shock. 2017 , 42, 11-17	2
888	Complete revascularization versus culprit-only revascularization in ST-segment elevation myocardial infarction and multivessel disease patients undergoing primary percutaneous coronary intervention: A meta-analysis and trial sequential analysis. 2017 , 228, 844-852	10
887	Cuitabia - DOV Danaba Jabibisia - Thomasia - 2017 (67 00	_
007	Switching P2Y Receptor Inhibiting Therapies. 2017 , 6, 67-89	8
886	Current Role of Platelet Function Testing in Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting. 2017 , 6, 151-166	4
ŕ	Current Role of Platelet Function Testing in Percutaneous Coronary Intervention and Coronary	
886	Current Role of Platelet Function Testing in Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting. 2017 , 6, 151-166 Coronary flow reserve and relative flow reserve measured by N-13 ammonia PET for	4
886	Current Role of Platelet Function Testing in Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting. 2017, 6, 151-166 Coronary flow reserve and relative flow reserve measured by N-13 ammonia PET for characterization of coronary artery disease. 2017, 31, 144-152 Left ventricular diastolic dysfunction in patients with ST-elevation myocardial infarction following	12
886 885 884	Current Role of Platelet Function Testing in Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting. 2017, 6, 151-166 Coronary flow reserve and relative flow reserve measured by N-13 ammonia PET for characterization of coronary artery disease. 2017, 31, 144-152 Left ventricular diastolic dysfunction in patients with ST-elevation myocardial infarction following early and late reperfusion by coronary intervention. 2017, 228, 886-889	12
886 885 884 883	Current Role of Platelet Function Testing in Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting. 2017, 6, 151-166 Coronary flow reserve and relative flow reserve measured by N-13 ammonia PET for characterization of coronary artery disease. 2017, 31, 144-152 Left ventricular diastolic dysfunction in patients with ST-elevation myocardial infarction following early and late reperfusion by coronary intervention. 2017, 228, 886-889 STREAM characterisation correction - Authors' reply. 2017, 389, 2102-2103 Clinical benefit of drugs targeting mitochondrial function as an adjunct to reperfusion in ST-segment elevation myocardial infarction: A meta-analysis of randomized clinical trials. 2017,	4 12 6
886 885 884 883	Current Role of Platelet Function Testing in Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting. 2017, 6, 151-166 Coronary flow reserve and relative flow reserve measured by N-13 ammonia PET for characterization of coronary artery disease. 2017, 31, 144-152 Left ventricular diastolic dysfunction in patients with ST-elevation myocardial infarction following early and late reperfusion by coronary intervention. 2017, 228, 886-889 STREAM characterisation correction - Authors' reply. 2017, 389, 2102-2103 Clinical benefit of drugs targeting mitochondrial function as an adjunct to reperfusion in ST-segment elevation myocardial infarction: A meta-analysis of randomized clinical trials. 2017, 244, 59-66 Antiplatelet and antithrombotic treatment for secondary prevention in ischaemic heart disease.	4 12 6

878	Transradial Approach for Percutaneous Interventions. 2017 ,	1
877	Transcoronary Concentration Gradient of microRNA-133a and Outcome in Patients With Coronary Artery Disease. 2017 , 120, 15-24	33
876	Current perspectives on revascularization in multivessel ST elevation myocardial infarction. 2017 , 28, 498-506	2
875	Long-term outcome prediction by functional parameters derived from coronary computed tomography angiography. 2017 , 243, 533-537	11
874	Long-Term Clinical Outcomes of Patients Treated With Everolimus-Eluting Bioresorbable Stents in Routine Practice: 2-Year Results of the ISAR-ABSORB Registry. 2017 , 10, 1222-1229	21
873	6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel). 2017 , 10, 1202-1210	38
872	Underestimation of the incidence of new-onset post-coronary artery bypass grafting atrial fibrillation and its impact on 30-day mortality. 2017 , 154, 1260-1266	15
871	CT angiography to evaluate coronary artery disease and revascularization requirement before trans-catheter aortic valve replacement. 2017 , 11, 338-346	37
870	Antiplatelet Therapy, Platelet Function Testing, and Bleeding Complications in Cardiac Surgery Patients. 2017 , 43, 699-705	6
869	Safe Hydration Volume to Prevent Contrast-induced Acute Kidney Injury and Worsening Heart Failure in Patients With Heart Failure and Preserved Ejection Fraction After Cardiac Catheterization. 2017 , 70, 168-175	3
868	Drug-coated balloon: Long-term outcome from a real world three-center experience. 2017 , 30, 318-324	5
867	Time is still muscle and there is still room for improvement. 2017 , 103, 96-97	
866	Assessment of myocardial blood flow and coronary flow reserve with positron emission tomography in ischemic heart disease: current state and future directions. 2017 , 22, 441-453	17
865	Left Main Coronary Artery Compression in Patients With Pulmonary Arterial Hypertension and Angina. 2017 , 69, 2808-2817	60
864	Efficacy and Safety of Novel Oral P2Y12 Receptor Inhibitors in Patients With ST-Segment Elevation Myocardial Infarction Undergoing PCI: A Systematic Review and Meta-Analysis. 2017 , 69, 215-227	10
863	Antithrombotic therapy in end-stage renal disease. 2017 , 21, 453-471	6
862	PRotective Effect on the coronary microcirculation of patients with Diabetes by Clopidogrel or Ticagrelor (PREDICT): study rationale and design. A randomized multicenter clinical trial using intracoronary multimodal physiology. 2017 , 16, 68	4
861	Mortality in isolated coronary artery bypass surgery in elderly patients. A retrospective analysis over 14 years. 2017 , 64, 262-272	O

860	Diagnostic accuracy of a hybrid approach of instantaneous wave-free ratio and fractional flow reserve using high-dose intracoronary adenosine to characterize intermediate coronary lesions: Results of the PALS (Practical Assessment of Lesion Severity) prospective study. 2017 , 90, 1070-1076	6
859	Effects of coronary artery disease in patients undergoing transcatheter aortic valve implantation: A study of age- and gender-matched cohorts. 2017 , 243, 150-155	17
858	Surgical Revascularization in Older Adults with Ischemic Cardiomyopathy. 2017, 13, 571-580	4
857	A Test in Context: Fractional Flow Reserve: Accuracy, Prognostic Implications, and Limitations. 2017 , 69, 2748-2758	25
856	Drug-coated versus bare-metal stents for elderly patients: A predefined sub-study of the LEADERS FREE trial. 2017 , 243, 110-115	22
855	The impact of clinical and genetic factors on ticagrelor and clopidogrel antiplatelet therapy. 2017 , 18, 969-979	9
854	Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention. 2017 , 167, 17-25	30
853	Percutaneous Coronary Intervention of Left Main Disease: Pre- and Post-EXCEL (Evaluation of XIENCE Everolimus Eluting Stent Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization) and NOBLE (Nordic-Baltic-British Left Main Revascularization Study) Era.	11
852	Classical determinants of coronary artery disease as predictors of complexity of coronary lesions, assessed with the SYNTAX score. 2017 , 25, 490-497	4
851	One-Year Survival is Not Affected by Gastrointestinal Bleeding After Percutaneous Coronary Interventions. 2017 , 353, 381-386	2
850	Impact of intra-aortic balloon pump on short-term clinical outcomes in ST-elevation myocardial infarction complicated by cardiogenic shock: A âleal lifeâlingle center experience. 2017 , 41, 86-93	
849	Coronary sinus flow measurement-a useful addition to first pass myocardial perfusion cardiovascular magnetic resonance?. 2017 , 18, 860-861	
848	The quest for equilibrium: exploring the thin red line between bleeding and ischaemic risks in the management of acute coronary syndromes in chronic kidney disease patients. 2017 , 32, 1967-1976	11
847	Cirugã coronaria con doble arteria mamaria: nuestra experiencia inicial y resultados a corto plazo. 2017 , 24, 142-148	
846	Navvus FFR to reduce CONTRAst, Cost and radiaTion (CONTRACT); insights from a single-centre clinical and economical evaluation with the RXi Rapid-Exchange FFR device. 2017 , 233, 80-84	4
845	The Promus Premier everolimus-eluting platinum chromium stent with durable polymer evaluated in a real world all-comer population in Rotterdam cardiology hospital (the P-SEARCH registry). 2017 , 240, 103-107	1
844	Effect of acute coronary syndrome patients' education on adherence to dual antiplatelet therapy. 2017 , 29, 252-258	5
843	Parada cardiaca debido a hemorragia subaracnoidea simulando un stidrome coronario agudo. 2017 , 24, 316-317	

842	Mortality in isolated coronary artery bypass surgery in elderly patients. A retrospective analysis over 14 years. 2017 , 64, 262-272	
841	Risk stratification after acute coronary syndromes: Scores, scores and yet another score. 2017 , 36, 85-87	
840	Update on the Management of Chronic Total Occlusions in Coronary Artery Disease. 2017 , 19, 19	7
839	Continuity of care after percutaneous coronary intervention: The patient's perspective across secondary and primary care settings. 2017 , 16, 444-452	17
838	The Hidden Traps of Meta-Analyses on Cardiac Surgery Mortality Risk Scores. 2017 , 120, 337-338	1
837	Percutaneous revascularization of coronary chronic total occlusion: Toward a reappraisal of the available evidence. 2017 , 69, 799-807	5
836	Initiation and duration of dual antiplatelet therapy after inpatient percutaneous coronary intervention with stent implantation in Germany: An electronic healthcare database cohort study. 2017 , 120, 31-38	
835	Total Center Percutaneous Coronary Intervention Volume and 30-Day Mortality: A Contemporary National Cohort Study of 427 467 Elective, Urgent, and Emergency Cases. 2017 , 10,	10
834	First experience of drug-coated balloons for treatment of bioresorbable vascular scaffold restenosis. 2017 , 18, 482-486	6
833	Acute kidney injury: Intravenous hydration for the prevention of CIAKI. 2017 , 13, 264-266	3
832	Cangrelor: A New Route for P2Y12 Inhibition. 2017, 25, 133-139	21
831	'PERFSCORE' - a multidimensional score: a simple way to predict the success of cardiac rehabilitation. 2017 , 18, 617-624	8
830	Comparison of Outcomes in Men Versus Women After Percutaneous Coronary Intervention for Chronic Total Occlusion. 2017 , 119, 1931-1936	10
829	Long-term serial non-invasive multislice computed tomography angiography with functional evaluation after coronary implantation of a bioresorbable everolimus-eluting scaffold: the ABSORB cohort B MSCT substudy. 2017 , 18, 870-879	11
828	LAA occluder device for stroke prevention: Data on WATCHMAN and other LAA occluders. 2017 , 27, 435-446	3
827	Post-Hoc Study: Intravenous Hydration Treatment in Chinese Patients with High Risk of Contrast-Induced Nephropathy Following Percutaneous Coronary Intervention. 2017 , 7, 45023	10
826	Role of deferred stenting in patients with ST elevation myocardial infarction treated with primary percutaneous coronary intervention: A systematic review and meta-analysis. 2017 , 30, 264-273	15
825	Comparison of Transradial and Transfemoral Approaches in Women Undergoing Percutaneous Coronary Intervention in China: A Retrospective Observational Study. 2017 , 68, 799-806	3

824	Editor's Choice - Management of the Diseases of Mesenteric Arteries and Veins: Clinical Practice Guidelines of the European Society of Vascular Surgery (ESVS). 2017 , 53, 460-510	236
823	Bioresorbable Scaffolds versus Metallic Stents in Routine PCI. 2017 , 376, 2319-2328	279
822	An FFR diagnostic strategy versus usual care in patients with suspected coronary artery disease planned for invasive coronary angiography at German sites: one-year results of a subgroup analysis of the PLATFORM (Prospective Longitudinal Trial of FFR: Outcome and Resource Impacts) study.	4
821	Fractional Flow Reserve and Cardiac Events in Coronary Artery Disease: Data From a Prospective IRIS-FFR Registry (Interventional Cardiology Research Incooperation Society Fractional Flow Reserve). 2017 , 135, 2241-2251	96
820	Sex-Related 30-Day and Long-Term Mortality in Acute Myocardial Infarction Patients Treated with Percutaneous Coronary Intervention. 2017 , 26, 374-379	10
819	Spontaneous coronary artery dissection. 2017 , 103, 1043-1051	52
818	Reduced duration of dual antiplatelet therapy using an improved drug-eluting stent for percutaneous coronary intervention of the left main artery in a real-world, all-comer population: Rationale and study design of the prospective randomized multicenter IDEAL-LM trial. 2017 , 187, 104-111	10
817	The optimal discontinuation of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention with drug-eluting stents: A meta-analysis of randomized trials. 2017 , 235, 73-86	5
816	Effect of Tailored Antiplatelet Therapy to Reduce Recurrent Stent Thrombosis and Cardiac Death After a First Episode of Stent Thrombosis. 2017 , 119, 1500-1506	3
815	BIOFLOW-III satellite-One-year clinical outcomes of diabetic patients treated with a biodegradable polymer sirolimus-eluting stent and comprehensive medical surveillance. 2017 , 18, 338-343	3
814	Drug-Eluting Balloon In-Stent Restenosis Treatment: Why not?. 2017 , 26, e102-e103	
813	Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study. 2017 , 2, 478-487	17
812	Can we perform rotational atherectomy in patients with severe aortic stenosis? Substudy from the OCEAN TAVI Registry. 2017 , 18, 356-360	2
811	Bedside screening with the use of pocket-size imaging device can be useful for ruling out carotid artery stenosis in patients scheduled for cardiac surgery. 2017 , 34, 716-722	5
810	Use of the Instantaneous Wave-free Ratio or Fractional Flow Reserve in PCI. 2017, 376, 1824-1834	462
809	Instantaneous Wave-free Ratio versus Fractional Flow Reserve to Guide PCI. 2017 , 376, 1813-1823	459
808	Unrecognized coronary vasospasm in patients referred for percutaneous coronary intervention: Intracoronary nitroglycerin, the forgotten stepchild of cardiovascular guidelines. 2017 , 90, 1086-1090	3
807	Effect of coronary dominance on 2-year outcomes after percutaneous coronary intervention in patients with acute coronary syndrome. 2017 , 89, 549-554	3

806	Effect of Dose and Timing of Preoperative Statins on Mortality After Coronary Artery Bypass Surgery. 2017 , 104, 782-789	14
805	Long-Term Outcomes of Stenting the Proximal Left Anterior Descending Artery in the PROTECT Trial. 2017 , 10, 548-556	8
804	An Atelocollagen Coating for Efficient Local Gene Silencing by Using Small Interfering RNA. 2017 , 6, 290-301	5
803	S2k-Guideline Helicobacter pylori and gastroduodenal ulcer disease. 2017 , 55, 167-206	12
802	Updated evidence for left main coronary artery disease: Practice versus the consensus. 2017 , 153, 312-313	2
801	Atrial Fibrillation on Vitamin K Antagonist Undergoing Primary Percutaneous Coronary Intervention for Acute ST-Elevation Myocardial Infarction. 2017 , 79-94	
800	Antiplatelet agents in hemodialysis. 2017 , 30, 373-383	6
799	Impact of Patient and Lesion Complexity on Long-Term Outcomes Following Coronary Revascularization With New-Generation Drug-Eluting Stents. 2017 , 119, 501-507	7
798	Antiplatelet therapy in patients with glucose-6-phosphate dehydrogenases deficiency after percutaneous coronary intervention: A reappraisal for clinical and interventional cardiologists. 2017 , 18, 226-229	3
797	Recurrent in-stent restenosis, certainty of its origin, uncertainty about treatment. 2017 , 230, 91-96	17
796	Effect of Early Initiation of Mechanical Circulatory Support on Survival in Cardiogenic Shock. 2017 , 119, 845-851	197
795	Comparison of Outcomes of Staged Complete Revascularization Versus Culprit Lesion-Only Revascularization for ST-Elevation Myocardial Infarction and Multivessel Coronary Artery Disease. 2017 , 119, 508-514	8
794	P2Y receptor inhibition with prasugrel and ticagrelor in STEMI patients after fibrinolytic therapy: Analysis from the SAMPA randomized trial. 2017 , 230, 204-208	10
793	Reducing Mortality in the Perioperative Period. 2017,	1
792	A clinical model to identify patients with high-risk plaque by coronary computed tomography angiography. 2017 , 228, 260-264	8
791	Comparison of outcomes after treatment of in-stent restenosis using newer generation drug-eluting stents versus drug-eluting balloon: Patient-level pooled analysis of Korean Multicenter in-Stent Restenosis Registry. 2017 , 230, 181-190	16
790	The ReACT Trial: Randomized Evaluation of Routine Follow-up Coronary Angiography After Percutaneous Coronary Intervention Trial. 2017 , 10, 109-117	27
789	Recent Trends in Management and Inhospital Outcomes of Acute Myocardial Infarction in Renal Transplant Recipients. 2017 , 119, 542-552	8

788	A novel risk model including vascular access site for predicting 30-day mortality after primary PCI: The ALPHA score. 2017 , 18, 33-39	4
787	The year in cardiology 2016: coronary interventions. <i>European Heart Journal</i> , 2017 , 38, 1017-1027 9.5	О
786	[Left ventricular unloading in cardiogenic shock]. 2017 , 42, 18-26	4
785	Platelet function one and three months after coronary bypass surgery in relation to once or twice daily dosing of acetylsalicylic acid. 2017 , 149, 64-69	10
784	Clinical outcomes of femoral closure compared to radial compression devices following percutaneous coronary intervention: the FERARI study. 2017 , 32, 520-530	3
783	A randomized clinical trial comparing long-term clopidogrel vs aspirin monotherapy beyond dual antiplatelet therapy after drug-eluting coronary stent implantation: Design and rationale of the Harmonizing Optimal Strategy for Treatment of coronary artery stenosis-Extended Antiplatelet	8
782	The assessment of ischaemic burden: validation of a functional jeopardy score against cardiovascular magnetic resonance perfusion imaging. 2017 , 106, 259-270	4
781	Comparison of Bailout and Planned Rotational Atherectomy for Heavily Calcified Coronary Lesions: A Single-Center Experience. 2017 , 30, 124-133	16
780	Atrial Fibrillation on Vitamin K Antagonist Oral Anticoagulant Undergoing Urgent Percutaneous Coronary Intervention for Non-ST-Elevation Acute Coronary Syndrome. 2017 , 59-77	
779	Mechanisms, Consequences, and Prevention of Coronary Graft Failure. 2017 , 136, 1749-1764	113
779 778	Mechanisms, Consequences, and Prevention of Coronary Graft Failure. 2017, 136, 1749-1764 Dual antiplatelet therapy for secondary prevention of coronary artery disease. 2017, 4, e000651	113 28
		, in the second second
77 ⁸	Dual antiplatelet therapy for secondary prevention of coronary artery disease. 2017 , 4, e000651 Short and long-term outcome in very old patients with ST-elevation myocardial infarction after	28
77 ⁸	Dual antiplatelet therapy for secondary prevention of coronary artery disease. 2017 , 4, e000651 Short and long-term outcome in very old patients with ST-elevation myocardial infarction after primary percutaneous coronary intervention. 2017 , 249, 112-118	28
77 ⁸ 777 776	Dual antiplatelet therapy for secondary prevention of coronary artery disease. 2017, 4, e000651 Short and long-term outcome in very old patients with ST-elevation myocardial infarction after primary percutaneous coronary intervention. 2017, 249, 112-118 Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis. 2017, 70, 1760-1776 Efficacy and safety of instantaneous wave-free ratio in patients undergoing coronary	28
778 777 776	Dual antiplatelet therapy for secondary prevention of coronary artery disease. 2017, 4, e000651 Short and long-term outcome in very old patients with ST-elevation myocardial infarction after primary percutaneous coronary intervention. 2017, 249, 112-118 Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis. 2017, 70, 1760-1776 Efficacy and safety of instantaneous wave-free ratio in patients undergoing coronary revascularisation: protocol for a systematic review. 2017, 7, e017868 The Debut of Sirolimus-Eluting Balloons: The Final Nail in the Coffin for In-Stent Restenosis?. 2017,	28 10 100
778 777 776 775 774	Dual antiplatelet therapy for secondary prevention of coronary artery disease. 2017, 4, e000651 Short and long-term outcome in very old patients with ST-elevation myocardial infarction after primary percutaneous coronary intervention. 2017, 249, 112-118 Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis. 2017, 70, 1760-1776 Efficacy and safety of instantaneous wave-free ratio in patients undergoing coronary revascularisation: protocol for a systematic review. 2017, 7, e017868 The Debut of Sirolimus-Eluting Balloons: The Final Nail in the Coffin for In-Stent Restenosis?. 2017, 10, 2038-2039 Diagnostic accuracy of an artificial neural network compared with statistical quantitation of	28 10 100

[Contribution of intracoronary imaging in acute coronary syndrome]. **2017**, 66, 405-410

769	La cirugê de revascularizaciñ miocŷdica. Luces y sombras. 2017 , 52 , 145-149		О
768	Expression of matrix metalloproteinases-12 in ST-segment elevation myocardial infarction: A case-control study. 2017 , 96, e8035		3
767	When the cardiac surgeon says no: anatomical and clinical reasons for declining coronary artery bypass grafting. 2017 , 18 Suppl 1, e58-e63		
766	[Cardiogenic shock: Current evidence]. 2017, 42, 795-806		2
765	Percutaneous coronary intervention versus cardiac bypass surgery for left main coronary artery disease: A trial sequential analysis. 2017 , 96, e8115		3
764	FFR as a Clinical Tool and Its Applications in Specific Scenarios. 2017 , 209-221		
763	[Management of NSTEMI in a hospital without interventional cardiology and without use of GRACE score: Does the clinician appreciation match the GRACE score calculated retrospectively for the coronarography delay?]. 2017 , 66, 288-294		
762	Agreement of the Resting Distal to Aortic Coronary Pressure With the Instantaneous Wave-Free Ratio. 2017 , 70, 2105-2113		29
761	Similarity and Difference of Resting Distal´to Aortic Coronary Pressure and´Instantaneous Wave-Free Ratio. 2017 , 70, 2114-2123		39
760	Study protocol for a randomised controlled trial: harmonising optimal strategy for treatment of coronary artery stenosis - coronary intervention with next-generation drug-eluting stent platforms and abbreviated dual antiplatelet therapy (HOST-IDEA) trial. 2017 , 7, e016617		2
759	Thrombus Aspiration for ST-Segment-Elevation Myocardial Infarction in Modern Era: Still an Issue of Debate?. 2017 , 10,		17
758	[Focused update on dual antiplatelet treatment: ESC guidelines 2017]. 2017, 42, 739-745		3
757	2017 ESC/EACTS Guidelines for the management of valvular heart disease. <i>European Heart Journal</i> , 2017 , 38, 2739-2791	9.5	3615
756	Frontiers in the management of coronary artery disease: bioabsorable scaffolds, regenerative medicine, and gene therapy. <i>European Heart Journal</i> , 2017 , 38, 2517-2520	9.5	1
755	Effects of statin therapy on platelet reactivity after percutaneous coronary revascularization in patients with acute coronary syndrome. 2017 , 44, 355-361		9
754	Revascularization Strategies in STEMI with Multivessel Disease: Deciding on Culprit Versus Complete-Ad Hoc or Staged. 2017 , 19, 93		3
753	PCI Versus CABG in Patients With Type ´1 ´Diabetes ´and Multivessel Disease. 2017 , 70, 1441-1451		14

75 ²	Regional differences in coronary revascularization procedures and outcomes: a nationwide 11-year observational study. 2017 , 3, 243-248		9
751	Bivalirudin versus Heparin Monotherapy in Myocardial Infarction. 2017 , 377, 1132-1142		170
75º	Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. 2017, 377, 1513-1524		804
749	Comprehensive Assessment of the Coronary Circulation Using Pressure and Flow Measurements. 2017 , 251-260		
748	Protocol for an economic evaluation of the randomised controlled trial of culprit lesion only PCI versus immediate multivessel PCI in acute myocardial infarction complicated by cardiogenic shock: CULPRIT-SHOCK trial. 2017 , 7, e014849		1
747	In the modern era of percutaneous coronary intervention: Is cardiac rehabilitation engagement purely a patient or a service level decision?. 2017 , 24, 1351-1357		14
746	Safety and Efficacy of Polymer-Free Biolimus A9-Coated Versus Bare-Metal Stents in Orally Anticoagulated Patients: 2-Year Results of the LEADERS FREE Oral Anticoagulation Substudy. 2017 , 10, 1633-1642		8
745	Risk of Early Adverse Events After Clopidogrel Discontinuation in Patients Undergoing Short-Term Dual Antiplatelet Therapy: An Individual Participant Data Analysis. 2017 , 10, 1621-1630		11
744	Potential Implications of NORSTENT (Norwegian Coronary Stent Trial) in Contemporary Practice. 2017 , 136, 701-703		3
743	The impact of CYP2C19*2, CYP4F2*3, and clinical factors on platelet aggregation, CYP4F2 enzyme activity, and 20-hydroxyeicosatetraenoic acid concentration in patients treated with dual antiplatelet therapy. 2017 , 28, 658-664		4
742	High risk of stent thrombosis in the first 6 months after coronary stenting: Do not discontinue clopidogrel early after ACS. 2017 , 30, 421-426		5
74 ¹	Exploring Coronary Circulatory Response to Stenosis and Its Association With Invasive Physiologic Indexes Using Absolute Myocardial Blood Flow and Coronary Pressure. 2017 , 136, 1798-1808		33
740	Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995-2014. <i>European Heart Journal</i> , 2017 , 38, 3056-3065	9.5	174
739	Staged versus index procedure complete revascularization in ST-elevation myocardial infarction: A meta-analysis. 2017 , 30, 397-404		4
738	Contemporary Antiplatelet Treatment in Acute Coronary Syndrome Patients with Impaired Renal Function Undergoing Percutaneous Coronary Intervention. 2017 , 138, 186-194		3
737	Dual Antiplatelet Therapy Duration: Reconciling the Inconsistencies. 2017 , 77, 1733-1754		13
736	Bioresorbable Vascular Scaffolds for Patients With In-Stent Restenosis: The RIBS VI Study. 2017 , 10, 15	841-185	5121
735	Cardiac Surgery-Associated Acute Kidney Injury. 2017 , 7, 247-258		2

734	Temporary Mechanical Circulatory Support for Cardiogenic Shock. 2017 , 19, 77	11
733	3D fusion of coronary CT angiography and CT myocardial perfusion imaging: Intuitive assessment of morphology and function. 2017 , 11, 437-443	6
732	Percutaneous Coronary Intervention Versus Optimal Medical Therapy for Chronic Total Coronary Occlusion With Well-Developed Collaterals. 2017 , 6,	21
731	Validation Study of Image-Based Fractional Flow Reserve During Coronary Angiography. 2017, 10,	52
730	Computing Fractional Flow Reserve From Invasive Coronary Angiography: Getting Closer. 2017 , 10,	3
729	Cardiac rehabilitation in patients who underwent primary percutaneous coronary intervention for acute myocardial infarction: determinants of programme participation and completion. 2017 , 25, 618-628	19
728	A Prospective Evaluation of a Pre-Specified Absorb BVS Implantation Strategy in ST-Segment Elevation Myocardial Infarction: The BVS STEMI STRATEGY-IT Study. 2017 , 10, 1855-1864	19
7 2 7	The DELTA 2 Registry: A Multicenter Registry Evaluating Percutaneous Coronary Intervention With New-Generation Drug-Eluting Stents in Patients With Obstructive Left Main Coronary Artery Disease. 2017 , 10, 2401-2410	25
726	Criterios de gestifi de activos tecnolĝicos de imagen cardiovascular. 2018 , 71, 643-655	2
725	Safety of regadenoson for vasodilation in cardiac MRI stress tests. 2020 , 62, 213-221	1
724	Una historia resumida. Impacto de los avances en cardiopat∄ isquînica. 2017 , 17, 2-6	1
723	Use of vascular closure devices for endovascular interventions requiring a direct puncture of PETE grafts. 2018 , 47, 119-124	4
722	Long-Term Antithrombotic Treatments Prescribed for Cardiovascular Diseases in Patients with Hemophilia: Results from the French Registry. 2021 , 121, 287-296	2
721	Management of Chronic Total Occlusion of Coronary Artery. 2021 , 30, 48-52	1
720	Impact of computed tomography myocardial perfusion following computed tomography coronary angiography on downstream referral for invasive coronary angiography, revascularization and, outcome at 12 months. 2017 , 18, 969-977	18
719	In vivo relationship between near-infrared spectroscopy-detected lipid-rich plaques and morphological plaque characteristics by optical coherence tomography and intravascular ultrasound: a multimodality intravascular imaging study. 2021 , 22, 824-834	7
718	Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey. <i>European Heart Journal</i> , 2021 , 42, 339-351	24
717	Avoiding non-responders to cardiac resynchronization therapy: a practical guide. <i>European Heart Journal</i> , 2017 , 38, 1463-1472	117

716	Coincidental coronary artery disease impairs outcome in patients with takotsubo cardiomyopathy. 2017 , 110, 483-488	11
715	Diabetes and CYP2C19 Polymorphism Synergistically Impair the Antiplatelet Activity of Clopidogrel Compared With Ticagrelor in Percutaneous Coronary Intervention-treated Acute Coronary Syndrome Patients. 2020 , 76, 478-488	2
714	Coronary stent selection and optimal course of dual antiplatelet therapy in patients at high bleeding or thrombotic risk: navigating between limited evidence and clinical concerns. 2015 , 30, 325-32	8
713	Contemporary antiplatelet therapy in acute coronary syndromes: are there differences in outcomes and discontinuation between clopidogrel and ticagrelor?. 2017 , 47, 1298-1305	12
712	Wasp sting induced STEMI with complete coronary artery occlusion: a case of Kounis syndrome. 2017 , 2017,	6
711	Comparison of Instantaneous Wave-Free Ratio (iFR) and Fractional Flow Reserve (FFR) with respect to Their Sensitivities to Cardiovascular Factors: A Computational Model-Based Study. 2020 , 2020, 4094121	7
710	miR-96 and miR-183 differentially regulate neonatal and adult postinfarct neovascularization. 2020 , 5,	7
709	Impact of glycemic control status on patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention. 2020 , 20, 36	5
708	Impact of concomitant use of proton pump inhibitors and clopidogrel or ticagrelor on clinical outcomes in patients with acute coronary syndrome. 2016 , 13, 209-17	13
707	The serum anion gap is associated with disease severity and all-cause mortality in coronary artery disease. 2017 , 14, 392-400	16
706	Age-dependent impact of the SYNTAX-score on longer-term mortality after percutaneous coronary intervention in an all-comer population. 2018 , 15, 559-566	2
705	Prospective Identification of Stent Fracture by Enhanced Stent Visualization System During Percutaneous Coronary Intervention. 2016 , 81, 82-89	5
704	Clinical Characteristics and In-Hospital Mortality According to Left Main and Non-Left Main Culprit Lesions - Report From the Japan Acute Myocardial Infarction Registry (JAMIR). 2019 , 1, 601-609	4
703	Distinct Anti-Fibrotic Effects of Exosomes Derived from Endothelial Colony-Forming Cells Cultured Under Normoxia and Hypoxia. 2018 , 24, 6187-6199	14
702	Systemic Immune-Inflammatory Index Predicts Clinical Outcomes for Elderly Patients with Acute Myocardial Infarction Receiving Percutaneous Coronary Intervention. 2019 , 25, 9690-9701	25
701	Fractional flow reserve: Current applications and overview of the available data. 2015 , 3, 678-81	5
700	Release of Intracoronary Microparticles during Stent Implantation into Stable Atherosclerotic Lesions under Protection with an Aspiration Device. 2015 , 10, e0124904	13
699	High Platelet Reactivity in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Randomised Controlled Trial Comparing Prasugrel and Clopidogrel. 2015 , 10, e0135037	10

(2015-2016)

698	Revascularization Treatment of Emergency Patients with Acute ST-Segment Elevation Myocardial Infarction in Switzerland: Results from a Nationwide, Cross-Sectional Study in Switzerland for 2010-2011. 2016 , 11, e0153326	5
697	Duration of dual antiplatelet therapy in patients treated with percutaneous coronary intervention for coronary chronic total occlusion. 2017 , 12, e0176737	8
696	Contemporary use of P2Y12-inhibitors in patients with acute coronary syndrome undergoing percutaneous coronary intervention in Austria: A prospective, multi-centre registry. 2017 , 12, e0179349	7
695	A counseling program on nuisance bleeding improves quality of life in patients on dual antiplatelet therapy: A randomized controlled trial. 2017 , 12, e0182124	6
694	GDF-15 predicts cardiovascular events in acute chest pain patients. 2017 , 12, e0182314	15
693	Coronary angiography is related to improved clinical outcome of out-of-hospital cardiac arrest with initial non-shockable rhythm. 2017 , 12, e0189442	11
692	Mid-to-long term mortality following surgical versus percutaneous coronary revascularization stratified according to stent subtype: An analysis of 6,682 patients with multivessel disease. 2018 , 13, e0191554	2
691	CYP2C19*2 Allele Carrier Status and Coronary In-stent Restenosis: Is There an Association?. 2018 , 3, 55-60	3
690	Myocardial revascularization in patients with coronary heart disease and type 2 diabetes. 2016 , 19, 471-478	4
689	Myocardial revascularization in patients with type 2 diabetes mellitus: An overview of modern techniques. 2016 , 19, 406-413	5
688	Real-World Experience With a Tapered Biodegradable Polymer-Coated Sirolimus-Eluting Stent in Patients With Long Coronary Artery Stenoses. 2020 , 11, 219-225	6
687	Technical Considerations in Transradial Unprotected Left Main Stem Rotational Atherectomy-Assisted and IVUS-Guided Percutaneous Coronary Intervention Using the 7.5F Eaucath Sheathless Guiding Catheter System. 2018 , 9, 258-263	4
686	The first six-month clinical outcomes and risk factors associated with high on-treatment platelet reactivity of clopidogrel in patients undergoing coronary interventions. 2016 , 16, 967-973	5
685	A Practical Approach to Assessing Stent Results with IVUS or OCT. 2018 , 14, 32-41	3
684	CT Determination of Fractional Flow Reserve in Coronary Lesions. 2016 , 1, 237-241	3
683	In-Hospital and long term results of primary angioplasty and medical therapy in nonagenarian patients with acute myocardial infarction. 2017 , 9, 147-151	6
682	The EXCEL Trial: The Surgeons' Perspective. 2020 , 15, e67	1
681	Left Main Stem Percutaneous Coronary Intervention - Data and Ongoing Trials. 2015 , 10, 132-135	2

680	Preventive Percutaneous Coronary Intervention in ST-elevation Myocardial Infarction - The Primacy of Randomised Trials. 2015 , 10, 32-34	2
679	The Role of Percutaneous Haemodynamic Support in High-risk Percutaneous Coronary Intervention and Cardiogenic Shock. 2015 , 10, 39-44	2
678	Real World Outcomes of Left Atrial Appendage Occlusion. 2015 , 10, 109-111	2
677	Dual Antiplatelet Therapy After Drug-eluting Stent Implantation. 2016 , 11, 51-53	3
676	Patient Selection and Procedural Considerations for Coronary Orbital Atherectomy System. 2016 , 11, 33-38	19
675	The FAME Trials: Impact on Clinical Decision Making. 2016 , 11, 116-119	5
674	Fractional Flow Reserve Measurement by Computed Tomography: An Alternative to the Stress Test. 2016 , 11, 105-109	5
673	Expert Opinion Percutaneous Coronary Intervention in Older People: Does Age Make a Difference?. 2016 , 11, 93-97	3
672	Transradial Approach in Primary Percutaneous Coronary Intervention: Lessons from a High-volume Centre. 2016 , 11, 88-92	3
671	Fractional Flow Reserve: Does a Cut-off Value add Value?. 2016 , 11, 17-26	2
670	Expert Opinion: Transradial Coronary Artery Procedures: Tips for Success. 2017 , 12, 18-24	15
669	Contemporary Management of Stent Failure: Part One. 2019 , 14, 10-16	12
668	Drug-coated Balloons for Small Coronary Vessel Interventions: A Literature Review. 2019 , 14, 131-136	9
667	Left Main Coronary Artery Interventions. 2019 , 14, 124-130	3
666	[Percutaneous coronary intervention in stable coronary artery disease]. 2014, 155, 1952-9	1
665	Timing of dual antiplatelet therapy in acute coronary syndrome: a problem of coronary artery bypass grafting accessibility for patients. 2020 , 25, 3812	1
664	2020 Clinical practice guidelines for Chronic heart failure. 2020 , 25, 4083	95
663	Short-term results of synchronous coronary artery bypass grafting and carotid endarterectomy. 2017 , 10, 4	5

662	[Role of measurement of fractional flow reserve in coronary artery atherosclerosis]. 2015, 87, 106-113	2
661	IN-HOSPITAL RESULTS OF MINIMALLY INVASIVE OFF-PUMP CORONARY ARTERY BYPASS GRAFTING. 2019 , 8, 58-67	2
660	Akut koroner sendromda kontrast nefropati gelilmi ile Syntax Skoru aras ñ daki ili l li. 2019 , 44, 1181-1188	1
659	Summary of Practice Considerations for Percutaneous Coronary Intervention of Left Main Bifurcation Disease. 2020 , 14, 69	1
658	Trends and Perspectives of Stress Myocardial Perfusion Imaging in Japan. 2017, 3, 186-189	2
657	. 2019 , 59, 68-78	2
656	[The Strategy of Management Patients with non-ST Elevation Acute Coronary Syndrome]. 2019, 59, 40-51	О
655	[Impact of Diabetes Mellitus and blood glucose levels on the results of treatment of patients with ST-elevation myocardial infarction undergoing percutaneous coronary interventions]. 2019 , 59, 16-22	3
654	[Predictors for development of major cardiovascular events in elderly patients with severe and extremely severe chronic obstructive pulmonary disease in combination with early stages of chronic kidney disease]. 2019 , 59, 43-51	1
653	[Double antiplatelet therapy in patients with acute coronary syndrome after percutaneous coronary intervention: individual efficacy and hemorrhagic safety of P2Y12 blockers of ticagrelor and clopidogrel in actual clinical practice]. 2019 , 59, 27-36	1
652	Intravascular ultrasound guidance in drug-eluting stents implantation: a meta-analysis and trial sequential analysis of randomized controlled trials. 2017 , 8, 59387-59396	3
651	Comparison of coronary artery bypass grafting and percutaneous coronary intervention in patients with heart failure with reduced ejection fraction and multivessel coronary artery disease. 2018 , 9, 21201-2121	o ⁵
650	Optimal hydration volume among high-risk patients with advanced congestive heart failure undergoing coronary angiography. 2018 , 9, 23738-23748	6
649	Risk Assessment of Cardiac Events in Patients with Stable Ischemic Heart Disease After Percutaneous Coronary Intervention, Accompanied by Myocardial Damage. 2019 , 6, 15-24	2
648	Continuing aspirin before coronary artery bypass grafting surgery: old fears challenged by new evidences. 2016 , 4, S34	3
647	Hybrid approach to multivessel coronary artery disease: a commentary. 2016 , 4, S52	2
646	Diabetes mellitus and multivessel coronary artery disease: an ongoing battle for an ideal treatment strategy. 2017 , 5, 261	2
645	Adverse Outcomes of Perioperative Red Blood Cell Transfusions in Coronary Artery Bypass Grafting in Hospital Universiti Sains Malaysia. 2019 , 26, 49-63	1

644	CABG Surgery Remains the best Option for Patients with Left Main Coronary Disease in Comparison with PCI-DES: Meta-Analysis of Randomized Controlled Trials. 2017 , 32, 408-416	4
643	Hemolysis and Inflammatory Response to Extracorporeal Circulation during On-Pump CABG: Comparison between Roller and Centrifugal Pump Systems. 2018 , 33, 64-71	7
642	Diagnostic Performance of QFR for the Evaluation of Intermediate Coronary Artery Stenosis Confirmed by Fractional Flow Reserve. 2019 , 34, 165-172	6
641	Benefits of Fasting Abbreviation with Carbohydrates and Omega-3 Infusion During CABG: a Double-Blind Controlled Randomized Trial. 2019 , 34, 125-135	6
640	Effect of Using Triclosan-Impregnated Polyglactin Suture to Prevent Infection of Saphenectomy Wounds in CABG: A Prospective, Double-Blind, Randomized Clinical Trial. 2019 , 34, 588-595	1
639	NOBLE and EXCEL: The debate for excellence in dealing with left main stenosis. 2018 , 2018, 3	4
638	Predictive Value of Methods Measuring Platelet Activation for Ischemic Events in Patients Receiving Clopidogrel: A Systematic Review and Meta-analysis. 2018 , 24, 5313-5333	1
637	Aspirin Hypersensitivity in Patients Undergoing Percutaneous Coronary Intervention. What Should We be Doing?. 2019 , 17, 326-331	3
636	Percutaneous Coronary Intervention in the Elderly: Are Drug-coated Balloons the Future?. 2018 , 14, 45-52	3
635	The Ultimaster coronary stent system: 5-year worldwide experience. 2020 , 16, 251-261	5
634	Coronary artery bypass grafting in patients with low ejection fraction: what are the risk factors?. 2019 , 60, 396-405	8
633	Percutaneous coronary intervention in patients refused from surgery: a different entity?. 2018, 66, 562-568	2
632	The Synergy stent in high-bleeding risk patients: why design matters. 2018 , 66, 646-658	2
631	High-risk percutaneous coronary intervention: how to define it today?. 2018 , 66, 576-593	6
630	Management of aspirin intolerance in patients undergoing percutaneous coronary intervention. The role of mono-antiplatelet therapy: a retrospective, multicenter, study. 2019 , 67, 94-101	4
629	Routine iso-osmolar contrast media use and acute kidney injury following percutaneous coronary intervention for ST elevation myocardial infarction. 2019 , 67, 380-391	4
628	Prinzmetal Angina in a Young Patient with Essential Thrombocythemia, After Anagrelide Initiation - Case Report and Literature Review. 2018 , 24, 46-54	1
627	CTA Evaluation of Bioresorbable Scaffolds versus Metallic Coronary Stents âla Feasibility Study. 2018 , 3, 152-159	3

(2017-2015)

626	The clinical efficacy of a comprehensive program of rehabilitation after coronary artery bypass grafting in patients with coronary artery disease under outpatient department cardio rehabilitation - III stage of rehabilitation. 2015 , 6, 6-14	4
625	Russian clinical guidelines Coronary artery bypass grafting in patients with ischemic heart disease: rehabilitation and secondary prevention. 2016 , 7, 5-71	35
624	iFR-Messung: Hmodynamische Relevanz von Koronarläionen.	O
623	Update of the Brazilian Guideline on Nuclear Cardiology - 2020. 2020 , 114, 325-429	4
622	Brazilian Cardiovascular Rehabilitation Guideline - 2020. 2020 , 114, 943-987	15
621	Update of the Brazilian Guidelines for Valvular Heart Disease - 2020. 2020 , 115, 720-775	7
620	INACTIVATION OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM. WHICH CLASS OF ANTIHYPERTENSIVE MEDICINE PRODUCTS TO PREFER?. 2020 , 64-78	1
619	Early experience and favorable clinical outcomes of everolimus-eluting bioresorbable scaffolds for coronary artery disease in Korea. 2018 , 33, 922-932	2
618	Percutaneous coronary intervention in patients with multi-vessel coronary artery disease: a focus on physiology. 2018 , 33, 851-859	2
617	Cardiac Magnetic Resonance Imaging in the Diagnosis of Ischemic Heart Disease. 2018 , 19, 1-10	2
616	Nursing Management of Patients Requiring Acute Mechanical Circulatory Support Devices. 2020 , 40, e1-e11	4
615	The Current Status of Intervention for Intermediate Coronary Stenosis in the Korean Percutaneous Coronary Intervention (K-PCI) Registry. 2019 , 49, 1022-1032	5
614	Optimization of Percutaneous Coronary Intervention Using Optical Coherence Tomography. 2019 , 49, 771-793	14
613	Statin reload before off-pump coronary artery bypass graft: Effect on biomarker release kinetics. 2020 , 23, 27-33	1
612	Modifying risks to improve outcome in cardiac surgery: An anesthesiologist's perspective. 2017 , 20, 226-233	10
611	Early Prediction of 3-month Survival of Patients in Refractory Cardiogenic Shock and Cardiac Arrest on Extracorporeal Life Support. 2017 , 21, 138-145	2
610	Do practice gaps exist in evidence-based medication prescription at hospital discharge in patients undergoing coronary artery bypass surgery & coronary angioplasty?. 2017 , 146, 722-729	1
609	Angiographic outcomes of Orsiro biodegradable polymer sirolimus-eluting stents and Resolute Integrity durable polymer zotarolimus-eluting stents: results of the ORIENT trial. 2017 , 12, 1623-1631	18

608	Complete or incomplete coronary revascularisation in patients with myocardial infarction and multivessel disease: a propensity score analysis from the "real-life" BleeMACS (Bleeding complications in a Multicenter registry of patients discharged with diagnosis of Acute Coronary	22
607	Ischaemic and bleeding outcomes in elderly patients undergoing a prolonged versus shortened duration of dual antiplatelet therapy after percutaneous coronary intervention: insights from the PRODIGY randomised trial. 2017 , 13, 78-86	15
606	Reliability of physiological assessment of coronary stenosis severity using intracoronary pressure techniques: a comprehensive analysis from a large cohort of consecutive intermediate coronary lesions. 2017 , 13, e193-e200	4
605	At least seven days delayed stenting using minimalist immediate mechanical intervention (MIMI) in ST-segment elevation myocardial infarction: the SUPER-MIMI study. 2017 , 13, 390-396	5
604	Clinical, angiographic, IVUS, and OCT predictors for irregular protrusion after coronary stenting. 2017 , 12, e2204-e2211	17
603	Long-term clinical outcomes of patients with coronary chronic total occlusion treated with percutaneous coronary intervention versus medical therapy according to presence of diabetes mellitus. 2017 , 13, 970-977	15
602	Israel: coronary and structural heart interventions from 2010 to 2015. 2017 , 13, Z32-Z36	1
601	Italy: coronary and structural heart interventions from 2010 to 2015. 2017 , 13, Z37-Z41	2
600	Changes in high-sensitivity troponin after drug-coated balloon angioplasty for drug-eluting stent restenosis. 2017 , 13, 962-969	3
599	Impact of presentation and transfer delays on complete ST-segment resolution before primary percutaneous coronary intervention: insights from the ATLANTIC trial. 2017 , 13, 69-77	13
598	Safety and efficacy of early anticoagulation drug regimens after WATCHMAN left atrial appendage closure: three-month data from the EWOLUTION prospective, multicentre, monitored international WATCHMAN LAA closure registry. 2017 , 13, 877-884	54
597	Incidence and outcome of switching of oral platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: the SCOPE registry. 2017 , 13, 459-466	65
596	Pressure wire versus microcatheter for FFR measurement: a head-to-head comparison. 2018 , 13, e1850-e1856	5 14
595	The ATI score (age-thrombus burden-index of microcirculatory resistance) determined during primary percutaneous coronary intervention predicts final infarct size in patients with ST-elevation myocardial infarction: a cardiac magnetic resonance validation study. 2017 , 13, 935-943	18
594	One-year clinical outcomes after unrestricted implantation of the Absorb bioresorbable scaffold (RAI registry). 2018 , 14, e546-e553	5
593	Clinical significance of concordance or discordance between fractional flow reserve and coronary flow reserve for coronary physiological indices, microvascular resistance, and prognosis after elective percutaneous coronary intervention. 2018 , 14, 798-805	9
592	Prognostic impact of non-culprit chronic total occlusions in infarct-related cardiogenic shock: results of the randomised IABP-SHOCK II trial. 2018 , 14, e306-e313	16
591	Outcome of percutaneous coronary intervention with the Absorb bioresorbable scaffold: data from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). 2017 , 13, 1303-1310	3

590	State of the art: optimal medical therapy - competing with or complementary to revascularisation in patients with coronary artery disease?. 2017 , 13, 751-759	4
589	State of the art: coronary angiography. 2017 , 13, 634-643	17
588	State of the art: evolving concepts in the treatment of heavily calcified and undilatable coronary stenoses - from debulking to plaque modification, a 40-year-long journey. 2017 , 13, 696-705	74
587	State of the art: balloon catheter technologies - drug-coated balloon. 2017 , 13, 680-695	22
586	State of the art: the inception, advent and future of fully bioresorbable scaffolds. 2017, 13, 734-750	20
585	State of the art: pressure wire and coronary functional assessment. 2017 , 13, 666-679	10
584	Intravenous enoxaparin anticoagulation in percutaneous left atrial cardiac procedures. 2017, 13, 1226-1233	2
583	State of the art: coronary artery stents - past, present and future. 2017 , 13, 706-716	41
582	Step-by-step manual for planning and performing bifurcation PCI: a resource-tailored approach. 2018 , 13, e1804-e1811	8
581	Efficacy of Optical Coherence Tomography-derived Morphometric Assessment in Predicting the Physiological Significance of Coronary Stenosis: Head-to-Head Comparison with Intravascular Ultrasound. 2018 , 13, e2210-e2218	14
580	Percutaneous coronary intervention for the left main stem and other bifurcation lesions: 12th consensus document from the European Bifurcation Club. 2018 , 13, 1540-1553	127
579	SYNTAX score in relation to intravascular ultrasound and near-infrared spectroscopy for the assessment of atherosclerotic burden in patients with coronary artery disease. 2019 , 14, 1408-1415	5
578	Drug-eluting stents versus bare metal stents for saphenous vein graft revascularisation: a meta-analysis of randomised trials. 2018 , 14, 215-223	9
577	Quality difference of neointima following the implantation of everolimus-eluting bioresorbable scaffolds and metallic stents in patients with ST-elevation myocardial infarction: quantitative assessments by light intensity, light attenuation, and backscatter on optical coherence tomography	11
576	Angiographic and clinical performance of a paclitaxel-coated balloon compared to a second-generation sirolimus-eluting stent in patients with in-stent restenosis: the BIOLUX randomised controlled trial. 2018 , 14, 1096-1103	17
575	Qualitative resting coronary pressure wave form analysis to predict fractional flow reserve. 2019 , 14, e1601-e1608	2
574	What are the causes of a suboptimal FFR after coronary stent deployment? Insights from a consecutive series using OCT imaging. 2018 , 14, e1324-e1331	21
573	Percutaneous coronary intervention in left main coronary artery disease: the 13th consensus document from the European Bifurcation Club. 2018 , 14, 112-120	61

57 ²	Joint consensus on the use of OCT in coronary bifurcation lesions by the European and Japanese bifurcation clubs. 2019 , 14, e1568-e1577	32
571	Ten-year clinical outcome of patients treated with a drug-eluting stent in the proximal left anterior descending artery segment compared with patients stented in other non-left main coronary segments. 2018 , 14, 764-771	5
57°	A randomised comparison of healing response between the BuMA Supreme stent and the XIENCE stent at one-month and two-month follow-up: PIONEER-II OCT randomised controlled trial. 2018 , 14, e1306-e1315	8
569	Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summary. 2018 , 13, 1574-1586	26
568	Long-term outcome of FFR-guided PCI for stable coronary artery disease in daily clinical practice: a propensity score-matched landmark analysis. 2016 , 11, e1257-66	12
567	STENTYS Self-Apposing sirolimus-eluting stent in ST-segment elevation myocardial infarction: results from the randomised APPOSITION IV trial. 2016 , 11, e1267-74	20
566	Long-term prognosis after extracorporeal life support in refractory cardiogenic shock: results from a real-world cohort. 2016 , 11, 1363-71	23
565	Long-term outcomes after Resolute zotarolimus-eluting stent implantation in patients with ST-segment elevation acute myocardial infarction: insights from the RESOLUTE All Comers Trial and the RESOLUTE Global Clinical Trial Program. 2016 , 12, 1207-1214	7
564	A tool for predicting the outcome of reperfusion in ST-elevation myocardial infarction using age, thrombotic burden and index of microcirculatory resistance (ATI score). 2016 , 12, 1223-1230	20
563	One-year clinical outcomes of patients treated with everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a propensity score comparison of patients enrolled in the ABSORB EXTEND and SPIRIT trials. 2016 , 12, 1255-1262	5
562	How should I treat recurrent chest pain and systolic dysfunction after chemotherapy with anthracyclines?. 2017 , 12, 1674-1677	2
561	What determines long-term outcomes using fully bioresorbable scaffolds - the device, the operator or the lesion?. 2017 , 12, 1684-1687	22
560	Evaluation of vascular healing of polymer-free sirolimus-eluting stents in native coronary artery stenosis: a serial follow-up at three and six months with optical coherence tomography imaging. 2016 , 12, e574-83	12
559	Design and rationale for a randomised comparison of everolimus-eluting stents and coronary artery bypass graft surgery in selected patients with left main coronary artery disease: the EXCEL trial. 2016 , 12, 861-72	51
558	Trends in rates, patient selection and prognosis of coronary revascularisations in Finland between 1994 and 2013: the CVDR. 2016 , 12, 1117-1125	16
557	External validity of a contemporaneous primary percutaneous coronary intervention trial in patients with acute ST-elevation myocardial infarction: insights from a single-centre investigation. 2016 , 12, 1135-1143	3
556	Impact of time to treatment on the effects of bivalirudin vs. glycoprotein IIb/IIIa inhibitors and heparin in patients undergoing primary percutaneous coronary intervention: insights from the HORIZONS-AMI trial. 2016 , 12, 1144-1153	1
555	Contemporary considerations in left main stem treatment. 2017 , 13, 1144-1147	1

554	cFFR as an alternative to FFR: please do not contrast simplicity!. 2017, 13, e1487-e1488	4
553	EXCEL and NOBLE: stents or surgery for left main stem stenosis?. 2017 , 13, e604-e608	2
552	The Compare-Acute trial of fractional flow reserve-guided multivessel angioplasty in myocardial infarction. 2017 , 13, e613-e616	2
551	Current trends in coronary interventions: an overview from the EAPCI registries. 2017 , 13, Z8-Z10	17
550	Current use of intracoronary imaging in interventional practice - Results of a European Association of Percutaneous Cardiovascular Interventions (EAPCI) and Japanese Association of Cardiovascular Interventions and Therapeutics (CVIT) Clinical Practice Survey. 2018 , 14, e475-e484	31
549	Clinical use of intracoronary imaging. Part 1: guidance and optimization of coronary interventions. An expert consensus document of the European Association of Percutaneous Cardiovascular Interventions. 2018 , 14, 656-677	53
548	Carbon dioxide-angiography for patients with peripheral arterial disease at risk of contrast-induced nephropathy. 2020 , 12, 76-90	5
547	Thrombus aspiration during primary percutaneous coronary intervention for acute myocardial infarction: A review of clinical evidence and guidelines. 2015 , 7, 889-94	6
546	Assessment of stable coronary artery disease by cardiovascular magnetic resonance imaging: Current and emerging techniques. 2017 , 9, 92-108	13
545	Coronary stenting: A matter of revascularization. 2017 , 9, 207-211	2
544	Provisional stenting: a falling dogma in interventional cardiology. 2020 , 30, 363-364	0
543	The use of adenosine in the assessment of stable coronary heart disease. 2019 , 49, 182-184	1
542	A Prospective Multicenter Study Evaluating Bleeding Risk after Endoscopic Ultrasound-Guided Fine Needle Aspiration in Patients Prescribed Antithrombotic Agents. 2018 , 12, 353-359	12
541	Trends in Percutaneous Coronary Intervention and Coronary Artery Bypass Surgery in Korea. 2016 , 49, S60-S67	5
540	Mid-Term Results of Minimally Invasive Direct Coronary Artery Bypass Grafting. 2018, 51, 8-14	3
539	Very Early Versus Early Percutaneous Coronary Intervention in Patients with Decreased e-GFR after Successful Fibrinolytic Therapy. 2020 , 15, 34	2
538	Impact of Clopidogrel Loading for Coronarography on Bleeding After Urgent First Time CABG. 2018 , 72, 319-324	4
537	Comparison of Obesity Related Index and Exercise Capacity Between Center-Based and Home-Based Cardiac Rehabilitation Programs. 2019 , 43, 297-304	2

536	Long-term outcomes of patients with multivessel coronary artery disease presenting non-ST-segment elevation acute coronary syndromes. 2019 , 26, 157-168	7
535	Predictors of periprocedural complications in patients undergoing percutaneous coronary interventions within coronary artery bypass grafts. 2019 , 26, 633-644	7
534	A Meta-Analysis of Randomized Clinical Trials Comparing Shorter (Less or Equal Than 6 Months) and Longer (More or Equal Than 12 Months) Dual Anti-Platelet Therapy Following Drug-Eluting Coronary Stents. 2015 , 17, e26904	4
533	Antiplatelet Therapy in Hemodialysis Patients Undergoing Percutaneous Coronary Interventions. 2015 , 7, e28099	14
532	Procedural and one-year clinical outcomes of bioresorbable vascular scaffolds for the treatment of chronic total occlusions: a single-centre experience. 2016 , 27, 345-349	5
531	Effects of Resistance Exercise Applied Early After Coronary Artery Bypass Grafting: a Randomized Controlled Trial. 2015 , 30, 620-5	7
530	Percutaneous Coronary Intervention in Chronic Total Occlusion. 2018, 110, 476-483	2
529	Comparison of clinical outcomes after drug-eluting balloon and drug-eluting stent use for in-stent restenosis related acute myocardial infarction: a retrospective study. 2018 , 6, e4646	4
528	Sex-Related Outcomes of Successful Drug-Coated Balloon Treatment in De Novo Coronary Artery Disease. 2021 , 62, 981-989	1
527	Comparative Safety and Effectiveness of Loading Doses of P2Y12 Inhibitors in Patients Undergoing Elective PCI: a Network Meta-analysis. 2021 , 1	O
526	Virtual (Computed) Fractional Flow Reserve: Future Role in Acute Coronary Syndromes. 2021 , 8, 735008	О
525	Prognostic Significance of Preprocedural N-Terminal Pro-B-Type Natriuretic Peptide Assessment in Diabetic Patients With Multivessel Coronary Disease Undergoing Revascularization. 2021 , 8, 721260	1
524	Factors Influencing Stent Failure in Chronic Total Occlusion Coronary Intervention. 2021, 16, e27	2
523	Back to the future: DCB use instead of DES for the treatment of complex, native coronary artery disease. 2021 , 23, E63-E67	1
522	Dual-energy CT plaque characteristics of post mortem thin-cap fibroatheroma in comparison to infarct-related culprit lesions. 2021 , 1	Ο
521	The Index of Microcirculatory Resistance after Primary Percutaneous Coronary Intervention Predicts Long-Term Clinical Outcomes in Patients with ST-Segment Elevation Myocardial Infarction. 2021 , 10,	1
520	Predictors of Adverse Events Among Chronic Total Occlusion Patients Undergoing Successful Percutaneous Coronary Intervention and Medical Therapy. 2021 , 16, 1847-1855	2
519	Elliptical stretch as a cause of side branch ostial compromise after main vessel stenting in coronary bifurcations: New insights from numerical analysis. 2020 , 27, 507-517	1

(2015-2015)

Antithrombotic Treatment Strategy in Patients Who Underwent Coronary Stent Implantation. 2015 , 88, 393 Managing the Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients on Oral Anticoagulation. 2015, 10, 139-141 Absorbable Polymer Technology - Viable Solutions for Unmet Needs in PCI: Proceedings of two satellite symposia held at EuroPCR, Paris in May 2015. 2015, 10, 162-166 Tug-Eluting Stents and Coronary Artery Disease. 2015, 495-524 Coronary Stent Thrombosis in 2015: A Comprehensive and Uptodated Review. 2015, 2, 131-149 Priventionsm@lichkeiten aus Sicht des Kardiologen. 2015, 37-48 CABG Versus PCI in Elderly Patients. 2015, 77-91 PCI in Elderly Patients with ACS. 2015, 61-76 Contemporary indications for percutaneous coronary revascularization in patients with chronic total occlusion of coronary arteries. 2015, 34, 174-178 Coronary Revascularization for Patients with Severe Coronary Artery Disease. 2015, 21, 267-271 Managing Heart Failure Patients with Multivessel Disease - Coronary Artery Bypass Graft versus Percutaneous Coronary Intervention. 2015, 1, 118-122 Managing Heart Failure Patients with Multivessel Disease - Coronary Artery Bypass Graft versus Percutaneous Coronary Intervention. 2015, 1, 118-122 Sofe Stress Echocardiography Versus Stress CMR. 2015, 655-671 DAPT After Stenting in Stable and Acute Coronary Syndromes- Does the Drug Combination Really Matter?. 2015, 255-269 Technical Aspects of Left Main Stem Percutaneous Coronary Intervention. 2015, 237-253	518	Percutaneous Coronary Intervention in Unprotected Left Main Stenosis: Medical Evidence from Randomized and Observational Studies. 2015 , 221-236	
Absorbable Polymer Technology - Viable Solutions for Unmet Needs in PCI: Proceedings of two satellite symposia held at EuroPCR, Paris in May 2015. 2015, 10, 162-166 Drug-Eluting Stents and Coronary Artery Disease. 2015, 495-524 Coronary Stent Thrombosis in 2015: A Comprehensive and Uptodated Review. 2015, 2, 131-149 Prüentionsmißlichkeiten aus Sicht des Kardiologen. 2015, 37-48 CABG Versus PCI in Elderly Patients. 2015, 77-91 PCI in Elderly Patients with ACS. 2015, 61-76 Contemporary indications for percutaneous coronary revascularization in patients with chronic total occlusion of coronary arteries. 2015, 34, 174-178 Coronary Revascularization for Patients with Severe Coronary Artery Disease. 2015, 21, 267-271 Managing Heart Failure Patients with Multivessel Disease - Coronary Artery Bypass Graft versus Percutaneous Coronary Intervention. 2015, 1, 118-122 Stress Echocardiography Versus Stress CMR. 2015, 655-671 Non-ST-Segment Elevation Myocardial Infarction (NSTEMI). 2015, 17-26 DAPT After Stenting in Stable and Acute Coronary Syndromes- Does the Drug Combination Really Matter?. 2015, 255-269	517		
515 satellite symposia held at EuroPCR, Paris in May 2015. 2015, 10, 162-166 514 Drug-Eluting Stents and Coronary Artery Disease. 2015, 495-524 515 Coronary Stent Thrombosis in 2015: A Comprehensive and Uptodated Review. 2015, 2, 131-149 516 Prûentionsmilichkeiten aus Sicht des Kardiologen. 2015, 37-48 517 CABG Versus PCI in Elderly Patients. 2015, 77-91 518 PCI in Elderly Patients with ACS. 2015, 61-76 519 Contemporary indications for percutaneous coronary revascularization in patients with chronic total occlusion of coronary arteries. 2015, 34, 174-178 520 Coronary Revascularization for Patients with Severe Coronary Artery Disease. 2015, 21, 267-271 521 Managing Heart Failure Patients with Multivessel Disease - Coronary Artery Bypass Graft versus Percutaneous Coronary Intervention. 2015, 1, 118-122 522 Stress Echocardiography Versus Stress CMR. 2015, 655-671 523 Non-ST-Segment Elevation Myocardial Infarction (NSTEMI). 2015, 17-26 524 DAPT After Stenting in Stable and Acute Coronary Syndromes- Does the Drug Combination Really Matter?. 2015, 255-269	516		
Coronary Stent Thrombosis in 2015: A Comprehensive and Uptodated Review. 2015, 2, 131-149 Průentionsmilichkeiten aus Sicht des Kardiologen. 2015, 37-48 CABG Versus PCI in Elderly Patients. 2015, 77-91 PCI in Elderly Patients with ACS. 2015, 61-76 Contemporary indications for percutaneous coronary revascularization in patients with chronic total occlusion of coronary arteries. 2015, 34, 174-178 Coronary Revascularization for Patients with Severe Coronary Artery Disease. 2015, 21, 267-271 Managing Heart Failure Patients with Multivessel Disease - Coronary Artery Bypass Graft versus Percutaneous Coronary Intervention. 2015, 1, 118-122 3 Stress Echocardiography Versus Stress CMR. 2015, 655-671 So Non-ST-Segment Elevation Myocardial Infarction (NSTEMI). 2015, 17-26 1 DAPT After Stenting in Stable and Acute Coronary Syndromes- Does the Drug Combination Really Matter?. 2015, 255-269	515		
Priventionsmiglichkeiten aus Sicht des Kardiologen. 2015, 37-48 CABG Versus PCI in Elderly Patients. 2015, 77-91 PCI in Elderly Patients with ACS. 2015, 61-76 Contemporary indications for percutaneous coronary revascularization in patients with chronic total occlusion of coronary arteries. 2015, 34, 174-178 Coronary Revascularization for Patients with Severe Coronary Artery Disease. 2015, 21, 267-271 Managing Heart Failure Patients with Multivessel Disease - Coronary Artery Bypass Graft versus Percutaneous Coronary Intervention. 2015, 1, 118-122 Stress Echocardiography Versus Stress CMR. 2015, 655-671 Non-ST-Segment Elevation Myocardial Infarction (NSTEMI). 2015, 17-26 DAPT After Stenting in Stable and Acute Coronary Syndromes- Does the Drug Combination Really Matter?. 2015, 255-269	514	Drug-Eluting Stents and Coronary Artery Disease. 2015 , 495-524	
CABG Versus PCI in Elderly Patients. 2015, 77-91 PCI in Elderly Patients with ACS. 2015, 61-76 Contemporary indications for percutaneous coronary revascularization in patients with chronic total occlusion of coronary arteries. 2015, 34, 174-178 Coronary Revascularization for Patients with Severe Coronary Artery Disease. 2015, 21, 267-271 Managing Heart Failure Patients with Multivessel Disease - Coronary Artery Bypass Graft versus Percutaneous Coronary Intervention. 2015, 1, 118-122 Stress Echocardiography Versus Stress CMR. 2015, 655-671 Non-ST-Segment Elevation Myocardial Infarction (NSTEMI). 2015, 17-26 DAPT After Stenting in Stable and Acute Coronary Syndromes- Does the Drug Combination Really Matter?. 2015, 255-269	513	Coronary Stent Thrombosis in 2015: A Comprehensive and Uptodated Review. 2015 , 2, 131-149	
PCI in Elderly Patients with ACS. 2015, 61-76 Contemporary indications for percutaneous coronary revascularization in patients with chronic total occlusion of coronary arteries. 2015, 34, 174-178 Coronary Revascularization for Patients with Severe Coronary Artery Disease. 2015, 21, 267-271 Managing Heart Failure Patients with Multivessel Disease - Coronary Artery Bypass Graft versus Percutaneous Coronary Intervention. 2015, 1, 118-122 Stress Echocardiography Versus Stress CMR. 2015, 655-671 Non-ST-Segment Elevation Myocardial Infarction (NSTEMI). 2015, 17-26 DAPT After Stenting in Stable and Acute Coronary Syndromes- Does the Drug Combination Really Matter?. 2015, 255-269	512	Prŵentionsmÿlichkeiten aus Sicht des Kardiologen. 2015 , 37-48	
Contemporary indications for percutaneous coronary revascularization in patients with chronic total occlusion of coronary arteries. 2015, 34, 174-178 Coronary Revascularization for Patients with Severe Coronary Artery Disease. 2015, 21, 267-271 Managing Heart Failure Patients with Multivessel Disease - Coronary Artery Bypass Graft versus Percutaneous Coronary Intervention. 2015, 1, 118-122 Stress Echocardiography Versus Stress CMR. 2015, 655-671 Non-ST-Segment Elevation Myocardial Infarction (NSTEMI). 2015, 17-26 DAPT After Stenting in Stable and Acute Coronary Syndromes- Does the Drug Combination Really Matter?. 2015, 255-269	511	CABG Versus PCI in Elderly Patients. 2015 , 77-91	
total occlusion of coronary arteries. 2015, 34, 174-178 Coronary Revascularization for Patients with Severe Coronary Artery Disease. 2015, 21, 267-271 Managing Heart Failure Patients with Multivessel Disease - Coronary Artery Bypass Graft versus Percutaneous Coronary Intervention. 2015, 1, 118-122 Stress Echocardiography Versus Stress CMR. 2015, 655-671 Non-ST-Segment Elevation Myocardial Infarction (NSTEMI). 2015, 17-26 DAPT After Stenting in Stable and Acute Coronary Syndromes- Does the Drug Combination Really Matter?. 2015, 255-269	510	PCI in Elderly Patients with ACS. 2015 , 61-76	
Managing Heart Failure Patients with Multivessel Disease - Coronary Artery Bypass Graft versus Percutaneous Coronary Intervention. 2015, 1, 118-122 Stress Echocardiography Versus Stress CMR. 2015, 655-671 Non-ST-Segment Elevation Myocardial Infarction (NSTEMI). 2015, 17-26 DAPT After Stenting in Stable and Acute Coronary Syndromes- Does the Drug Combination Really Matter?. 2015, 255-269	509		
Percutaneous Coronary Intervention. 2015, 1, 118-122 506 Stress Echocardiography Versus Stress CMR. 2015, 655-671 505 Non-ST-Segment Elevation Myocardial Infarction (NSTEMI). 2015, 17-26 DAPT After Stenting in Stable and Acute Coronary Syndromes- Does the Drug Combination Really Matter?. 2015, 255-269	508	Coronary Revascularization for Patients with Severe Coronary Artery Disease. 2015, 21, 267-271	
Non-ST-Segment Elevation Myocardial Infarction (NSTEMI). 2015, 17-26 DAPT After Stenting in Stable and Acute Coronary Syndromes- Does the Drug Combination Really Matter?. 2015, 255-269	507	Managing Heart Failure Patients with Multivessel Disease - Coronary Artery Bypass Graft versus Percutaneous Coronary Intervention. 2015 , 1, 118-122	3
DAPT After Stenting in Stable and Acute Coronary Syndromes- Does the Drug Combination Really Matter?. 2015 , 255-269	506	Stress Echocardiography Versus Stress CMR. 2015 , 655-671	
Matter?. 2015 , 255-269	505	Non-ST-Segment Elevation Myocardial Infarction (NSTEMI). 2015 , 17-26	1
Technical Aspects of Left Main Stem Percutaneous Coronary Intervention. 2015 , 237-253	504		
	503	Technical Aspects of Left Main Stem Percutaneous Coronary Intervention. 2015 , 237-253	
Percutaneous Coronary Intervention in Patients Who Have an Indication for Oral Anticoagulation - an Evidence-based Approach to Antithrombotic Therapy. 2015 , 10, 16-21	502		
501 Actualits thrapeutiques de lâInfarctus du myocarde. 2015 , 60, 36-38	501	Actualits thrapeutiques de lâIhfarctus du myocarde. 2015 , 60, 36-38	

500	La revascularisation coronaire du patient diablique. 2015 , 199, 835-847
499	Antithrombotic therapy in the anticoagulated patient undergoing percutaneous coronary intervention with coronary stenting. 2015 , 30, 319-24
498	Current approaches for the diagnosis, risk stratification and interventional treatment of patients with acute coronary syndromes without st-segment elevation. 2015 , 6, 59-84
497	Dynamic Single-Photon Emission Computed Tomography Data Analysis: Capabilities for Determining Functional Significance of Coronary Artery Atherosclerosis. 2016 , 79, 01080
496	Percutaneous Coronary Intervention with Newer Generation Stents. 2016 , 643-647
495	Comparative analysis of hybrid myocardial revascularization and multivascular percutaneous coronary interventions in patients with stable coronary artery disease and multivascular coronary disease. 30-day results. 2016 , 9, 17
494	The Use of Protection Devices in Vein Graft Intervention. 2016 , 665-674
493	Prikaz sluāja u svetlu preporuka za kardioloģu evaluaciju bolesnika koji su upuāni na nekardijalnu hirurgiju. 2016 , 35, 28-31
492	Combined Coronary Revascularization: Single-Center 10-Year Experience. 2016 , 11, 40-45
491	Left Main Stem Stenosis: How to Proceed. 2016 , 91-98
490	Advances in coronary artery imaging. 2016 , 22, 39-44
489	Percutaneous Coronary Intervention of Saphenous Vein Graft Failure. 2016 , 595-602
488	Current Topics in Bypass Surgery. 2016 , 195-208
487	Percutaneous Coronary Intervention for Distal Anastomotic Lesions. 2016 , 655-660
486	Advances in coronary stent. 2016 , 22, 34-38
485	Does Percutaneous Coronary Interventions of Coronary Chronic Total Occlusions to Patients with Prior Coronary Artery Bypass Graft Surgery Have Poorer Pocedural Outcome?. 2016 , 2, 1-8
484	'Triple therapy' in high risk patient after primary PCI: Case report and practical application of current ESC and ACC/AHA guidelines. 2016 , 35, 6-9
483	Lipid Management and Graft Failure. 2016 , 341-349

482	Guidelines Regarding the Revascularization in Patients with Prior CABG. 2016 , 573-579	
481	Stent Restenosis in Coronary Grafts. 2016 , 675-681	
480	Future directions in the treatment of coronary artery disease. 2016 , 22, 56-59	
479	Coronary artery revascularization for ischemic cardiomyopathy. 2016 , 22, 210-216	
478	Role of Cardiovascular Magnetic Resonance Imaging in Heart Failure. 2016 , 149-181	1
477	Efficacy and safety of short-term (âld months) duration of dual antiplatelet therapy after drug-eluting stents: a meta-analysis of randomized controlled trials. 2017, 17, 168-175	1
476	The change in right ventricular systolic function according to the revascularisation method used, following acute ST -segment elevation myocardial infarction. 2016 , 27, 37-44	3
475	Peri- and Post-procedural Antithrombotic Therapy in Women. 2017 , 73-100	O
474	Interventional Treatment of Acute Coronary Syndrome: ST-Segment Elevation Myocardial Infarction (STEMI). 2017 , 61-71	
473	Cardiac function in hypertensive patients with metabolic syndrome and microalbuminuria. 2016 , 18, 184-190	
472	Intracoronary Imaging and Intracoronary Functional Tests. 2017 , 23-35	
471	Interventional in-stent restenosis treatment with usage of dedicated drug coated balloons SeQuent Please. 2016 , 15, 114-118	
470	La chirurgie cardiaque en 2025. 2016 , 200, 1677-1691	
469	Atrial Fibrillation on Non-vitamin K Antagonist Oral Anticoagulant Undergoing Elective Percutaneous Coronary Intervention for Stable Effort Angina. 2017 , 19-38	
468	Atrial Fibrillation on Vitamin K Antagonist Undergoing Elective Percutaneous Coronary Intervention for Stable Effort Angina. 2017 , 1-18	
467	Kardiologie. 2017 , 203-314	
466	[Triple antianginal combinations in the treatment of elderly and senile patients with stable angina]. 2016 , 88, 33-40	2
465	What is the optimal strategy of prehospital pretreatment of STEMI patients with P2Y12 inhibitors?. 2016 , 15, 162-164	

Major Bleeding Early After Percutaneous Coronary Intervention in a Patient with Atrial Fibrillation 464 on Triple Therapy with Vitamin K antagonist, Aspirin, and Clopidogrel. 2017, 183-195 Major Bleeding Early After Percutaneous Coronary Intervention in a Patient with Atrial Fibrillation on Triple Therapy with a Non-vitamin K-Antagonist Oral Anticoagulant, Aspirin, and Clopidogrel. 463 **2017**, 197-212 Urgent Surgery Early After Percutaneous Coronary Intervention in a Patient with Atrial Fibrillation 462 on Triple Therapy with a Vitamin K Antagonist, Aspirin, and Clopidogrel. 2017, 153-167 Atrial Fibrillation on Vitamin K Antagonist Oral Anticoagulant Undergoing Primary Percutaneous 461 Coronary Intervention for ST-Elevation Acute Myocardial Infarction. 2017, 95-120 Urgent Surgery Early After Percutaneous Coronary Intervention in a Patient with Atrial Fibrillation 460 on Triple Therapy of Non-vitamin K Antagonist Oral Anticoagulant, Aspirin, and Clopidogrel. 2017, 169-182 Atrial Fibrillation on Vitamin K Antagonist Undergoing Urgent Percutaneous Coronary Intervention 459 for Non-ST-Elevation Acute Coronary Syndrome. 2017, 39-58 458 Reducing Perioperative Mortality with the Intra-Aortic Balloon Pump. 2017, 73-77 Care of the patient with stable angina pectoris in general practitioner office. 2016, 13, 220-224 457 Does Rivaroxaban Better than Vitamin K Antagonists in Atrial Fibrillation Patients Undergoing PCI?. 456 2016, 1, 005-006 Modified Shock Index as a Predictor of In-Hospital Outcome in Cases of ST-Segment Elevation 455 Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention. 2016, 7, New Developments in the Treatment of Acute Myocardial Infarction Associated with 454 Out-of-Hospital Cardiac Arrest. A Review. 2016, 2, 151-158 Indicaciñ del tratamiento con doble antiagregaciñ mŷ allŷdel aô. A quiñ y por qu. 2017, 17, 24-29 453 Thrombus aspiration during primary percutaneous coronary intervention: Where are we now?. 2017 452 , 36, 245-248 Short and Medium-Term Evaluation of Patients in Coronary Post-Angioplasty: Prliminary results at the Cardiology Department of the Hospital University Aristide Le Dantec of Dakar (Senegal): Study 451 on 38 Cases. **2017**, 2, 008-012 Leitsymptom Dyspnoe, Leistungsschwähe. 2017, 115-226 450 The Cardiovascular System and the Coronary Circulation. **2017**, 13-59 449 Transradial Approach for STEMI: Focus on Technique Using a Single MAC Guiding Catheter for 448 Transradial Primary PCI. 2017, 119-141 Don't think twice: BMS is never nice. **2017**, 12, 1566-1567

446	Cardiogenic Shock. 2017 , 163-207	
445	Use of Intravascular Ultrasound Imaging in Percutaneous Coronary Intervention to Treat Left Main Coronary Artery Disease. 2017 , 12, 8-12	3
444	Type of revascularization and outcome in patients with ischaemic cardiomyopathy and multivessel coronary disease. 2017 , 36, 238-244	
443	Arterial tonometry-derived subendocardial viability ratio in coronary artery disease patients: the jury is still out. 2017 , 17, 44-45	
442	B-Type Natriuretic Peptide as a Predictor of Short-Term Mortality in On-Pump Coronary Artery Bypass Grafting. 2017 , 32, 462-467	
441	Collateral Circulation. 2017 , 65-77	O
440	Atherosclerosis. 2017 , 285-306	
439	Optimal duration of dual antiplatelet therapy after drug eluting stent implantation: a network meta-analysis. 2017 , 18, 251-260	2
438	Management of Cardiogenic Shock. 2017 , 95-102	
437	The Systematic Evaluation of Identifying the Infarct Related Artery Utilizing Cardiac Magnetic Resonance in Patients Presenting with ST-Elevation Myocardial Infarction. 2017 , 12, e0169108	O
436	Validation of iFR: Clinical Registries. 2017 , 225-231	
435	Stable Coronary Artery Disease: Exercise-Based Cardiac Rehabilitation Reduces the Risk of Recurrent Angina After PCI in the Case of Arterial Hypertension. 2017 , 181-191	
434	Revascularization Strategies in Chronic Kidney Disease: Percutaneous Coronary Intervention Versus Coronary Artery Bypass Graft Surgery. 2017 , 317-327	
433	Demonstration of Ischemia in Myocardial Perfusion Scintigraphy before Coronary Revascularization Decreases Acute Coronary Syndrome-related Hospitalizations. 2017 , 16, 212-217	
432	[Individual learning curves for microsurgical myocardial revascularization]. 2017, 11-18	0
431	Mechanical circulatory support in high-risk PCI and acute coronary syndrome. 2017 , 2017, 29	78
430	The role of intracoronary imaging in acute coronary syndromes: OCT in focus. 2016 , 2016, e201636	
429	[Prognostic factors in patients with non-ST-segment elevation acute coronary syndrome concurrent with type 2 diabetes mellitus (according to the results of the registry)]. 2017 , 89, 65-71	3

428	First-in-man six-month results of a surface-modified coronary stent system in native coronary stenosis. 2017 , 12, 2118-2127	1
427	Unprotected left main percutaneous coronary intervention - state of the art. 2017 , 16, 12-17	
426	[The diagnostic value of measuring the momentary blood flow reserve versus non-invasive methods to detect myocardial ischemia in assessing the functional significance of borderline coronary artery stenoses]. 2017 , 89, 15-21	
425	Optimal implantation is the way to prevent scaffold thrombosis: a hypothesis to be tested. 2017 , 13, e142-e144	O
424	Monosit say š̃/ yksek yolinluklu lipoprotein oran ̃, STEMI'de enfarktla ilikili arterin oklżyonunu liglir̃	
423	A sweet decision: treatment of stable coronary artery disease in patients with diabetes mellitus. 2017 , 5, 315	
422	Coronary Flow Reserve Assessment in Patients with Cad by Dynamic Single-Photon Emission Computed Tomography. 2017 , 72-81	1
421	Case Report: RETROGRADE APPROACH FOR CTO LESIONS: SERIAL CASE. 2017 , 52, 296	
420	Assessment of Native Coronary Artery Disease. 2018 , 69-100	
419	Acute Thrombotic Coronary Occlusion in a Patient with Coronary Artery Anomaly. 2017 , 2, 266-269	
418	Do the results of the SYNTAX trial apply to my centre?. 2017 , 13, 781-783	1
417	Bioresorbable vascular scaffold in ST-segment elevation myocardial infarction: Clinical evidence, tips, and tricks. 2017 , 369-378	
416	Dual antiplatelet therapy after acute coronary syndromes: no time for a CHANGE. 2017, 13, 1133-1135	1
415	Hemodynamically insignificant but high-risk morphology left main stenosis.Revascularization or conservative therapy?. 2017 , 16, 120-122	
414	Antiplatelet therapy after BVS implantation. 2017 , 16, 103-105	
413	Myocardial revascularisation in high-risk subjects. 2018 , 104, 166-179	
412	The features of the coronary blood flow in the right ventricle myocardial infarction. 2017, 12, 30-34	
411	Koronarsonografie. 2018 , 151-188	

410	The Development of Antiplatelet Therapy after Percutaneous Coronary Intervention. 2017 , 2,	
409	Stressechokardiografie. 2018 , 189-244	
408	Current percutaneous left ventricular assist devices. 2018 , 11, 35	
407	Coronary Artery Bypass Surgery for Patients Presenting with Ventricular Arrhythmias: Propensity Matched Early and Late Outcome. 2018 , 08, 40-50	
406	In-Stent Restenosis. 2018 , 469-481	
405	Mechanical Complications of Acute Myocardial Infarction. 2018 , 341-357	
404	Method comparison for cardiac image registration of coronary computed tomography angiography and 3-D echocardiography. 2018 , 5, 014001	
403	OBSOLETE: Non-ST-Elevation Myocardial Infarction: Management. 2018,	
402	Does Moderate Coronary Stenosis Affect the Fate of the Left Internal Thoracic Artery Graft?. 2018 , 33, 567-572	
401	Current consensus and future perspective of anti-thrombotic therapy for coronary artery disease. 2018 , 24, 161-165	
400	Planning Coronary Intervention: The âtolden Rulesâteratient Checklist and Troubleshooting. 2018, 103-117	
399	Cardiogenic Shock and Mechanical Circulatory Support. 2018 , 315-326	
398	Hemodynamic Changes During Heart Displacement in Aorta No-Touch Off-Pump Coronary Artery Bypass Surgery: A Pilot Study. 2018 , 33, 469-475	
397	Everolimus-eluting bioresorbable vascular scaffolds for the left anterior descending coronary artery disease: 12-month follow up. 2018 , 13, 41	
396	Bleeding Associated with Angiography and Percutaneous Coronary Intervention. 2018, 503-522	
395	Stent Technology. 2018 , 137-159	
394	Major adverse cardiac events and drug-coated balloon size in coronary interventions. 2018 , 19, 382-387	
393	Surgical treatment of acquired heart diseases combined with endovascular repair of coronary artery disease. 2018 , 11, 71	

392	[The results of coronary artery bypass grafting by using of surgical microscope]. 2018, 18-22	O
391	Culprit Vessel Only Versus Complete Revascularisation in Patients with ST-Segment Elevation Myocardial Infarction - Should we Stay or Stage?. 2018 , 13, 129-134	1
390	Application of the appropriate use criteria for coronary revascularization in patients with acute coronary syndrome in the Russian Federation (data from the federal registry). 2018 , 13, 17	O
389	Traitement de l'infarctus du myocarde avec sus-dcalage du segment ST. 2018 , 99-122.e3	
388	Percutaneous Coronary Intervention: Adjunctive Pharmacology. 2018, 161-180	
387	How to deal with invasive ischemia detection. 2018 , 24, 89-93	
386	Percutaneous Coronary Intervention for Left Ventricular Systolic Dysfunction. 2018, 263-274	
385	Left Main Coronary Artery Intervention. 2018 , 373-395	
384	Coronary Intervention in the Chronic Kidney Disease, Diabetic and Elderly Populations. 2018, 291-303	
383	Management of Cardiogenic Shock. 2018 , 91-116	
383	Management of Cardiogenic Shock. 2018 , 91-116 INFLUENCE OF THE MAIN LEFT CORONARY ARTERY DISEASE ON THE LEFT VENTRICULAR CONTRACTILE FUNCTION IN THE LONG TERM PERIOD. 2018 , 20, 37-41	
	INFLUENCE OF THE MAIN LEFT CORONARY ARTERY DISEASE ON THE LEFT VENTRICULAR	1
382	INFLUENCE OF THE MAIN LEFT CORONARY ARTERY DISEASE ON THE LEFT VENTRICULAR CONTRACTILE FUNCTION IN THE LONG TERM PERIOD. 2018 , 20, 37-41 Coronary endarterectomy and shunt plasty in coronary artery bypass surgery: is there any	1
382	INFLUENCE OF THE MAIN LEFT CORONARY ARTERY DISEASE ON THE LEFT VENTRICULAR CONTRACTILE FUNCTION IN THE LONG TERM PERIOD. 2018 , 20, 37-41 Coronary endarterectomy and shunt plasty in coronary artery bypass surgery: is there any difference in short-term results?. 2018 , 11, 53 Acute coronary syndrome for patients with prior coronary artery bypass grafting: current state of	
382 381 380	INFLUENCE OF THE MAIN LEFT CORONARY ARTERY DISEASE ON THE LEFT VENTRICULAR CONTRACTILE FUNCTION IN THE LONG TERM PERIOD. 2018 , 20, 37-41 Coronary endarterectomy and shunt plasty in coronary artery bypass surgery: is there any difference in short-term results?. 2018 , 11, 53 Acute coronary syndrome for patients with prior coronary artery bypass grafting: current state of the matter. 2018 , 13, 57	
382 381 380 379	INFLUENCE OF THE MAIN LEFT CORONARY ARTERY DISEASE ON THE LEFT VENTRICULAR CONTRACTILE FUNCTION IN THE LONG TERM PERIOD. 2018, 20, 37-41 Coronary endarterectomy and shunt plasty in coronary artery bypass surgery: is there any difference in short-term results?. 2018, 11, 53 Acute coronary syndrome for patients with prior coronary artery bypass grafting: current state of the matter. 2018, 13, 57 Mitral valve replacement for ischemic mitral regurgitation. 2018, 24, 64-70 Comparison of coronary angiography and intracoronary imaging with fractional flow reserve for	1
382 381 380 379 378	INFLUENCE OF THE MAIN LEFT CORONARY ARTERY DISEASE ON THE LEFT VENTRICULAR CONTRACTILE FUNCTION IN THE LONG TERM PERIOD. 2018, 20, 37-41 Coronary endarterectomy and shunt plasty in coronary artery bypass surgery: is there any difference in short-term results?. 2018, 11, 53 Acute coronary syndrome for patients with prior coronary artery bypass grafting: current state of the matter. 2018, 13, 57 Mitral valve replacement for ischemic mitral regurgitation. 2018, 24, 64-70 Comparison of coronary angiography and intracoronary imaging with fractional flow reserve for coronary artery disease evaluation: An anatomical-functional mismatch. 2018, 20, 182-189 Place de lâBssistance circulatoire dans le choc cardioghique en France en 2018: revue de la	2

(2018-2018)

374	Emergency Percutaneous Coronary Intervention. 2018 , 14, 506-512	
373	Overview of the Expertâd Meeting âdxcellence in Croatian Hypertensiology and Cardiology âd Selected Topicsâd 2018 , 13, 207-15	
372	Prognosis of Percutaneous Intervention of a Left Main Coronary Artery Stenosis Without the Use of Intravascular Imaging. 2018 , 10, e2857	
371	Cardiorenal syndrome in the early stages of coronary bypass surgery. 2018 , 90, 35-40	
370	Acute coronary syndromes: time to go further. 2018 , 14, 616-618	
369	The use and impact of clinical practice guidelines in interventional cardiology. 2018 , 14, 607-608	
368	Percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation: too early to draw conclusions. 2018 , 14, e487-e489	
367	1) Current Status and Future in Percutaneous Coronary Intervention. 2018 , 107, 1724-1730	
366	Comorbidities in heart failure. 2018 , 64, 867-873	
365	Polymer-free drug-coated stents: workhorse or "niche horse"?. 2018 , 14, 732-735	
364	SEARCH OF THE STRESS INDUSED VENTRICULAR TACHICARDIA REASONS âÎTHE METABOLIC THERAPY OPPORTUNITIES. 2018 , 8, 394-402	
363	Long-term prognostic impact of non-invasive follow-up with computed tomography angiography in patients with left main coronary artery stenting. 2018 , 66, 528-535	2
362	Akut miyokard infarktŝûde yeni geli∄n atriyal fibrilasyon ile SYNTAX skoru arasñdaki ili l ii.	
361	Evaluation of the effectiveness and prognostic significance of the use of CMR in determining the viability of the myocardium. 2018 , 17, 131-140	
360	The use of stress test in patients after coronary artery bypass grafting to assess the effectiveness of surgery, determination of rehabilitation possibilities and prognosis. 2018 , 17, 221-228	0
359	Inferior Wall ST-elevation Myocardial Infarction Complicated by Ventricular Septal Defect and Free Wall Pseudoaneurysm with Rupture. 2018 , 10, e3805	0
358	. 2018 , 58, 22-32	0
357	. 2018 , 58, 22-29	2

356	. 2018 , 58, 5-12	2
355	Stable Angina and Revascularization in Type 1 Diabetic Patient. 2019 , 167-178	
354	Evaluation of Myocardial Ischemia with iFR (Instantaneous Wave-Free Ratio in the Catheterization Laboratory: A Pilot Study. 2020 , 114, 256-264	1
353	Effectiveness of Saphenous Vein Y-Grafts in Patients Undergoing Off-Pump Complete Myocardial Revascularization. 2019 , 25, 598-604	1
352	[Immediate results of three methods of surgical myocardial revascularization in multivessel lesion of the coronary bed]. 2019 , 25, 135-140	1
351	Early defibrillation: A key for successful outcome of out-of-hospital cardiac arrest treatment. 2019 , 53, 26-31	
350	Antithrombotic Strategy in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention. 2019 , 8, 8-14	
349	Heart Teams as a New Gold Standard of Cardiac Care. 2019 , 1-9	
348	Diabetes and Cardiovascular Disease. 2019 , 709-730	
347	Minimally invasive coronary artery bypass surgery. 2019 , 12, 377	1
347 346	Minimally invasive coronary artery bypass surgery. 2019 , 12, 377 Ageism in cardiac surgery: is less really more?. 2019 , 11, 1-2	1
346	Ageism in cardiac surgery: is less really more?. 2019 , 11, 1-2	
346 345	Ageism in cardiac surgery: is less really more?. 2019 , 11, 1-2 Heart and Vascular Disorders: Gender Differences in Acute Coronary Syndrome. 2019 , 167-175 [Outcomes of revascularizing operations on lower-limb arteries in patients with critical ischaemia	1
346 345 344	Ageism in cardiac surgery: is less really more?. 2019, 11, 1-2 Heart and Vascular Disorders: Gender Differences in Acute Coronary Syndrome. 2019, 167-175 [Outcomes of revascularizing operations on lower-limb arteries in patients with critical ischaemia and multifocal atherosclerosis]. 2019, 25, 114-121	1
346 345 344 343	Ageism in cardiac surgery: is less really more?. 2019, 11, 1-2 Heart and Vascular Disorders: Gender Differences in Acute Coronary Syndrome. 2019, 167-175 [Outcomes of revascularizing operations on lower-limb arteries in patients with critical ischaemia and multifocal atherosclerosis]. 2019, 25, 114-121 Myocardial revascularization in diffuse atherosclerotic coronary artery disease. 2019, 12, 321	1
346 345 344 343 342	Ageism in cardiac surgery: is less really more?. 2019, 11, 1-2 Heart and Vascular Disorders: Gender Differences in Acute Coronary Syndrome. 2019, 167-175 [Outcomes of revascularizing operations on lower-limb arteries in patients with critical ischaemia and multifocal atherosclerosis]. 2019, 25, 114-121 Myocardial revascularization in diffuse atherosclerotic coronary artery disease. 2019, 12, 321 Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome. 2019, 12, 141	1

(2019-2019)

stable ischemic heart disease using different types of stents with antiproliferative coating. 2019, 338 14, 33 Akutes Koronarsyndrom (ACS). 2019, 61-66 337 A focused review on optimal coronary revascularisation in patients with chronic kidney disease: 336 2 Coronary revascularisation in kidney disease.. **2019**, 5, 32-40 CORONARY ARTERY STENOSIS: IS REVASCULARIZATION ALWAYS REASONABLE?. 2019, 8, 42-51 335 FEDERAL STATE BUDGETARY INSTITUTION âRESEARCH INSTITUTE FOR COMPLEX ISSUES OF 334 1 CARDIOVASCULAR DISEASESâ[2019, 8, 6-14 The Effects of Dual Antiplatelet Therapy on the Occurrence of Recurrent Cardiovascular Events 333 After Myocardial Infarction in Obese Patients. 2019, 1, 34-38 The Effectiveness of Off-the-Job Training Using a Newly Developed Endoscopic Vessel Harvesting 332 Model. 2019, 48, 103-106 12-MONTHS RESULTS OF LEFT MAIN STENTING IN PATIENTS WITH HIGH SYNTAX SCORES. **2019**, 8, 30-41 331 Percutaneous coronary intervention in left main disease: 10-year follow-up. 2019, 7, 85 330 THE ROLE OF MYOCARDIAL REVASCULARIZATION IN THE SURVIVAL OF PATIENTS WITH ALTERED 329 CORONARY BLOOD FLOW DETECTED BY TRANSTHORACIC ULTRASOUND. 2019, 34, 54-60 THE ROLE OF MYOCARDIAL REVASCULARIZATION IN THE SURVIVAL OF PATIENTS WITH ALTERED 328 1 CORONARY BLOOD FLOW DETECTED BY TRANSTHORACIC ULTRASOUND. 2019, 34, 54-60 Therapeutic Strategies in Patients with Stable Coronary Artery Disease: The Role of Coronary 327 Revascularization]. **2019**, 108, 401-409 326 Trials Comparing Percutaneous And Surgical Myocardial Revascularization: A Review. 2019, 14, 95-105 O (Tryton - an alternative to established bifurcation techniques?). 2019, 61, e285-e289 325 Patients pr\u00e9entant un syndrome coronarien aigu avec sus-d\u00e9alage du segment ST admis en 324 structure daurgence apr\(\begin{aligned} \text{rgulation par un Centre 15. 2019, 9, 284-288} \end{aligned} To Whom Thrombus Aspiration May Concern?. **2019**, 7, 1774-1781 323 INNOVATIVE APPROACH â[MINIMALLY INVASIVE MULTIVESSEL CORONARY GRAFTING THROUGH 322 1 A LEFT ANTERIOR THORACOTOMY. 2019, 55, 65-76 Beta blocker therapy in the intensive care unit. 2019, 26, 249-258 321

Long-term results of stenting unprotected left main of the left coronary artery in patients with a

320	[Cardiogenic Shock in Patients with Myocardial Infarction]. 2019, 59, 64-71	Ο
319	[Clinical and prognostic value of the residual activity of platelets in patients with acute coronary syndrome without st segment elevation]. 2019 , 59, 40-46	
318	A simplified formula to calculate fractional flow reserve in sequential lesions circumventing the measurement of coronary wedge pressure: The APIS-S pilot study. 2019 , 26, 310-321	2
317	Chronic coronary artery occlusion: when does the benefit outweigh the risk?. 2019 , 116-123	
316	[Cardiogenic shock in patients with acute coronary syndrome (data from Russian Federal Acute Coronary Syndrome Registry)]. 2019 , 91, 47-52	O
315	[Morphological and Immunohystochemical Characteristics of Aspirated Thrombi in Patients with ST-Elevation Myocardial Infarction]. 2019 , 91, 21-25	2
314	DyeVertâPLUS EZ system for Preventing Contrast-Induced Acute Kidney Injury in Patients Undergoing Diagnostic Coronary Angiography and/or Percutaneous Coronary Intervention: A UK-Based Cost-Utility Analysis.	
313	Current Imaging Approaches and Challenges in the Assessment of Coronary Artery Disease. 2020 , 229-244	
312	Relevance of Syntax Score as a Marker of Complex Coronary Artery Disease and Plaque Burden in Young Coronary Artery Disease - A Single Centre Multifactorial Analysis. 2019 , 8, 3039-3043	
311	The effect of coronary stent type on the long-term results of coronary artery bypass surgery after stenting clinically related artery in acute coronary syndrome in patients with multivessel coronary artery disease. 2019 , 34, 144-152	
310	Raiders of the Lost Wire.	
309	Functional features of innate immunity in the development of postpericardiotomy syndrome in patients after coronary artery bypass grafting. 2019 , 10, 71-79	1
308	Effect of Acute Mechanical Circulatory Support on Kidney Function. 2020, 259-273	
307	Influence of Despotic Leadership on Personnel Lives via Emotional Exhaustion and Moderating role of Perceived Supervisory Support. A Testing of COR Model. 56-69	O
306	PERCUTANEOUS CORONARY INTERVENTIONS: INTRAVASCULAR IMAGING AND ASSESSMENT OF INTRACORONARY HAEMODYNAMICS. 2020 , 18, 513-522	1
305	The Utility of New Biomarker-based Predictive Model for Clinical Outcomes Among ST-elevation Myocardial Infarction Patients. 2020 , 10, 23-37	
304	Cardiac risk stratification in stable coronary artery disease. 2020 , 14, 24-33	
303	Predictors of procedural and clinical outcome in rotational atherectomy: analysis of a single center registry. 2020 , 68, 126-133	1

302	Outcome at Six Months After Primary Percutaneous Coronary Interventions Performed at a Rural Satellite Center of Sindh Province of Pakistan. 2020 , 12, e8345	O
301	Periprocedural and clinical outcomes of percutaneous coronary intervention of chronic total occlusions in patients with low- and mid-range ejection fractions. 2020 , 72, 28	1
300	[Efficacy and safety of new oral anticoagulants as part of triple antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome. Data from an observational study]. 2020 , 60, 53-63	O
299	Topical issues of dabigatran use in combination antithrombotic therapy in patients with acute coronary syndrome and nonvalvular atrial fibrillation. 2020 , 82-90	
298	Optimal duration of dual antiplatelet therapy following PTA of the superficial femoral artery: the DAPT-SFA protocol. 2020 , 61, 380-381	
297	Treatment of patients with acute coronary syndrome in 2019 (data from federal registry of acute coronary syndrome). 2020 , 37-45	
296	Problems of performing coronary artery bypass grafting after preliminary stenting of coronary arteries due to acute coronary syndrome (review of literature). 2020 , 179, 100-106	
295	Antiplatelet therapy after PCI in patients with high risk of bleeding. 2020 , 67, 135-143	O
294	Intra-aortic balloon pump entrapment without rupture: a case series. 2020 , 16, 425-432	
293	Stent Selection for Primary Angioplasty and Outcomes in the Era of Potent Antiplatelets. Data from the Multicenter Randomized Prague-18 Trial. 2021 , 10,	
292	A Large Ascending Aorta Thrombus in a Patient with Acute Myocardial Infarction-Case Report. 2021 , 57,	O
291	Evolution of the Crush Technique for Bifurcation Stenting. 2021 , 14, 2315-2326	O
290	Long-term Patient Prognostication by Coronary Flow Reserve and Index of Microcirculatory Resistance: International Registry of Comprehensive Physiologic Assessment. 2020 , 50, 890-903	2
289	Transcatheter aortic valve implantation in patient with mechanical circulation support complicated with postoperative right ventricle failure. 2020 , 79-86	
288	Transit time flow measurement in patients with diffuse coronary artery disease during coronary artery bypass grafting. 2020 , 22-27	
287	Guidelines for enhanced recovery after cardiac surgery. Consensus document of Spanish Societies of Anesthesia (SEDAR), Cardiovascular Surgery (SECCE) and Perfusionists (AEP). 2020 , 5-77	
286	The usefulness of cardiac CT integrated with FFRCT for planning myocardial revascularization in complex coronary artery disease: a lesson from SYNTAX studies. 2020 , 10, 2036-2047	
285	Operations on working heart in lesion of left main coronary artery in acute coronary syndrome. 2019 , 27, 375-384	

284	Short-term outcomes after off-pump coronary artery bypass surgery in patients with left main coronary artery disease presenting with acute and chronic coronary syndrome. 2020 , 13, 315	
283	Evolution of Angioplasty Devices. 2020 , 31-52	2
282	Clinical Indications of CTO Revascularization. 2020 , 1-8	
281	Various treatment strategies in patients with acute coronary syndrome after previous coronary artery bypass grafting. 2020 , 13, 186	1
280	Management of Cardiogenic Shock. 2020 , 87-93	
279	Troponin Elevations after Cardiac Surgery: Just âllroponitisâll 2020 , 113-124	
278	Early Results of Coronary Artery Bypass Graft (CABG) in Patients with Low Ejection Fraction. 2020 , 10, 319-328	1
277	Comparing 5-year Outcomes of Aorta-Coronary Bypass Surgery and Percutaneous Coronary Intervention Performed with New-Generation Drug-Eluting Stents in Non-Diabetic Patients with Multivessel Acute Coronary Syndrome Patients and Intermediate Syntax Score. 2020 , 35, 121-127	
276	Intracoronary Imaging for Assessment of Vascular Healing and Stent Follow-up in Bioresorbable Vascular Scaffolds. 2020 , 16, 123-134	
275	ERKRANKUNGEN DES HERZENS UND DES KREISLAUFS. 2020 , D-1-D17-4	
274	[Does an attempt to save a limb always prolong the patient's life?]. 2020, 26, 121-128	
273	[Complete myocardial revascularization in patients with multiple-vessel coronary artery disease and partial or complete absence of the grafts for coronary artery bypass surgery]. 2020 , 109-115	
272	LONG-TERM CONSEQUENCES OF PRIMARY PERCUTANEOUS CORONARY INTERVENTION IN PATIENTS WITH ST-ELEVATION MYOCARDIAL INFARCTION. 2020 , 73, 662-667	
271	Therapeutic Considerations with Revascularization in Chronic Kidney Disease: Radial Versus Femoral Arterial Access. 2020 , 85-101	
270	Treatment of chronic total occlusion. 2020 , 587-621	
269	The prevalence of acute erosive-ulcerative gastroduodenal lesions in patients with cardiovascular diseases, taking anticoagulants and antiplatelet agents. 2020 , 65-74	
268	Assessment of skeletal muscle in patients with stable coronary artery disease: clinical significance and associations. 2020 , 19, 24-31	3
267	What is better for a patient with stable coronary artery disease âlbypass surgery or percutaneous coronary intervention?. 2020 , 75, 46-53	Ο

266	Dapt Review. 2020 , 5, 060-066	Ο
265	âDe-novo DCB-onlyâlın complex coronary interventions and chronic total occlusion percutaneous coronary intervention. 2020 , 15, 54-56	
264	Consenso colombiano de cuidados perioperatorios en cirug\(\textit{B}\) cardiaca del paciente adulto. 2020 , 20, 118-157	
263	The 50 Most Highly Cited Reviews of 2013â�2017. 2021 , 48, 168-184	1
262	P2Y12 inhibition in acute coronary syndromes treated with percutaneous intervention - Understanding the debate on Prasugrel or Ticagrelor. 2021 , 108029	O
261	Optimum Treatment Strategy in Chronic Coronary Syndromes: the New Trials vs the Current Guidelines. 2021 , 17, 761-770	
260	Influence of reconstruction kernels on the accuracy of CT-derived fractional flow reserve. 2021, 1	1
259	Extremely Late In-Stent Thrombosis 12 Years After Implantation of a Drug-Eluting Stent. 2020 , 12, e9053	O
258	Angiotensin-converting enzyme gene D-allele and the severity of coronary artery disease. 2020 , 20, 3407-341	12
257	Proton Pump Inhibitors in Cardiovascular Disease: Drug Interactions with Antiplatelet Drugs. 2015,	
256	Koroner arter hastalfida SYNTAX skorunun yeri.	
255	Thromboelastography (TEG[] 5000 and TEG[] 6s Hemostasis Analyzers with TEG Manager[] Software). 2021 , 313-331	1
254	Use of native Y-saphenous vein graft in multi-vessel coronary bypass surgery. 2020 , 5, 96-99	
253	Total Arterial Myocardial Revascularization on a Beating Heart in Patients with Atherosclerotic Damage of Coronary Vessels. 2020 , 9-14	
252	Rationale for revascularization to improve prognosis in stable coronary artery disease: the data from ISCHEMIA trial. 2020 , 25, 3819	1
251	Post Cardiac Surgery Rehabilitation. 2021 , 687-696	
250	Myocardial revascularization in chronic coronary syndromes: does viability matter?. 2020 , 68, 386-392	2
249	[Cardiovascular preventive recommendations. PAPPS 2020 update]. 2020 , 52 Suppl 2, 5-31	O

248	How long should dual antiplatelet therapy be continued following implantation of drug eluting stents?. 2015 , 3, S10	
247	Major themes for 2014 in cardiothoracic and vascular anaesthesia and intensive care. 2015 , 7, 101-9	
246	Risk factors and clinical characteristics of in-hospital death in acute myocardial infarction with IABP support. 2015 , 8, 8032-41	4
245	In-stent restenosis: local drug delivery with a stent or balloon?. 2015 , 7, 1691-2	2
244	High risk percutaneous coronary interventions-significance of left ventricular assist device for clinical practice. 2015 , 7, 1716-8	1
243	Treatment of coronary in-stent restenosis-evidence for universal recommendation?. 2015 , 7, 1672-5	4
242	Network meta-analyses on in-stent restenosis treatment: dealing with complexity to clarify efficacy and safety. 2015 , 7, 1678-83	1
241	Hemostatic management of patients undergoing ear-nose-throat surgery. 2015 , 14, Doc07	2
240	Time for science to catch up with clinical practice?. 2015 , 7, E603-6	2
239	When clinical experiences clashes against evidence based medicine: the case of aspiration thrombectomy in primary percutaneous coronary intervention (PCI). 2016 , 8, E115-7	
238	Aspiration thrombectomy in 2015: a TOTAL defeat?. 2016 , 8, 10-3	1
237	Bivalirudin in Patients Undergoing PCI: State of Art and Future Perspectives. 2016 , 14, 54-63	1
236	The Cost Effectiveness of LAA Exclusion. 2016 , 8, 1374	2
235	Predictive value of SYNTAX score II for clinical outcomes in octogenarian undergoing percutaneous coronary intervention. 2016 , 13, 733-739	6
234	Minimally invasive surgical techniques in the era of hybrid coronary revascularization: additional benefits for the elderly patients?. 2016 , 13, 875-879	
233	Application of drug-coated balloon in coronary artery intervention: challenges and opportunities. 2016 , 13, 906-913	7
232	ANMCO/GICR-IACPR/SICI-GISE Consensus Document: the clinical management of chronic ischaemic cardiomyopathy. 2017 , 19, D163-D189	
231	The impact of clinical and angiographic factors on percutaneous coronary angioplasty outcomes in patients with acute ST-elevation myocardial infarction. 2016 , 1, e150-e157	5

230	Initiation of Intra-Aortic Balloon Counterpulsation before Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction and High-Risk Features Might be Beneficial: Questions Remain. 2017 , 33, 578-580	
229	Contemporary Trends and Outcomes Associated With the Preprocedural Use of Oral P2Y12 Inhibitors in Patients Undergoing Percutaneous Coronary Intervention: Insights From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). 2017 , 29, 340-351	2
228	Impact of triple antithrombotic therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention in real-world practice. 2017 , 14, 679-687	1
227	Long term outcomes of drug-eluting stent versus coronary artery bypass grafting for left main coronary artery disease: a meta-analysis. 2018 , 15, 162-172	2
226	Effect of Selective Thrombus Aspiration on Serum Lipoprotein-Associated Phospholipase A2 in Patients with ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention with High Thrombus Burden. 2018 , 34, 233-241	4
225	Optimal timing of staged percutaneous coronary intervention in ST-segment elevation myocardial infarction patients with multivessel disease. 2018 , 15, 356-362	1
224	Association between baseline platelet count and severe adverse outcomes following percutaneous coronary intervention. 2018 , 15, 346-355	1
223	Relationship between ST-Segment Shifts in Lead aVR and Coronary Complexity in Patients with Acute Coronary Syndrome. 2019 , 35, 11-19	1
222	A Propensity Score Matching Analysis of Transradial Versus Transfemoral Approaches in Octogenarians Undergoing Percutaneous Coronary Intervention. 2019 , 35, 301-307	2
221	Clinical outcomes of rotational atherectomy in severely calcified in-stent restenosis: a single-center, retrospective study. 2019 , 81, 313-323	1
220	Evaluation of Door-To-Balloon Time for Performing Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction Patients Transferred by Pre-Hospital Emergency System in Tehran. 2019 , 24, 281-285	
219	Use of Intracoronary Imaging for Optimization of Bioresorbable Vascular Scaffold Implantation and Left Main Disease. 2019 , 35, 437-438	
218	[Clinical effect and safety of clopidogrel combined with aspirin in antithrombotic therapy for children with Kawasaki disease complicated by small/medium-sized coronary artery aneurysms]. 2019 , 21, 801-805	
217	A Pilot Study to Predict Future Cardiovascular Events by Novel Four-dimensional Echocardiography Global Area Strain in ST-Elevation Myocardial Infarction Patients Managed by Primary Percutaneous Coronary Intervention. 2020 , 30, 82-87	o
216	Perioperative Blood Management Strategies for Patients Undergoing Total Hip Arthroplasty: Where Do We Currently Stand on This Matter?. 2020 , 8, 646-655	
215	Invasive versus medically managed acute coronary syndromes with prior bypass (CABG-ACS): insights into the registry versus randomised trial populations. 2021 , 8,	1
214	Invasive versus medically managed acute coronary syndromes with prior bypass (CABG-ACS): insights into the registry versus randomised trial populations. 2021 , 8, e001453	1
213	Long-term mortality after ST-elevation myocardial infarction in the reperfusion and modern secondary prevention therapy era according to coronary artery disease extent: The FAST-MI registries. 2021 , 114, 647-655	

212	Adoption and patterns of use of invasive physiological assessment of coronary artery disease in a large cohort of 40821 real-world procedures over a 12-year period. 2021 , 40, 771-781	
211	Preoperative beta-blocker in ventricular dysfunction patients: need a more granular quality metric. 2021 , 21, 552	
210	New Ultrasound-Controlled Paclitaxel Releasing Balloon vs. Asymmetric Drug-Eluting Stent in Primary ST-Segment Elevation Myocardial Infarction - A Prospective Randomized Trial. 2021 ,	0
209	Thrombus Aspiration: Is It the Art or the Science?. 2021 , 10, e023483	
208	Early Trimetazidine Therapy in Patients Undergoing Primary Percutaneous Coronary Intervention for ST Segment Elevation Myocardial Infarction Reduces Myocardial Infarction Size. 2021 , 1	1
207	Acute coronay syndrome in a patient with severe hemophilia A: Dificult decisions 2021 , 40, 985.e1-985.e5	
206	Active Versus Conventional Side Branch Protection Strategy for Coronary Bifurcation Lesions. 2021 , 62, 1241-1248	
205	Sādrome coronĝia aguda em doente com hemofilia A grave: decisās difāeis. 2021 , 40, 985.e1-985.e1	
204	Type IV myocardial infarction associated with acute stent thrombosis in the early period after revascularization in a patient with new coronavirus infection COVID-19. 2021 , 99, 369-374	
203	Clinical Characteristics and Short-Term Outcomes of Patients Presenting with Acute Myocardial Infarction having Multi-vessel disease - A Single Middle- eastern Tertiary-Care Center Experience. 2021 ,	
202	Patienten nach Stentimplantation: Worauf ist zu achten?.	
201	Fraktionelle Flussreserve: Chancen und Grenzen des Verfahrens.	
200	Recommendations for traveling to altitude with neurological disorders 2021 , 13, 11795735211053448	0
199	夏明殿°周围。 即即明 2021 , 150-155	
198	Surgical Myocardial Revascularization in a Sub-Saharan African Country: Indications and Results. 2021 , 11, 95-103	
197	Society for Cardiovascular Magnetic Resonance perspective on the 2021 AHA/ACC Chest Pain Guidelines 2022 , 24, 8	1
196	Safety and Efficacy of Drug-Coated Balloons Versus Drug-Eluting Stents in Acute Coronary Syndromes: A Prespecified Analysis of BASKET-SMALL 2 2022 , CIRCINTERVENTIONS121011325	1
195	Hybrid coronary revascularization in multivessel coronary artery disease: a systematic review 2022	

194	Kardiotoxizità onkologischer Therapien (2): KHK, Vitien, Arrhythmien, Hypertonie und Thrombosen.	О
193	Influence of meldonium on the Quality of Life of patients with Coronary Artery Disease and Concomitant Arterial hypertension During the Recovery Treatment period After percutaneous Coronary Intervention. 2021 , 63, 289-294	
192	50 (1) 2017 (1) 2021, 22-36	
191	Coronary revascularisation outcome questionnaire: validation study of the Serbian version 2022 , 1	
190	IACTS position statement on "2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization": section 7.1-a consensus document 2022 , 38, 126-133	1
189	Percutaneous coronary intervention in unprotected left main coronary artery stenosis: Mid-term outcomes of a single-center observational study 2022 ,	
188	JCS 2018 Guideline on Revascularization of Stable Coronary Artery Disease 2022, 86,	3
187	Prognostic Value of the Pattern of Non-Adherence to Anti-Platelet Regimen in Stented Patients (PARIS) Bleeding Risk Score for Long-Term Mortality After Percutaneous Coronary Intervention 2022 , 63, 15-22	
186	Intravascular lithotripsy: plaque modification in preparation for stenting. 2022, 299-310	
185	Effect of Coronary Calcification Severity on Measurements and Diagnostic Performance of CT-FFR With Computational Fluid Dynamics: Results From CT-FFR CHINA Trial 2021 , 8, 810625	o
184	Right Versus Left Radial Artery Access for Coronary Procedures: Efficacy Is More Dependent on an Operator Proficiency Than on the Access Site Selection. 1,	
183	Increased deformation of the left ventricle during exercise test measured by global longitudinal strain can rule out significant coronary artery disease in patients with suspected unstable angina pectoris 2022 ,	
182	Cardiac Surgery and Blood-Saving Techniques: An Update 2022 , 14, e21222	
181	Sex-Specific Outcomes After Coronary Intravascular Lithotripsy: A Patient-Level Analysis of the Disrupt CAD Studies. 2022 , 1, 100011	1
180	Acceptance and safety of femoral versus radial access for percutaneous coronary intervention (PCI): results from a large monitor-controlled German registry (QuIK) 2022 , 22, 7	1
179	The Comparison of Long-Term Outcome Between Patients with Single and Multiple Coronary Chronic Total Occlusions After Percutaneous Coronary Intervention 2022 , 15, 729-736	
178	Development and Validation of a Predictive Model for Chronic Kidney Disease After Percutaneous Coronary Intervention in Chinese 2022 , 28, 10760296211069998	
177	Increased left atrial volume index is associated with more cardiovascular events in patients with acute coronary syndrome: HIJ-PROPER study findings 2022 ,	

176	Publicly versus privately funded cardiac rehabilitation: access and adherence barriers. A cross-sectional study 2022 , 140, 108-114	1
175	2021 ESC/EACTS Guidelines for the management of valvular heart disease 2021 ,	14
174	Validation of the newly introduced CASTLE Score for predicting successful CTO recanalization 2022 , 38, 100942	
173	Preparation and support for physical activity following hospital discharge after coronary artery bypass graft surgery: A survey of current practice in New Zealand 2022 , e1940	
172	Clopidogrel-induced neutropenia in an 80-year-old patient with chronic kidney disease who underwent percutaneous coronary intervention: a case report and literature review 2022 , 22, 40	1
171	The Effect of Total Cholesterol Variability on Clinical Outcomes After Percutaneous Coronary Intervention 2022 , 10, 804031	1
170	High-speed rotational atherectomy in coronary artery calcification: The randomized ROTAXUS and PREPARE-CALC trials 2022 ,	0
169	Frequency and Outcomes of Periprocedural MI in Patients With Chronic Coronary Syndromes Undergoing PCI 2022 , 79, 513-526	1
168	Diagnostic performance of deep learning and computational fluid dynamics-based instantaneous wave-free ratio derived from computed tomography angiography 2022 , 22, 33	
167	Retrospective study of treatment with a drug-coated balloon alone is beneficial for ostial coronary lesions 2022 , 14, 1203-1211	
166	Cardiovascular Comorbidity in Patients Scheduled for TKA. 2022 , 139-150	
165	Omega-3 Polyunsaturated Fatty Acids: the Role in Prevention of Atrial Fibrillation in Patients with Coronary Artery Bypass Graft Surgery. 2022 , 18, 12-19	1
164	Ticagrelor versus clopidogrel in East Asian patients with acute coronary syndrome: A meta-analysis. 2022 , 2, 30-40	
163	Comparison of SYNTAX and Gensini Scores in the Decision of Surgery or Percutaneous Revascularization in Patients With Multivessel Coronary Artery Disease 2022 , 14, e22482	
162	Cardiovascular disease in hereditary haemophilia: The challenges of longevity 2022,	0
161	The adverse impact of coronary artery disease on left ventricle systolic and diastolic function in patients with type 2 diabetes mellitus: a 3.0T CMR study 2022 , 21, 30	Ο
160	Functional CAD-RADS using FFR on therapeutic management and prognosis in patients with coronary artery disease 2022 , 1	О
159	Effects of Aggressive PSP Strategy for Coronary Bioresorbable Vascular Scaffolds Implantation 2022 ,	

158	Effect of CYP2C19 genetic polymorphism on the pharmacodynamics and clinical outcomes for patients treated with ticagrelor: a systematic review with qualitative and quantitative meta-analysis 2022 , 22, 111	1
157	Variations in Coronary Revascularization Practices and Their Effect on Long-Term Outcomes 2022 , e022770	О
156	Case Report: Three-Dimensional Printing Model for Surgical Planning of Left Ventricular Aneurysm: Evolution Toward Tailoring Surgery 2022 , 9, 852682	Ο
155	Percutaneous Coronary Intervention for Left Main Coronary Artery Disease. 2022,	1
154	Deceleration Capacity Improves Prognostic Accuracy of Relative Increase and Final Coronary Physiology in Patients With Non-ST-Elevation Acute Coronary Syndrome 2022 , 9, 848499	0
153	CT or Invasive Coronary Angiography in Stable Chest Pain 2022 ,	7
152	Real-World Clinical and Economic Outcomes Associated with Surgiflo vs Floseal in Cardiovascular Surgeries in the US 2022 , 14, 129-138	
151	Eurasian clinical guidelines for cardiovascular complications of cancer treatments: diagnosis, prevention and treatment (2022). 2022 , 6-79	2
150	Impact of diabetes on coronary physiology evaluated by quantitative flow ratio in patients who underwent percutaneous coronary intervention 2022 ,	
149	Comparing clinical outcomes in patients with diabetes undergoing coronary artery bypass graft and percutaneous coronary intervention in real world practice in Iranian population 2022 , 22, 75	O
148	Comparison of Net Clinical Benefit Between Clopidogrel and Ticagrelor Following Percutaneous Coronary Intervention in Patients in China With Acute Coronary Syndrome 2021 , 39, 754	О
147	Platelet Function Test in Coronary Artery Bypass Grafting: Does It Predict Postoperative Bleeding?. 2021 , 05, 186-195	
146	Results of endovascular treatment of patients with acute myocardial infarction complicated by cardiogenic shock. 2021 , 48-52	
145	Bivalirudin Versus Heparin Monotherapy in ST-Segment-Elevation Myocardial Infarction 2021 , 14, e008969	1
144	Antithrombotic Treatment in Lower Extremity Peripheral Arterial Disease 2021, 8, 773214	1
143	Revascularization Strategies for Stable Left Main Coronary Artery Disease: Analysis of Current Evidence 2021 ,	
142	Measure Twice, Cut Once: Adjunctive Physiology and Imaging in Left Main PCI. 2021 , 14, 1	
141	Multiple arterial coronary bypass grafting is associated with better survival compared with second-generation drug-eluting stents in patients with stable multivessel coronary artery disease 2021 ,	

140	Analysis of Risk Factors for Perioperative Acute Kidney Injury and Management Strategies 2021, 8, 751793	0
139	Patient characteristics and safety outcomes in new users of ticagrelor and clopidogrel-An observational cohort study in Sweden. 2021 ,	O
138	Ischemic Heart Disease Selectively Modifies the Right Atrial Appendage Transcriptome 2021 , 8, 728198	0
137	Circulating Chromogranin B Is Associated With Left Ventricular Functional Recovery After Successful Recanalization of Chronic Total Occlusion 2021 , 8, 756594	O
136	Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers: which class of drugs should be preferable for patients with cardiovascular pathology?. 2021 , 13, 31-46	
135	Chronic Total Occlusion Percutaneous Coronary Intervention in Patients With Prior Coronary Artery Bypass Graft: Current Evidence and Future Perspectives 2022 , 9, 753250	O
134	Outcomes of Left Main Revascularization after Percutaneous Intervention or Bypass Surgery 2022 , 2022, 6496777	0
133	Table_1.DOCX. 2020 ,	
132	Radial artery diameter: a comprehensive systematic review of anatomy 2022,	Ο
131	The impact of clinical and angiographic factors on percutaneous coronary angioplasty outcomes in patients with acute ST-elevation myocardial infarction. 2016 , 1, 150-157	6
130	OUP accepted manuscript.	
129	Controversy: Critical Review of the Stich Trial and Assessment of Viability. âBack to the FutureâlOr Maybe Not. 2022 , 49, 63-68	
128	Integrated Analysis of Angiogenesis Related lncRNA-miRNA-mRNA in Patients With Coronary Chronic Total Occlusion Disease 2022 , 13, 855549	
127	Optimizing the Outcomes of Percutaneous Coronary Intervention in Patients with Chronic Kidney Disease 2022 , 11,	1
126	Reconsidering treatment guidelines for acute myocardial infarction during the COVID-19 pandemic 2022 , 22, 194	1
125	A comparison of risk scores' long-term predictive abilities for patients diagnosed with ST elevation myocardial infarction who underwent early percutaneous coronary intervention 2022 , 56, 56-64	
124	Gender specific performance of one- compared to two-catheter concepts in transradial coronary angiography - Insights from the randomized UDDC-Radial-Trial 2022 ,	
123	The Predictive Value of Combining Symptoms, Residual Syntax Score and Non-Invasive Tests in the Diagnosis of Significant Coronary Artery Disease in Elderly Post-PCI Patients 2022 , 15, 4603-4612	

122	Percutaneous Coronary Intervention of Arterial and Vein Grafts. 2022 , 221-227	
121	Specialized Balloons in Percutaneous Coronary Intervention. 2022 , 278-281	
120	High Risk Percutaneous Coronary Intervention. 2022 , 248-256	
119	Machine Learning Methods for Predicting Long-Term Mortality in Patients After Cardiac Surgery 2022 , 9, 831390	O
118	The Advantages of Dual Antiplatelet Therapy Combinations in Predicting Recurrent Cardiovascular Events in Obese Patients after Myocardial Infarction. 2022 , 7, 88-92	
117	Vasoactive and Antiarrhythmic Drugs During PCI. 2022 , 446-452	
116	Gua ESC/EACTS 2021 sobre el diagnatico y tratamiento de las valvulopatas. 2022 ,	O
115	The Management of Cardiogenic Shock and Hemodynamic Support Devices and Techniques. 2022 , 167-172	
114	Development and evaluation of the accuracy of an indicator of the appropriateness of interventional cardiology generated from a French registry 2022 , 80, 132	
113	Incorporation of Laboratory Test Biomarkers Into Dual Antiplatelet Therapy Score Improves Prediction of Ischemic and Bleeding Events in Post-percutaneous Coronary Intervention Patients. 2022 , 9,	
112	Use of intravascular ultrasound and long-term cardiac death or myocardial infarction in patients receiving current generation drug-eluting stents 2022 , 12, 8237	O
111	Pragmatic Clinical Studies: An Emerging Clinical Research Discipline for Improving Evidence-Based Practice of Cardiovascular Diseases in Asia. 2022 , 52, 401	
110	Hemin mitigates contrast-induced nephropathy by inhibiting ferroptosis via HO-1/Nrf2/GPX4 pathway.	О
109	Comparison of tenecteplase versus alteplase in STEMI patients treated with ticagrelor: A cross-sectional study. 2022 , 58, 52-56	O
108	Arterial access for cardiac procedures. 2022,	
107	Prħospitale Antikoagulation bei Patienten mit akutem Koronarsyndrom und chronischer Therapie mit oralen Antikoagulanzien. 2022 , 25, 273-274	
106	Coronary artery bypass surgery. 2022 ,	
105	Assessment of Myocardial Work of the Left Ventricle before and after PCI in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome by Pressure-Strain Loop Technology. 2022 , 2022, 1-8	O

Complete revascularization of multivessel coronary artery disease in patients with ST elevation acute coronary syndrome - for whom and when? A comprehensive review. Efficacy of Drug-Coated Balloon Approaches for de novo Coronary Artery Diseases: A Bayesian Network Meta-Analysis. 9, Revascularisation and HFpEF alTime for Randomised Trials. State-of-the-art development of anatomical and clinical-anatomical scores for choosing a myocardial revascularization strategy based on the SYNTAX study. 2022, 11, 116-124 99 Ticagrelor combined with aspirin displays the signature of regulating the gut microbiome in consistence with improving the immuno-inflammatory response in atherosclerosis. 98 Overview of Venoarterial Extracorporeal Membrane Oxygenation (VA-ECMO) Support for the Management of Cardiac Arrest and Cardiogenic Shock. 97 Emergency vs Delayed Coronary Angiogram in Survivors of Out-of-Hospital Cardiac Arrest. 2022, 7, 700 4 96 Prospective, single-centre evaluation of the safety and efficacy of percutaneous coronary interventions following a decision tree proposing a no-stent strategy in stable patients with coronary artery disease (SCRAP study). 95 Management of patients with 5T-segment myocardial infarction and multivessel disease: what are the options in 2022? Publish Alhead of Print. 94 Impact of Direct Cardiovascular Laboratory Activation by Emergency Physicians on False-Positive Activation Rates. 2016, 45, 351-356 95 State-of-the-art development of anatomical and clinical-anatomical scores for choosing a myocardial revascularization strategy based on the SYNTAX study. 2022, 11, 116-124 96 The Relationship Between the Severity of Atherosclerosis and Periodontal Disease Index in publisher Patients. 2022, 51, 49-156 97 Brigital outcomes of coronary artery bypass grafting in patients with coronary heart disease with previous percutaneous coronary intervention. 2022, 94, 822-826 97 Association of Chest Pain ProtocolaDiscordant Discharge With Outcomes Among Emergency Department Patients. With Modest E	104	Management of antithrombotic therapy in patients at high bleeding risk after percutaneous coronary intervention for acute coronary syndromes: a case report. 2022 , 6,	
Network Meta-Analysis. 9, Revascularisation and HFpEF aTime for Randomised Trials. State-of-the-art development of anatomical and clinical-anatomical scores for choosing a myocardial revascularization strategy based on the SYNTAX study. 2022, 11, 116-124 Ticagrelor combined with aspirin displays the signature of regulating the gut microbiome in consistence with improving the immuno-inflammatory response in atherosclerosis. Overview of Venoarterial Extracorporeal Membrane Oxygenation (VA-ECMO) Support for the Management of Cardiac Arrest and Cardiogenic Shock. Prospective, single-centre evaluation of the safety and efficacy of percutaneous coronary interventions following a decision tree proposing a no-stent strategy in stable patients with coronary artery disease (SCRAP study). Management of patients with ST-segment myocardial infarction and multivessel disease: what are the options in 2022?. Publish Ahead of Print, Impact of Direct Cardiovascular Laboratory Activation by Emergency Physicians on False-Positive Activation Rates. 2016, 45, 351-356 State-of-the-art development of anatomical and clinical-anatomical scores for choosing a myocardial revascularization strategy based on the SYNTAX study. 2022, 11, 116-124 The Relationship Between the Severity of Atherosclerosis and Periodontal Disease Index in previous percutaneous coronary intervention. 2022, 94, 822-826 Sepital outcomes of coronary artery bypass grafting in patients with coronary heart disease with previous percutaneous coronary intervention. 2022, 94, 822-826 Several non-salt and solid thienopyridine derivatives as oral P2Y12 receptor inhibitors with good stability. 2022, 75, 128969 A Comprehensive Review of Mechanical Circulatory Support Devices. 2022, 16, 37 o	103		
100 State-of-the-art development of anatomical and clinical-anatomical scores for choosing a myocardial revascularization strategy based on the SYNTAX study. 2022, 11, 116-124 99 Ticagrelor combined with aspirin displays the signature of regulating the gut microbiome in consistence with improving the immuno-inflammatory response in atherosclerosis. 98 Overview of Venoarterial Extracorporeal Membrane Oxygenation (VA-ECMO) Support for the Management of Cardiac Arrest and Cardiogenic Shock. 97 Emergency vs Delayed Coronary Angiogram in Survivors of Out-of-Hospital Cardiac Arrest. 2022, 7, 700 4 96 Prospective, single-centre evaluation of the safety and efficacy of percutaneous coronary interventions following a decision tree proposing a no-stent strategy in stable patients with coronary artery disease (SCRAP study). 95 Management of patients with ST-segment myocardial infarction and multivessel disease: what are the options in 2022?. Publish Ahead of Print. 94 Impact of Direct Cardiovascular Laboratory Activation by Emergency Physicians on False-Positive Activation Rates. 2016, 45, 351-356 95 State-of-the-art development of anatomical and clinical-anatomical scores for choosing a myocardial revascularization strategy based on the SYNTAX study. 2022, 11, 116-124 92 The Relationship Between the Severity of Atherosclerosis and Periodontal Disease Index in Diabetic Patients. 2022, 25, 149-156 90 Bipital outcomes of coronary artery bypass grafting in patients with coronary heart disease with previous percutaneous coronary intervention. 2022, 94, 822-826 90 Department Patients With Modest Elevations of High-Sensitivity Troponin. 2022, 5, e2226809 91 Several non-salt and solid thienopyridine derivatives as oral P2Y12 receptor inhibitors with good stability. 2022, 75, 128969 81 A Comprehensive Review of Mechanical Circulatory Support Devices. 2022, 16, 37 92 Ocean Incidence and Predictors of Outcome in the Treatment of In-Stent Restenosis with Drug-Eluting	102		
Ticagrelor combined with aspirin displays the signature of regulating the gut microbiome in consistence with improving the immuno-inflammatory response in atherosclerosis. Overview of Venoarterial Extracorporeal Membrane Oxygenation (VA-ECMO) Support for the Management of Cardiac Arrest and Cardiogenic Shock. Emergency vs Delayed Coronary Angiogram in Survivors of Out-of-Hospital Cardiac Arrest. 2022, 7, 700 4 Prospective, single-centre evaluation of the safety and efficacy of percutaneous coronary interventions following a decision tree proposing a no-stent strategy in stable patients with coronary artery disease (SCRAP study). Management of patients with ST-segment myocardial infarction and multivessel disease: what are the options in 2022? Publish Ahead of Print, Impact of Direct Cardiovascular Laboratory Activation by Emergency Physicians on False-Positive Activation Rates. 2016, 45, 351-356 State-of-the-art development of anatomical and clinical-anatomical scores for choosing a myocardial revascularization strategy based on the SYNTAX study. 2022, 11, 116-124 The Relationship Between the Severity of Atherosclerosis and Periodontal Disease Index in Diabetic Patients. 2022, 25, 149-156 Bapital outcomes of coronary artery bypass grafting in patients with coronary heart disease with previous percutaneous coronary intervention. 2022, 94, 822-826 Association of Chest Pain Protocolabiscordant Discharge With Outcomes Among Emergency Department Patients With Modest Elevations of High-Sensitivity Troponin. 2022, 5, e2226809 Several non-salt and solid thienopyridine derivatives as oral P2Y12 receptor inhibitors with good stability. 2022, 75, 128969 A Comprehensive Review of Mechanical Circulatory Support Devices. 2022, 16, 37 o Incidence and Predictors of Outcome in the Treatment of In-Stent Restenosis with Drug-Eluting	101	Revascularisation and HFpEF âlTime for Randomised Trials.	
Overview of Venoarterial Extracorporeal Membrane Oxygenation (VA-ECMO) Support for the Management of Cardiac Arrest and Cardiogenic Shock. Prospective, single-centre evaluation of the safety and efficacy of percutaneous coronary interventions following a decision tree proposing a no-stent strategy in stable patients with coronary artery disease (SCRAP study). Management of patients with ST-segment myocardial infarction and multivessel disease: what are the options in 2022?. Publish Ahead of Print. Impact of Direct Cardiovascular Laboratory Activation by Emergency Physicians on False-Positive Activation Rates. 2016, 45, 351-356 State-of-the-art development of anatomical and clinical-anatomical scores for choosing a myocardial revascularization strategy based on the SYNTAX study. 2022, 11, 116-124 The Relationship Between the Severity of Atherosclerosis and Periodontal Disease Index in Diabetic Patients. 2022, 25, 149-156 Baspital outcomes of coronary artery bypass grafting in patients with coronary heart disease with previous percutaneous coronary intervention. 2022, 94, 822-826 Association of Chest Pain ProtocolàDiscordant Discharge With Outcomes Among Emergency Department Patients With Modest Elevations of High-Sensitivity Troponin. 2022, 5, e2226809 A Comprehensive Review of Mechanical Circulatory Support Devices. 2022, 16, 37 o Incidence and Predictors of Outcome in the Treatment of In-Stent Restenosis with Drug-Eluting	100		
Prospective, single-centre evaluation of the safety and efficacy of percutaneous coronary interventions following a decision tree proposing a no-stent strategy in stable patients with coronary artery disease (SCRAP study). Management of patients with ST-segment myocardial infarction and multivessel disease: what are the options in 2022?. Publish Ahead of Print, Impact of Direct Cardiovascular Laboratory Activation by Emergency Physicians on False-Positive Activation Rates. 2016, 45, 351-356 State-of-the-art development of anatomical and clinical-anatomical scores for choosing a myocardial revascularization strategy based on the SYNTAX study. 2022, 11, 116-124 The Relationship Between the Severity of Atherosclerosis and Periodontal Disease Index in Diabetic Patients. 2022, 25, 149-156 Bepital outcomes of coronary artery bypass grafting in patients with coronary heart disease with previous percutaneous coronary intervention. 2022, 94, 822-826 Association of Chest Pain ProtocolaDiscordant Discharge With Outcomes Among Emergency Department Patients With Modest Elevations of High-Sensitivity Troponin. 2022, 5, e2226809 A Comprehensive Review of Mechanical Circulatory Support Devices. 2022, 16, 37 o Incidence and Predictors of Outcome in the Treatment of In-Stent Restenosis with Drug-Eluting	99		
Prospective, single-centre evaluation of the safety and efficacy of percutaneous coronary interventions following a decision tree proposing a no-stent strategy in stable patients with coronary artery disease (SCRAP study). Management of patients with ST-segment myocardial infarction and multivessel disease: what are the options in 2022?. Publish Ahead of Print, Impact of Direct Cardiovascular Laboratory Activation by Emergency Physicians on False-Positive Activation Rates. 2016, 45, 351-356 State-of-the-art development of anatomical and clinical-anatomical scores for choosing a myocardial revascularization strategy based on the SYNTAX study. 2022, 11, 116-124 The Relationship Between the Severity of Atherosclerosis and Periodontal Disease Index in Diabetic Patients. 2022, 25, 149-156 Bapital outcomes of coronary artery bypass grafting in patients with coronary heart disease with previous percutaneous coronary intervention. 2022, 94, 822-826 Association of Chest Pain ProtocolâDiscordant Discharge With Outcomes Among Emergency Department Patients With Modest Elevations of High-Sensitivity Troponin. 2022, 5, e2226809 Several non-salt and solid thienopyridine derivatives as oral P2Y12 receptor inhibitors with good stability. 2022, 75, 128969 A Comprehensive Review of Mechanical Circulatory Support Devices. 2022, 16, 37 Incidence and Predictors of Outcome in the Treatment of In-Stent Restenosis with Drug-Eluting	98		
interventions following a decision tree proposing a no-stent strategy in stable patients with coronary artery disease (SCRAP study). Management of patients with ST-segment myocardial infarction and multivessel disease: what are the options in 2022? Publish Ahead of Print, Impact of Direct Cardiovascular Laboratory Activation by Emergency Physicians on False-Positive Activation Rates. 2016, 45, 351-356 State-of-the-art development of anatomical and clinical-anatomical scores for choosing a myocardial revascularization strategy based on the SYNTAX study. 2022, 11, 116-124 The Relationship Between the Severity of Atherosclerosis and Periodontal Disease Index in Diabetic Patients. 2022, 25, 149-156 Bispital outcomes of coronary artery bypass grafting in patients with coronary heart disease with previous percutaneous coronary intervention. 2022, 94, 822-826 Association of Chest Pain ProtocoláDiscordant Discharge With Outcomes Among Emergency Department Patients With Modest Elevations of High-Sensitivity Troponin. 2022, 5, e2226809 Several non-salt and solid thienopyridine derivatives as oral P2Y12 receptor inhibitors with good stability. 2022, 75, 128969 A Comprehensive Review of Mechanical Circulatory Support Devices. 2022, 16, 37 Incidence and Predictors of Outcome in the Treatment of In-Stent Restenosis with Drug-Eluting	97	Emergency vs Delayed Coronary Angiogram in Survivors of Out-of-Hospital Cardiac Arrest. 2022 , 7, 700	4
the options in 2022?. Publish Ahead of Print, Impact of Direct Cardiovascular Laboratory Activation by Emergency Physicians on False-Positive Activation Rates. 2016, 45, 351-356 State-of-the-art development of anatomical and clinical-anatomical scores for choosing a myocardial revascularization strategy based on the SYNTAX study. 2022, 11, 116-124 The Relationship Between the Severity of Atherosclerosis and Periodontal Disease Index in Diabetic Patients. 2022, 25, 149-156 Bispital outcomes of coronary artery bypass grafting in patients with coronary heart disease with previous percutaneous coronary intervention. 2022, 94, 822-826 Association of Chest Pain ProtocolâDiscordant Discharge With Outcomes Among Emergency Department Patients With Modest Elevations of High-Sensitivity Troponin. 2022, 5, e2226809 Several non-salt and solid thienopyridine derivatives as oral P2Y12 receptor inhibitors with good stability. 2022, 75, 128969 A Comprehensive Review of Mechanical Circulatory Support Devices. 2022, 16, 37 olicidence and Predictors of Outcome in the Treatment of In-Stent Restenosis with Drug-Eluting	96	interventions following a decision tree proposing a no-stent strategy in stable patients with	
Activation Rates. 2016, 45, 351-356 State-of-the-art development of anatomical and clinical-anatomical scores for choosing a myocardial revascularization strategy based on the SYNTAX study. 2022, 11, 116-124 The Relationship Between the Severity of Atherosclerosis and Periodontal Disease Index in Diabetic Patients. 2022, 25, 149-156 Bespital outcomes of coronary artery bypass grafting in patients with coronary heart disease with previous percutaneous coronary intervention. 2022, 94, 822-826 Association of Chest Pain ProtocolâDiscordant Discharge With Outcomes Among Emergency Department Patients With Modest Elevations of High-Sensitivity Troponin. 2022, 5, e2226809 Several non-salt and solid thienopyridine derivatives as oral P2Y12 receptor inhibitors with good stability. 2022, 75, 128969 A Comprehensive Review of Mechanical Circulatory Support Devices. 2022, 16, 37 Incidence and Predictors of Outcome in the Treatment of In-Stent Restenosis with Drug-Eluting	95		1
myocardial revascularization strategy based on the SYNTAX study. 2022, 11, 116-124 The Relationship Between the Severity of Atherosclerosis and Periodontal Disease Index in Diabetic Patients. 2022, 25, 149-156 Bispital outcomes of coronary artery bypass grafting in patients with coronary heart disease with previous percutaneous coronary intervention. 2022, 94, 822-826 Association of Chest Pain ProtocolâDiscordant Discharge With Outcomes Among Emergency Department Patients With Modest Elevations of High-Sensitivity Troponin. 2022, 5, e2226809 Several non-salt and solid thienopyridine derivatives as oral P2Y12 receptor inhibitors with good stability. 2022, 75, 128969 A Comprehensive Review of Mechanical Circulatory Support Devices. 2022, 16, 37 Incidence and Predictors of Outcome in the Treatment of In-Stent Restenosis with Drug-Eluting	94		
Diabetic Patients. 2022, 25, 149-156 Bispital outcomes of coronary artery bypass grafting in patients with coronary heart disease with previous percutaneous coronary intervention. 2022, 94, 822-826 Association of Chest Pain ProtocolâDiscordant Discharge With Outcomes Among Emergency Department Patients With Modest Elevations of High-Sensitivity Troponin. 2022, 5, e2226809 Several non-salt and solid thienopyridine derivatives as oral P2Y12 receptor inhibitors with good stability. 2022, 75, 128969 A Comprehensive Review of Mechanical Circulatory Support Devices. 2022, 16, 37 Incidence and Predictors of Outcome in the Treatment of In-Stent Restenosis with Drug-Eluting	93		
previous percutaneous coronary intervention. 2022, 94, 822-826 Association of Chest Pain ProtocolâDiscordant Discharge With Outcomes Among Emergency Department Patients With Modest Elevations of High-Sensitivity Troponin. 2022, 5, e2226809 Several non-salt and solid thienopyridine derivatives as oral P2Y12 receptor inhibitors with good stability. 2022, 75, 128969 A Comprehensive Review of Mechanical Circulatory Support Devices. 2022, 16, 37 Incidence and Predictors of Outcome in the Treatment of In-Stent Restenosis with Drug-Eluting	92		1
Department Patients With Modest Elevations of High-Sensitivity Troponin. 2022, 5, e2226809 Several non-salt and solid thienopyridine derivatives as oral P2Y12 receptor inhibitors with good stability. 2022, 75, 128969 A Comprehensive Review of Mechanical Circulatory Support Devices. 2022, 16, 37 Incidence and Predictors of Outcome in the Treatment of In-Stent Restenosis with Drug-Eluting	91		
stability. 2022, 75, 128969 A Comprehensive Review of Mechanical Circulatory Support Devices. 2022, 16, 37 Incidence and Predictors of Outcome in the Treatment of In-Stent Restenosis with Drug-Eluting	90		1
87 Incidence and Predictors of Outcome in the Treatment of In-Stent Restenosis with Drug-Eluting	89		O
	88	A Comprehensive Review of Mechanical Circulatory Support Devices. 2022 , 16, 37	0
	87		0

86	Spillover effects and other determinants of medical device uptake in the presence of a medical guideline: An analysis of drug-eluting stents in Germany and Italy. 2022 , 31, 157-178	1
85	Machine-learning-derived radiomics signature of pericoronary tissue in coronary CT angiography associates with functional ischemia. 13,	О
84	Cardiovascular Imaging in China. Publish Ahead of Print,	Ο
83	Symptomatic intracerebral hemorrhage after non-emergency percutaneous coronary intervention: Incidence, risk factors, and association with cardiovascular outcomes. 9,	O
82	Revascularization outcomes in diabetic patients presenting with acute coronary syndrome with non-ST elevation. 2022 , 21,	0
81	Left Main Disease. 2022 ,	O
80	Clinical usefulness of the pattern of non-adherence to anti-platelet regimen in stented patients (PARIS) thrombotic risk score to predict long-term all-cause mortality and heart failure hospitalization after percutaneous coronary intervention. 2022 , 17, e0274287	1
79	Acute Thrombosis of the Left Main on the Tennis Court in a Young Patient âla Case Report. 2022 , 8, 31-34	O
78	The factors influencing the efficiency of drug-coated balloons. 9,	1
77	Comparative analysis of instantaneous wave-free ratio and quantitative real-time myocardial contrast echocardiography for the assessment of myocardial perfusion. 9,	O
76	EFFECTIVENESS AND SAFETY COMPARISON OF P2Y12 RECEPTOR INHIBITORS IN PATIENTS WITH INVASIVE STRATEGY FOR ACUTE CORONARY SYNDROME. 2022 , 23, 108-116	0
75	Manganese-Enhanced Magnetic Resonance Imaging of the Heart.	O
74	Machine Learning From Quantitative Coronary Computed Tomography Angiography Predicts Fractional Flow Reserveâ Defined Ischemia and Impaired Myocardial Blood Flow. 2022, 15,	О
73	Comparative effectiveness of initial computed tomography and invasive coronary angiography in women and men with stable chest pain and suspected coronary artery disease: multicentre randomised trial. e071133	1
72	BMI Modifies Increased Mortality Risk of Post-PCI STEMI Patients with AKI. 2022, 11, 6104	1
71	Bioresorbable scaffolds vs. drug-eluting stents for patients with myocardial infarction: A systematic review and meta-analysis of randomized clinical trials. 9,	1
70	Impact of left ventricular ejection fraction on outcomes after left main revascularization: g-LM Registry. Publish Ahead of Print,	О
69	Hauptstammintervention ʿâllst ein Stent doch besser als zwei?.	O

68	Editorâl Pick: State of the Art of Aortic Valve Implantation: Indications, Outcomes, and Controversies. 10-20	1
67	Current Approach to the Treatment of Coronary Chronic Total Occlusions. 17-20	O
66	Clinical Trials for the Diagnosis and Management of Stable Ischaemic Heart Disease: Context, Status, and Future Implications. 112-121	0
65	Treatment Options in Cardiogenic Shock with Intra-Aortic Balloon Counterpulsation. 54-62	O
64	Raiders of the Lost Wire.	0
63	Clinical outcomes of percutaneous coronary intervention for de novo lesions in small coronary arteries: A systematic review and network meta-analysis. 9,	1
62	Care of patients with ST-Elevation MI: an international analysis of Quality Indicators in the Acute Coronary Syndrome (ACS) STEMI Registry of the EURObservational Research Programme (EORP) and ACVC and EAPCI Associations of the European Society of Cardiology (ESC) in 11,462 patients.	0
61	Prediction of SYNTAX score II improvement by adding temporal heart rate changes between discharge and first outpatient visit in patients with acute myocardial infarction. 2022 , 22,	O
60	Temporary mechanical circulatory support devices: practical considerations for all stakeholders.	1
59	Analysis of the incidence and influencing factors associated with binary restenosis of target lesions after drug-coated balloon angioplasty for patients with in-stent restenosis. 2022 , 22,	O
58	Treatment of Coronary In-stent Restenosis with Drug-eluting Balloon Catheter: Real-world Outcome and Literature Review. 2013 , 42, 49-51	0
57	Percutaneous Coronary Intervention for Chronic Total Occlusion, A Review of Indications, Techniques, and Complications. 85-95	O
56	Drug-Coated Balloons and Coronary Bifurcation Lesions. 80-84	1
55	Contemporary Evidence, Treatment Strategies, and Indications for Chronic Total Occlusion-Percutaneous Coronary Intervention. 87-97	O
54	Drug-eluting balloon catheters in the treatment of left main coronary artery bifurcation lesions. 2022 , 15, 554	O
53	USING NON-INVASIVE METHODS FOR EVALUATING MYOCARDIAL ISCHEMIA IN ASSESSMENT OF THE FUNCTIONAL SIGNIFICANCE OF INTERMEDIATE CORONARY ARTERY STENOSES IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE. 2016 , 30-40	O
52	Recomendaciones preventivas cardiovasculares. Actualizacifi PAPPS 2022. 2022 , 54, 102444	O
51	IMPELLA VERSUS EXTRACORPOREAL MEMBRANE OXYGENATION IN CARDIOGENIC SHOCK: A SYSTEMATIC REVIEW AND META-ANALYSIS. 2022 , 58, 349-357	1

50	In-hospital Outcomes and Cost Associated With Treatments for NonâBT-elevation Myocardial Infarction. 2022 , 100532	О
49	Rotablation in complex ACS versus Non-ACS patients: Prospective follow up study from tertiary care centre in North India. 2022 , 74, 510-512	О
48	Invasive Coronary Physiology Study in Multivessel Coronary Artery Disease.	O
47	Novel Method to Detect Pitfalls of Intracoronary Pressure Measurements by Pressure Waveform Analysis. 2022 , 12, 2035	O
46	Drug Coated Balloon angioplasty, intraoperatively through Left Anterior Descending arteriotomy access, a novel Hybrid revascularization strategy; a case report.	0
45	The Multidisciplinary Heart Team in Cardiovascular Medicine. 2023 , 100160	Ο
44	Cardiovascular, renal, and lower limb outcomes in patients with type 2 diabetes after percutaneous coronary intervention and treated with sodiumaglucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors.	0
43	Intracoronary Brachytherapy for Drug-Eluting Stent Restenosis: Outcomes and Clinical Correlates. 2023 , 100550	О
42	Coronary Artery Bypass Surgery. 2023 , 29-41	0
41	A novel computational fluid dynamic method and validation for assessing distal cerebrovascular microcirculatory resistance. 2023 , 230, 107338	О
40	Diagnostic performance of angiography-derived fractional flow reserve in patients with NSTEMI.	1
39	Evolution of Drug-Eluting Stent Drug Elution Profile: Is a Crystalline Drug Form the Ideal Solution?. 55-67	O
38	Percutaneous Coronary Intervention for Bifurcation Lesions: A State-of-the-Art Review of Techniques and Dedicated Devices. 44-54	0
37	THE RISK OF ACUTE KIDNEY INJURY AFTER ELECTIVE VERSUS EMERGENCY CORONARY INTERVENTION. 2022 , 75, 3010-3017	O
36	Coronary artery bypass grafting vs. percutaneous coronary intervention in coronary artery disease patients with advanced chronic kidney disease: A Chinese single-center study. 9,	О
35	Multi-slice coronary computed tomography angiography in assessment of coronary artery disease on the basis of syntax score. 2023 , 54,	O
34	How Bioresorbable Vascular Can Be Beneficial for Patients in the Long-Term. 2-14	О
33	Percutaneous Coronary Intervention vs Coronary Artery Bypass Graft In- hospital Outcomes in Diabetes.	O

32	Sex-Specific Predictors of Long-Term Mortality in Elderly Patients with Ischemic Cardiomyopathy. 2023 , 12, 2012	O
31	The usefulness of arylesterase in predicting contrast-induced nephropathy in ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention. 2023 , 6, 244-249	O
30	Is it useful to do OCTA in coronary artery disease patients to improve SYNTAX-based cardiac revascularization decision?. 2023 , 42, 103540	0
29	Establishment of a Predictive Model for Poor Prognosis of Incomplete Revascularization in Patients with Coronary Heart Disease and Multivessel Disease. 2022 , 28, 107602962211392	O
28	Update on Transcatheter Aortic Valve Implantation. 91-99	0
27	Ultrasound during the COVID-19 Pandemic: A Global Approach. 2023 , 12, 1057	O
26	Thrombus Aspiration. 75-80	0
25	Extracorporeal membrane oxygenation for challenging percutaneous intervention. 2023, 1233-1241	O
24	Converting Surgical Turndowns Into PCI Successes. 2023 , 16, 274-276	O
23	Trends in mechanical circulatory support use and outcomes of patients with cardiogenic shock in Japan, 2010-2020: a nationwide inpatient database study.	O
22	Eficĝia da Hidratat\ Oral na Prevent\ da Nefropatia Induzida por Contraste em Indivtuos Submetidos a Intervent\ Soron\(\textrm{g} \)ias Eletivas. 2023 , 120,	O
21	Diagnosis and Treatment of Subacute Right Coronary Artery Stent Thrombosis After Dual-Antiplatelet Therapy Interruption for Coronary Artery Bypass Grafting Surgery. 2023 ,	O
20	Influence of socioeconomic status on the presence of obstructive coronary artery disease and cardiovascular outcomes in patients undergoing invasive coronary angiography.	O
19	Is it Worthy Enough to Revascularize Chronically Occluded Coronaries?. Publish Ahead of Print,	O
18	Comparison of Distal Transradial and Femoral Access in Endovascular Treatment of Non-coronary Arterial Disease. 000331972311633	O
17	Coronary Physiology: Modern Concepts for the Guidance of Percutaneous Coronary Interventions and Medical Therapy. 2023 , 12, 2274	O
16	Methods for assessing guideline adherence for invasive procedures in the care of chronic coronary artery disease: a scoping review. 2023 , 13, e069832	O
15	Abdominelles Aortenaneurysma (AAA). 2022, 93-138	O

CITATION REPORT

14	Past, Present, and Future of Left Main Coronary Artery PCI. 2,	О
13	The Supreme Biodegradable Polymer DES in Acute and Chronic Coronary Syndromes: A PIONEER III Substudy. 2023 , 100629	O
12	Role of acute mechanical circulatory support devices in cardiogenic shock.	О
11	Prevention of contrast-associated acute kidney injury in critically-ill and high-risk preoperative patient: Protocol for a systematic review and network meta-analysis. 2023 ,	O
10	Eficacia de la tromboaspiracifi en pacientes con shock cardioghico secundario a infarto agudo de miocardio y alta carga tromb l ica. 2023 ,	0
9	Clinical outcomes in ST-segment elevation myocardial infarction patients undergoing percutaneous coronary interventions later than 48 h after symptom onset.	O
8	SGLT2-inhibitors effects on the coronary fibrous cap thickness and MACEs in diabetic patients with inducible myocardial ischemia and multi vessels non-obstructive coronary artery stenosis. 2023 , 22,	O
7	Development of Comorbidity Index for In-hospital Mortality for Patients Underwent Coronary Artery Revascularization.	O
6	Five-Year Survival of Patients Treated with Minimally Invasive Direct Coronary Artery Bypass (MIDCAB) Compared with the General Swiss Population.	0
5	Redo CABG: History, Epidemiology, Surgical Treatment, and Outcomes. 2023 , 467-475	O
4	Multidisciplinary Approach to Treatment of Ischaemic Heart Disease: The Role of the Heart Team. 2023 , 335-344	0
3	Multi-Objective Optimisation of a Novel Bypass Graft with a Spiral Ridge. 2023 , 10, 489	O
2	State of the art mathematical methods of the coronary blood flow modelling: background and clinical value. 2023 , 63, 77-84	О
1	Comparative analysis of level of evidence and class of recommendation for 50 clinical practice guidelines released by the European Society of Cardiology from 2011 to 2022. 2023 ,	O